Synthesis, characterization and biological applications of some acetylpyridine, acetophenone derivatives and their metal complexes / Nura Suleiman Gwaram by Suleiman Gwaram, Nura
 
 
SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL 
APPLICATIONS OF SOME ACETYLPYRIDINE, 
ACETOPHENONE DERIVATIVES AND THEIR METAL 
COMPLEXES 
 
 
 
 
 
 
 
 
 
 
NURA SULEIMAN GWARAM 
 
 
 
 
 
 
 
 
 
 
FACULTY OF SCIENCE 
DEPARTMENT OF CHEMISTRY 
UNIVERSITY OF MALAYA 
 
 
 
2014 
 
 
SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL 
APPLICATIONS OF SOME ACETYLPYRIDINE, 
ACETOPHENONE DERIVATIVES AND THEIR METAL 
COMPLEXES 
 
 
 
 
 
 
NURA SULEIMAN GWARAM 
 
 
 
 
 
 
A THESIS SUBMITTED IN FULFILLMENT OF  
THE REQUIREMENT FOR THE DEGREE 
 OF DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
DEPARTMENT OF CHEMISTRY 
 FACULTY OF SCIENCE 
 UNIVERSITY OF MALAYA  
KUALA LUMPUR 
 
2014  
i 
 
UNIVERSITI MALAYA 
ORIGINAL LITERARY WORK DECLARATION 
Name of Candidate: Nura Suleiman Gwaram 
Registartion/Matric No: SHC100019 
Name of Degree: Doctor of Philosophy 
Title of the project paper / Research Report / Dissertation /Thesis (“this Work): Synthesis, 
characterization and biological applications of some acetylpyridine, acetophenone 
derivatives 
Field of Study: Inorganic Chemistry (Aspect: Synthesis & Biological applications) 
I do solemnly and sincerely declare that: 
1. I am the sole author/writer of this work; 
2. This work is original; 
3. Any use of  any work in which copyright exists was done by way of fair dealing and 
for permitted purposes and any excerpt or extract from, or reference to or 
reproduction or any copyright work has been disclosed expressly and sufficiently 
and the title of the work and its authorship have been acknowledged in this work; 
4. I do not have any actual knowledge nor do I ought reasonably to know that making 
of this work constitutes an infringement of any copyright work; 
5. I hereby assign all and every rights in the copyright to this work to the University of 
Malaya (“UM”), who henceforth shall be owner of the copyright in this work and 
that any reproduction or use in any form or by any means whatsoever is prohibited 
without the written consent of UM having been first and obtained; 
6.  I am fully aware that if in the course of making this work I have infringed any 
copyright whether intentionally or otherwise, I may be subject to legal action or any 
other action as may be determined by UM. 
 
 
Candidates Signature:                                   Date 
 
Subscribed and solemnly declared before, 
 
Witness’s Signature:                                    Date 
 
Name: Prof. Hapipah Mohd Ali 
Designation: Supervisor 
 
 
ii 
 
Dedication 
 
 
 
 
 
This thesis is dedicated to my late Father, who passed away on 6
th
 August, 2008. He is 
indeed a Father; his memory is still fresh in my mind may his gentle soul rest in perfect 
peace amen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Acknowledgement 
All praise and adoration is due to Allah the most beneficent the most merciful. The Creator 
and Sustainer of the universe, who is similar to nothing and nothing is comparable to Him.  
Apart from the efforts of me, the success of this thesis depends largely on the 
encouragement and guidelines of many others. I take this opportunity to express my 
gratitude to the people who have been instrumental in the successful completion of this 
thesis.  
I would like to express my deepest appreciation to all those who directly or indirectly 
provided me in one way or another, the possibility to complete this thesis report. A special 
gratitude I give to my supervisors Prof. Dr. Hapipah Mohd Ali and Prof. Dr. Mahmood 
Ameen Abdulla who’s their contributions, suggestions and encouragement, helped me to 
coordinate my project. 
My thanks and appreciations also go to my Lab mates, colleagues and friends both at 
Department of Chemistry and Faculty of Medicine, University of Malaya, as well as all 
other Staffs and technicians for their support both known and unknown to me and people 
who have willingly helped me out with their abilities. 
Furthermore I would also like to thank Umaru Musa Y'ar'adua University (UMYU) for the 
opportunity given to me to further my studies. I am grateful for the time and support both 
morally and financially which was vital for the success of my research project. 
Lastly, an appreciation to my family and my beloved wife, for their love, kindness and 
patience shown during the time it has taken me to finalize this task. Thank you 
 
 
 
iv 
 
Abstract 
A series of compounds derived from 2-acetylpyridne or acetophenones with morpholine, 
piperazine and piperidine moeity were synthesized and structurally characterized. The 
compounds were analysed for in silico, in vitro and in vivo biological applications (anti-
cancer, anti-bacteria, anti-Alzheimer and anti-ulcer). They were first screened for in vitro 
anti-bacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA), 
Acinetobacter baumanni (AC), Klebsiella pneumonie (KB) and Pseudomonas aeruginosa 
(PA) using the disc diffusion and micro broth dilution assays. Based on the overall results, 
they showed the highest activities against MRSA while a weak antibacterial activity was 
observed against A. baumanii and P. Aeruginosa. Another second series of 2-acetypyridine 
and acetophenone derivatives of gallic hydrazide-derivatives were synthesized and 
examined for their antioxidant activities and in vitro and in silico acetylcholinesterase 
inhibition. The ferric reducing antioxidant power (FRAP) and 2,2-diphenyl-1-
picrylhydrazyl (DPPH) assays revealed that all the compounds have strong antioxidant 
activities. 
Molecular docking simulation of the ligand-enzyme suggested that they positioned 
in the enzyme’s (acetylcholinesterase) active-site gorge. This work warrants further 
preclinical studies to assess the potential for these novel compounds for the treatment of 
Alzheimer Disease. Furthermore, some copper(II) and zinc(II) complexes were investigated 
for in vivo gastroprotective effects against ethanol-induced superficial hemorrhagic 
mucosal lesions in rats. Rats were divided into 7 groups. Groups 1 and 2 were orally 
administered with Tween 20 (10% v/v). Group 3 was orally administered with 20 mg/kg 
omeprazole/cimetidine (10% Tween 20). Groups 4–7 received 10, 20, 40, and 80 mg/kg of 
the complex (10% Tween 20), respectively. Tween 20 (10% v/v) was given orally to group 
v 
 
1 and absolute ethanol was given orally to groups 2–7, respectively. Rats were sacrificed 
after 1 h. Group 2 exhibited severe superficial hemorrhagic mucosal lesions. This study 
describes a model to produce extensive gastric necrosis in rats by induction with absolute 
ethanol. The administration of complexes at 1hour before induction with absolute ethanol 
reduced or totally eliminated lesions. 
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Abstrak 
Satu siri sebatian yang diperolehi daripada 2 acetylpyridne atau acetophenones dengan 
morpholine, piperazine dan piperidine moeity telah disintesis dan struktur ciri-ciri.  
Sebatian dianalisis untuk  dalam silico, in vitro dan in vivo aplikasi biologi (Anti-kanser, 
anti-bakteria, Anti-Alzheimer dan Anti-ulser). y ini telah mula ditayangkan dalam vitro 
Satu aktiviti nti-bakteria terhadap Methicillin tahan  Staphylococcus aureus (MRSA), 
Acinetobacter baumanni (AC), Klebsiella pneumonie  (KB) dan Pseudomonas aeruginosa 
(PA) menggunakan penyebaran cakera dan pencairan sup mikro  ujian. Berdasarkan 
keputusan keseluruhan, y menunjukkan aktiviti yang tinggi terhadap  MRSA manakala 
aktiviti antibakteria lemah diperhatikan terhadap A. baumanii dan  P. aeruginosa. Satu lagi 
siri kedua  2-acetypyridine dan derivatif acetophenone daripada Gallic hydrazide-deriv 
atives telah disintesis dan diperiksa untuk aktiviti antioksidan dan in vitro dan in silico  
perencatan acetylcholinesterase. The kuasa penurunan ferik (FRAP) dan  2,2-Diphenyl-1-
picrylhydrazyl (DPPH) ujian menunjukkan bahawa semua bahan  mempunyai aktiviti 
antioksidan yang kuat. Simulasi dok Molekul  es kompleks ligan-enzim mencadangkan 
bahawa y diletakkan dalam (acetylcholinesterase) yang aktif tapak gaung enzim ini. Th 
adalah waran kerja lagi kajian pra-klinikal untuk menilai  berpotensi untuk sebatian novel 
untuk rawatan A lzheimer D isease. Tambahan pula, beberapa kuprum (II) dan zink (II) 
kompleks telah disiasat dalam kesan gastroprotective vivo terhadap etanol yang disebabkan 
luka-luka mukosa berdarah cetek pada tikus.  Tikus telah dibahagikan kepada 7 kumpulan. 
Kumpulan 1 dan 2 telah secara lisan ditadbir dengan Tween 20 (10% v / v). Kumpulan 3 
telah secara lisan ditadbir dengan 20 mg / kg omeprazole / cimetidine (10% Tween 20). 
Kumpulan 4-7 menerima 10, 20, 40, dan 80 mg / kg kompleks (10% Tween 20), masing-
masing. Tween 20 (10% v / v) telah diberikan secara lisan kepada kumpulan 1 dan mutlak 
vii 
 
etanol telah diberikan secara lisan kepada kumpulan 2-7, masing-masing. Tikus 
dikorbankan selepas 1 h. Kumpulan 2 dipamerkan teruk cetek  luka-luka mukosa berdarah.  
Kajian ini menerangkan model untuk menghasilkan gastrik luas  nekrosis pada tikus secara 
aruhan dengan etanol mutlak. Pentadbiran es kompleks pada 1 jam sebelum induksi dengan 
etanol mutlak dikurangkan atau benar-benar  dihapuskan luka-luka. 
  
    Keywords: M kompleks etal; kristalografi sinar-X; A nti-bakteria; perencatan sakit; 
Satu kajian nti-kanser; M dok olecular; ulser gastrik dan mekanisme. 
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1. Introduction    
1.1 Imine formation in ketones - the general picture 
The electrophilic carbon atoms of ketones can be targets of nucleophilic attack by amines. 
The end result of this reaction is a compound in which the C=O double bond is replaced by 
a C=N double bond. Mechanistically, the formation of an imine involves two steps. First, 
the amine nitrogen acts as a nucleophile, attacking the carbonyl carbon. This is closely 
analogous to hemiacetal and hemiketal formation. Based on knowledge for the mechanism 
of acetal and ketal formation, you might expect that the next step would be attack by a 
second amine to form a compound with a carbon bound to two amine groups – the nitrogen 
version of a ketal. Instead, what happens next is that the nitrogen is deprotonated, and the 
electrons from this N-H bond ‘push’ the oxygen off of the carbon, leaving us with a C=N 
double bond (an imine) and a displaced water molecule. 
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Figure 1.1: The formation of ketimine 
The formation of ketimine (Figure 1.1) is an equilibrium system. The reaction is normally 
conducted under slightly acidic conditions ca. pH 4.5. The reaction begins with a 
nucleophilic attack at the carbonyl carbon of the ketone by the lone pair on the N atom of 
the incoming primary amine. A proton is moved from the positively charged nitrogen to the 
negatively charged oxygen producing a neutral carbinolamine. The OH group is then 
protonated by the acid, forming OH2
+
, which is a better leaving group than the OH group. 
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This dehydration step leads to the formation of an iminium ion. The next step is the 
deprotonation of the nitrogen of the iminium ion by water and the formation of the final 
product, an imine. As the formation of water is one of the driving forces of the reaction, its 
removal should push the reaction to the right and maximize yields. 
Imines derived ligands have played significant important roles in chemistry; because they 
are potentially capable of forming stable complexes with metal ions (Souza, 1985). Many 
complexes derived from ketones show excellent activity in various reactions at high 
temperature (>100 °C) and in the presence of moisture.  
In the field of coordination chemistry, ketimines of the general type [Figure 1.2a] and 
Figure 1.2b] that the intramolecular hydrogen bonds between the (O) and the (N) atoms 
plays a significant role in the formation of metal complexes, the Schiff base compounds 
show photochromism and thermochromism in the solid state by proton transfer from the 
hydroxyl (O) to the ketimine (N) atoms (Elerman, 2002). 
 
 
Figure 1.2: Ketimine complexes of acetophenone and acetylpyridine 
Condensation between ketones and amines in different reaction conditions has been 
realized, and in different solvents. The formations of ketones derived Schiff bases 
(ketimines) have been successful in the presence of dehydrating agents. Acid salts (usually 
MgSO4 or Na2SO4) are commonly employed as dehydrating agents. Primary alcohols such 
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as ethanol have been widely used as a solvent for the preparation of ketimines. They have 
been purified by crystallization methods because separation of Schiff bases using silica gel 
can cause some degree of decomposition, through hydrolysis. If the compounds are 
insoluble in hexane or cyclohexane, they can be purified by stirring the crude reaction in a 
mixture of solvents, sometimes adding a small portion of relatively polar solvent e.g diethyl 
ether and dichloromethane, in order to eliminate impurities. In general, Schiff bases are 
stable solids and can be stored without many precautions (Cozzi, 2004). 
1.2 Biological activities of ketimines and their metal complexes 
In the area of bioinorganic chemistry the interest in the complexes lies in that they provide 
synthetic models for the metal-containing sites in metalloproteins/enzymes and also 
contributed enormously to the development of medicinal chemistry, radio immunotherapy, 
cancer diagnosis and treatment of tumor (Quiroga, 2004). In addition, some of the 
complexes containing N and O donor atoms are effective as stereospecific catalysts for 
oxidation (Kureshy, 1999) reduction (Aoyama, 1986), biocidal activity (Sengupta, 2001) 
and other transformations of organic and inorganic chemistry. 
It is known that the existence of metal ions bonded to biologically active compounds may 
enhance their activities (Prakash, 2010). They showed great diversity in their varied 
biological activities as anticonvulsant (Sridhar, 2002), antifungal (Bharti, 2010; Kalagouda,  
2006; Cukurovali, 2006; Tansir, 2008 and Manabu, 1990), anti-HIV (Pandeya, 1999), 
antiviral and anticancer (Zhang, 2009) antimicrobial (Mandal, 2011, Yusnita, J., et. al. 
2009, Pignatello, 1994; Ceyhan, 2011; Tajudeen, 2009; Bagihalli, 2008) and antibacterial 
(Ispir, 2008) agents. 
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Morpholine is an extremely versatile chemical with many important applications. The 
physiological activity of the morpholine nucleus is attested by the number of 
pharmaceutical applications which have been found for it. A platinum(II) complexes 
involving chelating diamine 2-morpholinoethylamine as the carrier ligand were reported by 
the direct reaction between cis-[Pt(MPEA)I2] and the disilver salt of corresponding 
dicarboxylic acid. The cytotoxicity of the complexes was evaluated in the human lung 
cancer cell lines A549 and A549/ATCC. The 2-morpholinoethylaminoplatinum(II) 
complexes with dicarboxylates did not show any significant cytotoxicity, but cis-
[Pt(MPEA)Cl2] was more active than carboplatin against both the sensitive and resistant 
cells, and had less cross-resistance activities with cisplatin. 
Jian-Ying Miao (2011) reported two new mononuclear bromido-coordinated zinc and 
copper complexes, from 2-[2-(1-pyridin-2- ylethylideneamino)ethylamino]ethanol and N’-
(1-pyridin-2- ylethylidene)ethane-1,2-diamine, synthesized and structurally characterized 
by IR spectra and X-ray crystallography. The Zn atom is five-coordinate in a trigonal-
bipyramidal geometry, and the Cu atom is five coordinate in a square pyramidal geometry.      
Both Schiff bases coordinate to the metal atoms through the pyridine N, imine N and amine 
N atoms.  
Over the long period of time, many reports on homogeneous and heterogeneous catalysis of 
Schiff base ligands and their complexes has been done, and reported by (Naeimi, 2007 and 
Lippard and Berg, 1994). Recently Zhong-Lu You (2010) reported a synthesis, 
characterization and urease inhibitory activity of oxovanadium(V) complexes with 
analogous salicylaldehydes derived Schiff bases. The structure–activity relationship 
indicates that the shorter the terminal groups of the Schiff base ligands are, the stronger the 
urease inhibitory activities of the oxovanadium(V) complexes. Considering that the 
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oxovanadium complexes have interesting biological activities and have been widely used in 
medicine (Chohan, 2010), the complexes may be used in the treatment of infections caused 
by urease producing bacteria. 
1.3 Summarized biological information of some compounds used in this thesis 
(1) 2-Acetylpyridine was one of a group of pyridine derivatives screened for mutagenicity 
and carcinogenicity data to identify candidate chemicals for genetic toxicity testing in the 
National Cancer Institute, Division of Cancer Biology's (NCI/DCB's) Short-term Testing 
Program. Very limited toxicological information was found on 2-acetylpyridine.  
N
CH3
O
 
Figure 1.3: Structure of 2-acetylpyridine 
2-acetylpyridine (Figure 1.3)  has been detected as a flavor or aroma constituent of various 
consumed food products; some sources include peppermint and spearmint oils, coriander 
oil, licorice extract, heated corn oil, roasted sesame seed oil, and beer and whiskey, in 
which pyridines are especially associated with off-flavor (STN International, 1996). 2-
Acetylpyridine has been identified as a volatile Maillard reaction product thermally 
generated and released during corn flour extrusion cooking (Nair, 1994). 2-Acetylpyridine 
can be prepared by the catalytic air oxidation of 2-ethylpyridine in the liquid phase (Goe, 
1982). Two other preparative methods are described in the recent chemical literature as 
follows:  
 
6 
 
N
N
2-cyanopyridine
CH3Li
N O
2-acetylpyridine
CH3MgI/
 
 
Grignard reaction of 2-cyanopyridine with organolithium (CH3Li) or alkylmagnesium 
halide (CH3MgI) (Kim, 1993) oxidation of ethylpyridine using tert.-butylhydroperoxide 
and a chromium zinc hydrotalcite-like catalyst (Choudary, 1996). 
 
 
N
ethylpyridine
O
OH
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N O
2-acetylpyridine
 
 
(2) Morpholine undergoes most chemical reactions typical for other secondary amines, 
though the presence of the ether oxygen withdraws electron density from the nitrogen, 
rendering it less nucleophilic (and less basic) than structurally similar secondary amines 
such as piperidine. For this reason, it forms stable chloramines (Lindsay, 1993). It is 
commonly used to generate enamines (Noyori, 1988). A number of morpholine derivatives 
have been described as analgesics and local anesthetics.  
N
O
Br                         
N
O
S
 
Figure 1.4(a): 4-(4- Bromobenzyl) morpholine             (b) 4-tbutylmercaptomorpholine 
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4-(4- Bromobenzyl) morpholine (Figure 1.4a), for instance, is reported to be only 25% as 
toxic as procaine, but almost equal to it in activity. Other pharmaceutical fields in which 
morpholine have found application includes choleretics, antispasmodics, analeptics, and 
antimalarials. In addition to its use as a corrosion inhibitor, 4-tbutylmercaptomorpholine 
has been employed as an antioxidant for lubricating oils. Di-4-morpholinyl monosulfide 
has been claimed as a lubricating oil stabilizer, and multifunctional oil additives that 
possess antioxidant properties and can be prepared from wax-phenols, formaldehyde, and 
morpholine.   
 
H2N
N O
 
Figure 1.5: Structure of 2-Morpholin-4-yl-ethylamine 
(3) Piperidine is a widely used secondary amine. It is widely used to convert ketones to 
enamines (Vinayak, 1990) Enamines derived from piperidine can be used in the Stork 
enamine alkylation reaction (March's, 2001) Piperidine is also commonly used in chemical 
degradation reactions, such as the sequencing of DNA in the cleavage of particular 
modified nucleotides.  
 
H2N
N
 
Figure 1.6: structure of 2-Piperidin-1-yl-ethylamine  
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(4) Piperazine is an organic compound that consists of a six-membered ring containing two 
opposing nitrogen atoms Piperazine was introduced to medicine as a solvent for uric acid. 
When taken into the body the drug is partly oxidized and partly eliminated unchanged. 
Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a 
soluble urate, but in clinical experience it has not proved equally successful (Noyori, 1988; 
Klaus, 2003). 
 
H2N
N NH
 
Figure 1.6: Structure of 2-Piperazin-1-yl-ethylamine 
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1.3 SUMMARY OF PROPOSED LIGANDS IN THIS RESEARCH 
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1.4 SUMMARY OF PROPOSED COMPLEXES IN THIS RESEARCH 
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1.5 OBJECTIVES OF THIS RESEARCH THESIS 
- This research aims at synthesizing ligands derived from condensation reactions of 
2-acetylpyridine or acetophenone derivatives with different types of amines [4- (2-
aminoethyl) morpholine, 4-(2-aminoethyl) piperazine, 4-(2-aminoethyl) piperidine, 
N,N-dimethylethylenediamine, gallic hydrazide and benzene sulfanohydrazide] 
- The synthesized ligands will be reacted with different kind of transition metal ions 
[Mn, Co, Ni, Cu, Zn and Cd their (acetates, halides, thiocyanates and azides)] 
derivatives to form different complexes of different geometries. 
- Also both the synthesized ligands and their corresponding metal complexes will 
then be structurally characterized by using spectroscopic techniques (CHN, FT-IR, 
UV-Visible, FT-NMR) and singe crystal X-ray crystallography. 
- Lastly the synthesized and fully characterized compounds will be analyzed for their 
biological applications which include in vitro anti-oxidants, both in vitro and in  
silico anti-Alzheimer, in vitro anti-bacterial studies against methicillin resistant 
Staphylococcus aureus (MRSA), Pseudomonas aeruginosa (PA), Acinetobacter 
baumannii (AC), and vancomycin resistant enterococci (VRE)  and in vitro anti-
cancer as well as in vivo anti-ulcer activities.   
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2.0 EXPERIMENTAL 
Reagents 
4-(2-aminoethyl)piperidine,  4-(2-aminoethyl)morpholine, 4-(2-aminoethyl)piperazine, 
N,N-dimethylethyldiamine, 2-acetylpyridne, 2-hydroxyacetophenone, manganese(II) 
acetate, manganese(II) chloride, cobalt(II) acetate, nickel(II) acetate, nickel(II) chloride, 
copper(II) acetate, copper(I) bromide, copper(II) chloride, zinc(II) acetate, zinc(II) chloride, 
cadmium(II) acetate,  cadmium(II) chloride, ammonium thiocyanate, Sodium thiocyanate, 
sodium azide, sodium iodide, hydrochloric acid,  glacial acetic acid, triethylamine, absolute 
ethanol (99.8%), ethanol (95%), dimethylsulphoxide, deuterated dimethylsulphoxide, 
acetonitrile and tween 20 that have been used in this research were reagent-grade quality 
and purchased from Sigma, Fluka or Merck. TagametTM 200 mg (cimetidine) and 
omeprazole were purchased from Caring Pharmacy. 
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2.1 SYNTHESIS OF IMINE LIGANDS 
2.1.1 Preparation of 2-morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine (LMA) 
 
 
  
A mixture of 4-(2-aminoethyl)morpholine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 
mmol) in ethanol (50 ml) was refluxed for 2 h followed by addition of a few drops of 
glacial acetic acid to adjust the pH. An oily solution was formed. The solid product was 
dissolved in methanol and heated to 60 °C. After evaporation of the solvent under reduced 
pressure, an orange colored solid was formed. This ligand was characterized by using 
elemental analysis, IR, NMR and UV/Vis-spectroscopy. 
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2.1.2 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenol (LMH) 
 
 
 
The ligand was obtained from the condensation reaction of 2-hydroxyacetophenone with 4-
(2-aminoethyl) morpholine in the presence of a few drops of glacial acetic acid to adjust the 
pH. An oily solution was formed. The solid product was dissolved in methanol and heated 
to 60 °C. After evaporation of the solvent under reduced pressure, a yellowish colored solid 
was formed. This ligand was characterized by elemental analysis, IR, NMR and UV/Vis-
spectroscopy. 
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2.1.3 Preparation of 2-(piperazin-1-yl)-N-(1-(pyridin-2-yl)ethylidene)ethanamine (LPA) 
 
 
 
A mixture of 4-(2-aminoethyl)piperazine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 
mmol) in ethanol (50 ml) at a temperature of 75–85 °C was refluxed for three hours 
followed by addition of a few drops of glacial acetic acid to adjust the pH. Same procedure 
as LMA was applied in the isolation of this Schiff base. 
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2.1.4 Preparation of 2-(piperidin-1-yl)-N-(1-(pyridin-2-yl)ethylidene)ethanamine 
(LPiA) 
 
 
 
A mixture of 4-(2-aminoethyl)piperidine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 
mmol) in ethanol (50 ml) was refluxed for 2 h followed by addition of few drops of glacial 
acetic acid to adjust the pH. After evaporating all the solvent to dryness using rotary 
evaporator, a yellowish orange colored solid was formed.  
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2.1.5 Preparation of N1,N1-dimethyl-N2-(1-(pyridin-2-yl)ethylidene)ethane-1,2-
diamine (LNA) 
 
 
 
An accurately measured amount 2-acetylpyridine (0.61 g, 5 mmol) and N,N-
dimethylethyldiamine (0.44 g, 5 mmol) in ethanol (25 mL) at a temperature of 75–85 °C 
was refluxed for three hours. The progress of the reaction was monitored by using thinlayer 
chromatography (TLC), eluent ethylacetate:Hexane in a ratio (1:4),  and confirmed by one 
spot different from the starting maerials. After the reaction reached completion the solvent 
was evaporated to dryness and the solid obtained was isolated and washed several time with 
ethanol.  
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2.1.6 Preparation of 2-(1-(2-(dimethylamino)ethylimino)ethyl)phenol (LNH) 
 
 
 
A measured amount of 2-hydroxyacetophenone (0.61 g, 5 mmol) and N,N-
dimethylethyldiamine (0.44 g, 5 mmol) in ethanol (25 mL) at a temperature of 75–85 °C 
was heated under refluxfor three hours, to give a yellowish-orange solution. After the 
reaction reached completion the solvent was evaporated to dryness using a rotary evaporaor 
and the solid obtained was isolated washed several time with methanol to obtain a pure 
product.  
 
 
 
 
 
 
 
 
 
19 
 
2.2 SYNTHESIS OF METAL COMPLEXES 
2.2.1 Preparation of Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene] 
ethanaminek
3
N,N',N"}manganese(II) [Mn(LMA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.2 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 g, 
1.65 mmol in ethanol (20 ml) was heated under  reflux for 2 hr followed by addition of a 
solution of manganese(II) chloride (0.206 g, 1.65 mmol) in a minimum amount of water. 
The resulting solution was heated under reflux for 30 min, and then set aside at room 
temperature. The crystals of the manganese(II) complex were obtained after a few days. 
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2.2.2 Preparation of Aqua{2-(morpholin-4-yl)-N-[1-(2-pyridyl)ethylidene]ethanamine 
k
3N,N’,N”} bis(thiocyanato-kN)- manganese(II) [Mn(LMA)(NCS)2(H2O)] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under  reflux for 2 hr followed by addition of a 
solution of manganese(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and ammonium 
thiocyanate (0.13 g, 1.65 mmol) in a minimum amount of ethanol. The resulting solution 
was heated under reflux for 30 min, and then left at room temperature. The crystals of the 
title complex were obtained in a week.  
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2.2.3 Preparation of Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene] 
ethanamineκ3 N,N’,N”} cobalt(II) [Co(LMA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml), was refluxed. After 2 hr a solution of cobalt(II) chloride 
anhydrous (0.21 g, 1.65 mmol) in a minimum amount of water was added. The resulting 
solution was refluxed for 30 min, and then left at room temperature. The crystals of the title 
complex were obtained in a few days. 
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2.2.4 Preparation of Cobalt(III)tris(azido-κN){2-Morpholino-N-[1-(2-
pyridyl)ethylidene] ethanamine-κ3N,N’,N”} [Co(LMA)(N3)3] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was refluxed for 2 hr followed by addition of a solution of 
cobalt(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and sodium azide(0.22 g, 3.30 mmol) in 
a minimum amount of water. The resulting solution was refluxed for 30 min, and then left 
at room temperature. The crystals of the title complex were obtained in a few days; the 
resulting pure crystal was filtered off, washed with cold ethanol and dried under vacuum 
over silica gel. 
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2.2.5 Preparation of Aqua{2-morpholino-N-[1-(2-pyridyl)- ethylidene]ethanamine-
k3N,N’,N”-bis(thiocyanato-kN)cobalt(II) [Co(LMA)(NCS)2(H2O)] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of cobalt(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and sodium thiocyanete 
(0.134 g, 1.65 mmol) in a minimum amount of water. The resulting solution was heated 
under reflux for 30 min, then left at room temperature. The crystals of the title complex 
were obtained in a few days.  
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2.2.6 Preparation of Aqua{2-morpholino-N-[1-(2-pyridyl)-ethylidene]ethanamine-
k3N,N',N"}-bis(thiocyanato-kN)nickel(II) [Ni(LMA)(NCS)2(H2O)] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of nickel(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and sodium thiocyanate 
(0.134 g, 1.65 mmol) in a minimum amount of water. The resulting solution was heated 
under reflux for 30 min, then left at room temperature. The crystals of the title complex 
were obtained in a week. 
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2.2.7 Nickel(II)poly(azido-κN){2-Morpholino-N-[1-(2-pyridyl)ethylidene] ethanamine-
κ3N,N’,N”} [Ni2(LMA)2(N3)2(H2O)2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was refluxed for 2 hr followed by addition of a solution of 
nickel(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and sodium azide (0.22 g, 3.30 mmol) in 
a minimum amount of water. The resulting solution was heated under reflux for 30 min, 
and then left at room temperature. The crystals of the title complex were obtained in a 
week; the resulting pure crystal was filtered off, washed with cold ethanol and dried over 
silica gel. 
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2.2.8 Preparation of Dichlorido{2-(morpholin-4-yl)-N-[1-(pyridin-2-
yl)ethylidene]ethanaminek
3
N,N',N"}copper(II) monohydrate [Cu(LMA)Cl2 .H2O] 
 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was refluxed. After 2 hr a solution of copper(II) chloride 
dihydrate (0.28 g, 1.65 mmol) in a minimum amount of ethanol was added and the resulting 
solution was heated under reflux for 30 min, then set aside at room temperature. The 
crystals of the title complex were obtained after a few days. 
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2.2.9 Preparation of {2-Morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-k
3
N,N',N"} 
bis(thiocyanato-kN)copper(II) [Cu(LMA)(NCS)2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was refluxed for 2 hr followed by addition of a solution of 
copper(II) acetate monohydrate (0.33 g, 1.65 mmol) and sodium thiocyanate (0.134 g, 1.65 
mmol) in a minimum amount of ethanol. The resulting solution was heated under reflux for 
30 min, and then left at room temperature. The crystals of the title complex were obtained 
in a week. 
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2.2.10 Preparation of Dibromido{2-morpholino-N-[1-(2-pyridyl)ethylidene] 
ethanaminek
3N,N’,N”} zinc(II) [Zn(LMA)Br2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl) morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux. After 2 hr a solution of zinc (II) 
acetate dihydrate (0.36 g, 1.65 mmol) and potassium bromide (0.196 g, 1.65 mmol) in a 
minimum amount of water was added.. The mixture was refluxed for 2-3 hours resulting in 
the formation of small precipitate. More precipitate was obtained by removal of some 
solvent by distillation. The product was collected by filtration, washed several times with 
ethanol until a milky colored compound is obtained.  
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2.2.11 Preparation of Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene] 
ethanaminek
3
 N,N’,N”}zinc(II) [Zn(LMA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in the presence of a few drops of HCl (37%) in ethanol (20 ml) was heated 
under reflux. After two hours, a solution of zinc(II) acetate dihydrate (0.36 g, 1.65 mmol) in 
a minimum amount of water was added and the resulting solution was refluxed for 30 min, 
then set aside at room temperature. The crystals of the title complex were obtained after a 
few days.  
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2.2.12 Preparation of Diiodido{2-(morpholin-4-yl)-N-[1-(2-pyridyl)ethylidene] 
ethanaminek
3 N,N’,N”}zinc [Zn(LMA)I2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for two hours, followed by 
addition of a solution of zinc(II) acetate dihydrate (0.36 g, 1.65 mmol) and potassium 
iodide (0.54 g, 3.3 mmol) in a minimum amount of water. The resulting solution was 
heated under reflux for 30 min and then left at room temperature. Brown crystals of the title 
complex were obtained in a few days. 
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2.2.13 Preparation of {2-Morpholino-N-[1-(2-pyridyl)-ethylidene]ethanamine-
k
3N,N’,N”} bis(thiocyanato-kN)zinc(II) [Zn(LMA)(NCS)2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of zinc(II) acetate dihydrate (0.36 g, 1.65 mmol) and sodium thiocyanate (0.134 g, 
1.65 mmol) in a minimum amount of water. The resulting solution was heated under reflux 
for 30 min, then left at room temperature. The crystals of the title complex were obtained in 
a few days. 
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2.2.15 Preparation of 2-Morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-
κ3N,N’,N”-bis(azido-κN)zinc(II) [Zn(LMA)(N3)2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of zinc(II) acetate dihydrate (0.36 g, 1.65 mmol) and sodium azide 0.22 g, 3.30 
mmol) in a minimum amount of water. The resulting solution was heated under reflux for 
30 min, and then left at room temperature. The crystals of the title complex were obtained 
in a few days; the resulting pure crystal was filtered off, washed with cold ethanol and dried 
over silica gel. 
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2.2.16 Preparation of Dibromido{2-(morpholin-4-yl)-N-[1-(2-pyridyl)ethylidene] 
ethanaminek
3N,N’,N”}cadmium [Cd(LMA)Br2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux. After 2 hr a solution of 
cadmium(II) acetate dihydrate (0.44 g, 1.65 mmol) and potassium bromide (0.196 g, 1.65 
mmol) in a minimum amount of water was added. The resulting solution was heated under 
reflux for 30 min, and then left at room temperature. The crystals of the title complex were 
obtained in a few days. 
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2.2.17 Preparation of Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene] 
ethanamine-k
3N,N’,N”}-cadmium [Cd(LMA)Cl2] 
 
 
 
A mixture of 4-(2-aminoethyl)morpholine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 
mmol) in ethanol (50 ml) was heated under reflux for 2 h followed by addition of a solution 
of cadmium(II) chloride (0.92 g, 5 mmol) in a minimum amount of water. The resulting 
solution was heated under reflux for 30 min, then evaporated partially and set aside at room 
temperature. The crystals of the cadmium(II) complex were obtained after a week. 
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2.2.18 Preparation of Aqua{2-morpholino-N-[1-(2-pyridyl)- ethylidene]ethanamine-
k
3N,N’,N”}-bis(thiocyanato-kN)cadmium(II) [Cd(LMA)(N3)2(H2O)] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of cadmium(II) acetate dihydrate (0.44 g, 1.65 mmol) and sodium azide (0.22 g, 
3.30 mmol) in a minimum amount of water. The resulting solution was heated under reflux 
for 30 min, and then left at room temperature. The crystals of the title complex were 
obtained in a few days; the resulting pure crystal was filtered off, washed with cold ethanol 
and dried over silica gel. 
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2.2.19 Preparation of Di-l-thiocyanato-k
2N
:S;k2S:N-bis({2-morpholino-N-[1-(2-
pyridyl) ethylidene]ethanamine-k
3
 N,N’,N”}(thiocyanatojN)cadmium) 
[Cd2(LMA)2(NCS)4] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 
g, 1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of cadmium(II) acetate dihydrate (0.44 g, 1.65 mmol) and sodium thiocyanate 
(0.268 g, 3.30 mmol) in a minimum amount of water. The resulting solution was heated 
under reflux for 30 min, and then left at room temperature. The crystals of the title complex 
were obtained in a week. 
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2.2.20 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenoxy)manganese(II) 
bromide [Mn(LMH)Cl] 
 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), 
manganese(II) acetate tetrahydrate (0.41 g, 1.65 mmol), potassium bromide (0.22 g, 1.85 
mmol) in a minimum amount of water (Gwaram, 2012) 
2.2.21 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenoxy)manganese(II) 
chloride [Mn(LMH)Cl] 
 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), 
manganese(II) chloride (0.24 g, 1.85 mmol) in a minimum amount of water. 
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2.2.22 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenoxy)nickel(II) bromide 
[Ni(LMH)Br] 
 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), 
nickel(II) acetate dihydrate (0.6 g, 3.7 mmol), potassium bromide (0.22 g, 1.85 mmol) in a 
minimum amount of water. 
2.2.23 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenoxy)nickel(II) chloride 
[Ni(LMH)Cl] 
 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), 
nickel(II) chloride (0.24g, 1.85mmol) in a minimum amount of ethanol. 
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2.2.24 Preparation of Bromido(2-{1-[(2-morpholinoethyl)-imino]ethyl}phenolato-
κ3N,N’,O) copper(II) [Cu(LMH)Br] 
 
 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), 
copper(II) chloride dihydrate (0.63 g, 3.7 mmol), potassium bromide (0.22 g, 1.85 mmol) in 
a minimum amount of water. 
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2.2.25 Preparation of Chlorido(2-{1-[(2-morpholinoethyl)-imino]ethyl}phenolato-
κ3N,N’,O)-copper(II) [Cu(LMH)Cl] 
 
 
 
A mixture of 2-hydroxyacetophenone (0.5 g, 3.7 mmol) and 4-(2-aminoethyl)morpholine 
(0.48 g, 3.7 mmol) in ethanol (20 ml), copper(II) chloride dihydrate (0.63 g, 3.7 mmol) in a 
minimum amount of ethanol. The resulting solution was refluxed for 30 min, and then left 
at room temperature. The crystals of the title complex were obtained after a few days.  
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2.2.26 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenoxy)zinc(II) bromide 
[Zn(LMH)Br] 
 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), zinc(II) 
acetate dihydrate (0.6 g, 3.7 mmol),  potassium bromide (0.22 g, 1.85 mmol) in a minimum 
amount of water. 
2.2.27 Preparation of 2-(1-(2-morpholinoethylimino)ethyl)phenoxy)zinc(II) chloride 
[Zn(LMH)Cl] 
 
The title compound was obtained through the reaction of 2-hydroxyacetophenone (0.5 g, 
3.7 mmol) and 4-(2-aminoethyl)morpholine (0.48 g, 3.7 mmol) in ethanol (20 ml), zinc(II) 
chloride (0.35g, 1.85 mmol) in a minimum amount of ethanol. 
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2.2.28 Preparation of Hexachloridobis{l2-2-(piperazin-1-yl)-N-[1-(2-
pyridyl)ethylidene] ethanamine}-trizinc dihydrate [Zn3(LPA)2(Cl)6] 
 
 
 
 
 
A mixture of 4-(2-aminoethyl) piperazine (0.2 g, 1.55 mmol) and 2-acetylpyridine (0.19 g, 
1.55 mmol) in ethanol (20 ml) was heated under reflux for 2 h and then an ethanolic 
solution of zinc (II) chloride (0.21 g, 1.55 mmol) was added. The resulting solution was 
heated under reflux for 30 min and then set aside at room temperature for a few days 
whereupon the prismatic crystals of the title compound were obtained. 
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2.2.29 Preparation of  Octachloridobis[l2-2-(piperazin-1-yl)-N-1-(2-pyridyl)ethylidene 
ethanamine-bis-4-(2-aminoethyl)piperazine]-tetracadminic [Cd4(LPA)2(PA)2(Cl)8] 
 
 
 
A mixture of 4-(2-aminoethyl)piperazine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 
mmol) in ethanol (50 ml) was heated under reflux for 2 h followed by addition of a solution 
of cadmium(II) chloride (0.92 g, 5 mmol) in a minimum amount of water was added. The 
resulting solution was heated under reflux for 30 min and then set aside at room 
temperature for one week where upon the tiny crystals of the chlorine bridged polymerized 
compound were obtained. 
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2.2.30 Preparation of Dichlorido{2-piperidino-N-[1-(2-pyridyl)ethylidene]ethanamine 
κ3N,N’,N”} zinc(II) [Zn(LPiA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)piperidine (0.21 g, 
1.65 mmol) in the presence of a few drops of HCl (37%) in ethanol (20 ml) was refluxed. 
After 2 hr a solution of zinc(II) acetate dihydrate (0.36 g, 1.65 mmol) in a minimum 
amount of water was added and the resulting solution was refluxed for 30 min, then set 
aside at room temperature. The crystals of the title complex were obtained after a few days. 
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2.2.31 Preparation of {2-piperido-N-[1-(2-pyridyl)-ethylidene]ethanamine-κ3N,N’,N”} 
bis(thiocyanato-k
N
)zinc(II)] [Zn(LPiA)(NCS)2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)piperidine (0.21 g, 
1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of zinc(II) acetate dihydrate (0.36 g, 1.65 mmol) and sodium thiocyanate (0.134 g, 
1.65 mmol) in a minimum amount of water. The resulting solution was heated under reflux 
for 30 min, and then left at room temperature. The crystals of the title complex were 
obtained in a few days 
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2.2.32 Preparation of Dichlorido{N,N-dimethyl-N0-[1-(2-pyridyl)ethylidene]ethane-
1,2-diaminek
3
 N,N',N"}manganese(II) [Mn(LNA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.61 g, 5 mmol) and N,N-dimethylethyldiamine (0.44 g, 5 
mmol) in ethanol (50 ml) was heated under reflux for 2 hr followed by addition of a 
solution of manganese(II) chloride (0.63 g, 5 mmol) in a minimum amount of water. The 
resulting solution was heated under reflux for 30 min, then set aside at room temperature. 
The crystals of the title compound were obtained after a few days. 
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2.2.33 Preparation of Aqua{N,N-dimethyl-N'-[1-(2-pyridyl)-ethylidene]ethane-1,2-
diaminek
3
N,N',N"}bis(thiocyanato-k
N
)nickel(II) [Ni(LNA)(NCS)2(H2O)] 
 
 
 
 
A mixture of 2-acetylpyridine (0.2 g, 1.65 mmol) and N,N-dimethylethyldiamine (0.15 g, 
1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 h followed by addition of a 
solution of nickel(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and sodium thiocyanate (0.27 
g, 3.3 mmol) in a minimum amount of water. The resulting solution was heated under 
reflux for 30 min, then set aside at room temperature. Brown crystals of the title compound 
were obtained by slow evaporation of the resulting reaction mixture. 
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2.2.34 Peparation of {N,N-Dimethyl-N'-[1-(2-pyridyl)ethylidene] ethane-1,2-diamine-
k
3
N,N',N"}- bis(thiocyanato-k
N
)copper(II) [Cu(LNA)(NCS)2] 
 
 
 
A mixture of 2-acetylpyridine (0.2 g, 1.65 mmol) and N,N-dimethylethyldiamine (0.15 g, 
1.65 mmol) in ethanol (20 ml) was heated under reflux. After 2 hr a solution of copper(II) 
chloride dihydrate (0.28 g, 1.65 mmol) and sodium thiocyanate (0.27 g, 3.3 mmol) in a 
minimum amount of water was added. The resulting solution was heated under reflux for 
an hour, then left at room temperature. The green crystals of the title compound were 
obtained in a few days. 
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2.2.35 Preparation of Dichlorido{N,N-dimethyl-N0-[1-(2-pyridyl)ethylidene]ethane-
1,2-diaminek
3
N,N',N"}zinc [Zn(LNA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and N,N-dimethylethyldiamine (0.15 g, 
1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of zinc(II) chloride (0.225 g, 1.65 mmol) in the minimum amount of water. The 
resulting solution was heated under reflux for 30 min, and then set aside at room 
temperature. The colorless crystals of the title compound were obtained in a few days. 
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2.2.36 N,N-Dimethyl-N'-[1-(2-pyridyl)ethylidene]ethane-1,2-diamine-k
3N,N′,N′′}bis 
(thiocyanate)zinc(II)  [Zn(LNA)(NCS)2] 
 
 
 
A mixture of 2-acetylpyridine (0.61 g, 5 mmol) and N,N-dimethylethyldiamine (0.44 g, 5 
mmol) in ethanol (50 mL) was heated under reflux for 2 h followed by addition of a 
solution of Zinc (II) acetate (0.92 g, 5 mmol) and sodium thiocyanate (0.406 g, 5 mmol) in 
a minimum amount of water. The mixture was heated under reflux for 2–3 h resulting in the 
formation of a white precipitate. More precipitate was obtained by removal of some 
solvent. The product was collected by filtration, washed several times with ethanol until a 
white colored compound is obtained. It was re-crystallized from the same solvent (ethanol), 
filtered to remove the suspended impurities. Yield = 72%. 
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2.2.37 Preparation of Dichlorido{N,N-dimethyl-N0-[1-(pyridin-2-yl)ethylidene]ethane-
1,2-diaminek
3
N,N',N"}cadmium [Cd(LNA)Cl2] 
 
 
 
A mixture of 2-acetylpyridine (0.61 g, 5 mmol) and N,N-dimethylethyldiamine (0.44 g, 5 
mmol) in ethanol (50 ml) was heated under reflux for 2 hr followed by addition of a 
solution of cadmium(II) chloride (0.92 g, 5 mmol) in a minimum amount of water. The 
resulting solution was heated under reflux for 30 min, then set aside at room temperature. 
The colorless crystals of the title compound were obtained after a few days.  
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2.2.38 Preparation of catena-Poly[[{N,N-dimethyl-N'-[1-(pyridin-2-
yl)ethylidene]ethane-1,2-diamine-k
3
N,N',N"}(thiocyanato-k
N
)-cadmium]-l-thiocyanato-
k2S:N] [Cdn(LNA)n(NCS)n]n 
 
 
 
A mixture of 2-acetylpyridine (0.2 g, 1.65 mmol) and N,N-dimethylethyldiamine (0.15 g, 
1.65 mmol) in ethanol (20 ml) was heated under reflux for 2 hr followed by addition of a 
solution of cadmium(II) acetate dihydrate (0.44 g, 1.65 mmol) and sodium thiocyanate 
(0.27 g, 3.3 mmol) in a minimum amount of water. The resulting solution was heated under 
reflux for 30 min, then set aside at room temperature. The crystals of the title compound 
were obtained in a few days.  
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2.2.39 Preparation of Bis(l-2-{1-[2-(dimethylamino)ethylimino] ethyl}phenolato)bis 
[bromido copper(II) monohydrate  [Cu2(LNH)2Br2] 
 
 
 
 
A solution of 2-hydroxyacetophenone (0.20 g, 1.65 mmol) and N,N-dimethylethyldiamine 
(0.14 g, 1.65 mmol) in ethanol (20 ml) was stirred at reflux for 2 hr. Then, a solution of 
copper (I) bromide (0.21 g, 1.65 mmol) in a minimum amount of ethanol was added. The 
resulting mixture was heated under reflux for 30 min, and then left at room temperature. 
The crystals of the title complex were obtained in a few days. 
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2.3 SYNTHESIS OF SECOND SERIES OF HYDRAZONE COMPOUNDS 
2.3.1 Preparation of N-(1-(5-Bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzo hydrazide  
 
N
H
OHO
HO
HO
N
CH3
HO
Br
Molecular Weight: 381.18
 
 
Gallic hydrazide (1.84 g, 0.01 M) in (20 mL) ethanol was added to an ethanolic solution 
(20 mL) of 5-bromo-2-hydroxyacetophenone (2.15 g, 0.01 M respectively). The mixture 
was stirred for 2–3 h whereupon the color of the solution turned yellowish. The pH was 
adjusted by adding a few drops of dilute HCl. The reaction was continued for another hour 
resulting in the formation of a yellow precipitate. More precipitate was obtained when 
reducing the solvent by distillation. The product was collected by filtration, washed several 
times with ethanol and dried in an oven. (Yield 75%),  
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2.3.2 Preparation of N-(1-(5-Chloro-2-hydroxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzo hydrazide  
 
N
H
OHO
HO
HO
N
CH3
HO
Cl
Molecular Weight: 336.73
 
 
An accurately weighed amount of gallic hydrazide (1.84 g, 0.01 M) in ethanol (20 mL) was 
added to the same ethanolic solution (20 mL) of 5-chloro-2-hydroxyacetophenone (2.15 g, 
0.01 M), and the mixture was stirred for 2–3 h as the color of the solution turned yellowish. 
The pH was adjusted by adding few drops of dilute HCl. The reaction was continued for 
another 1 h to give a yellow precipitate. More precipitate was obtained after reducing the 
solvent by distillation. The product was collected by filtration, washed several times with 
ethanol and dried in an oven. (Yield 75%)  
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2.3.3 Preparation of N-(1-(2-Hydroxy-5-methoxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzo hydrazide  
 
N
H
OHO
HO
HO
N
CH3
HO
O
CH3
Molecular Weight: 332.31
 
 
An ethanolic solution (20 mL) of gallic hydrazide (1.84 g, 0.01 M) was added to an 
ethanolic solution (20 mL) of 2-hydroxy-5-methoxyacetophenone (1.06 g, 0.01 M) in 1:1 
ratio. The mixture was refluxed for 2–3 h resulting in the formation of a slightly yellow 
precipitate. More precipitate was obtained by removal of some solvent by distillation. The 
product was collected by filtration, washed several times with ethanol until a milky colored 
compound is obtained. The ligand was re-crystallized by using the same solvent (ethanol), 
filtered to remove the suspended impurities and a single crystal was obtained suitable for 
X-ray analysis. (Yield = 65%) 
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2.3.4 Preparation of 3,4,5-Trihydroxybenzoic Acid [1-Pyridylethylidene] Hydrazide  
 
N
H
OHO
HO
HO
N
CH3
N
Molecular Weight: 287.27
 
A stoichiometric amount of gallic hydrazide (1.84 g, 0.01 M) in ethanol (20 mL) was added 
to a solution (20 mL) of 2-acetylpyridine (1.21 mL, 0.01 mmol) and the mixture was 
refluxed on a water bath for 2–3 h, resulting in the formation of a small amount of white 
precipitate. More precipitate was obtained after evaporating the solvent by distillation. The 
product was then collected by filtration, washed several times with ethanol until white 
powder product was formed. The white powder ligand was recrystallized by using DMF to 
obtained single crystals for X-ray structural determination. (Yield = 65%) 
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2.3.5 Preparation of N'-(1-(6-Acetylpyridin-2-yl)ethylidene)-3,4,5-trihydroxybenzo 
hydrazide 
  
 
N
H
OHO
HO
HO
N
CH3
N
O
CH3
Molecular Weight: 329.31
 
 
A weighed amount of gallic hydrazide (1.84 g, 0.01 M) in (20 mL) ethanol was added to 
the same volume (20 mL) of ethanolic solution of 2,6-diacetylpyridine (1.63 g, 0.01 M). 
The mixture was stirred for 2–3 h while the color of the solution turned yellowish. The pH 
was adjusted by adding few drops of dilute HCl. The reaction was continued for another 
one hour resulting in the formation of a yellow precipitate. The product was collected by 
filtration, washed several times with ethanol and dried in an oven. (Yield 90%) 
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2.3.6 Preparation of 2'-[1-(2-hydroxyphenyl) ethylidene] benzenesulfanohydrazide 
 
 
 
Benzenesulfanohydrazide (0.690 g, 0.0035mol) was accurately weighed on a digital 
balance in a 100 ml beaker and dissolved in 50 mL acidified ethanol (95;5, ethanol:acetic 
acid); 2-hydroxyacetophenone (0.60 g, 0.0035 mol) was also dissolved in another sample of 
acidified ethanol (50 mL). The two solutions were mixed together in a 500 mL flat bottom 
flask which was then clamped on a water bath and refluxed on a magnetic hot plate for 2 h 
while stirring. The resulting yellow precipitate was filtered into a conical flask and re-
crystallized in ethanol to yield pale yellow crystals. 
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2.3.7 Synthesis of 2’- (5-chloro -2-hydroxy benzylidene) benzenesulfanohydrazide 
 
 
 
Benzenesulfanohydrazide (0.690 g, 0.0035mol) was accurately weighed on a digital 
balance in a 100 ml beaker and dissolved in 50 mL acidified ethanol (95;5, ethanol:acetic 
acid); 5’-chloro-2’-hydroxyacetophenone (0.60 g, 0.0035 mol) was also dissolved in 
another sample of acidified ethanol (50 mL). The two solutions were mixed together in a 
500 mL flat bottom flask which was then clamped on a water bath and refluxed on a 
magnetic hot plate for 2 h while stirring. The resulting yellow precipitate was filtered into a 
conical flask and re-crystallized in ethanol to yield pale yellow crystals. 
 
 
 
 
 
 
61 
 
 
2.3.8 Synthesis of Zinc(II) complex of 2'-[1-(2-hydroxyphenyl) ethylidene] 
benzenesulfanohydrazide 
A solution of zinc(II) acetate (0.15 g, 0.0006 mole) in basified ethanol (50 ml) was mixed 
with a (50 ml) ethanolic solution of 20-[1-(2-hydroxyphenyl) ethylidene] benzenesulfonyl 
hydrazide (0.35 g, 0.0012 mol) at a 1:2 M ratio. The mixture was stirred and refluxed for 5 
h. Dark brown solid was formed. Yield =65% 
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RESULTS AND DISCUSSION 
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3.0 General characterization of Synthesized Compounds 
This part of the research thesis comprises of six types of ligands divided into two series 
which showed different modes of coordination. The first series of ligands involved an 
N,N’,N”-donor Schiff base ligands from the reaction of 2-acetylpridine with four different 
amines: 4-(2-aminoethyl)morpholine (LMA), 4-(2-aminoethyl)piperazine (LPA), 4-(2-
aminoethyl)piperidine (LPiA) and N,N’-dimethylethylenediane (LNA). The second series 
are N,N’,O-donor Schiff bases from the condensation reaction of 2-hydroxyacetophenone 
with two amines viz: 4-(2-aminoethyl)morpholine (LMH), and N,N’-
dimethylethylenediane (LNH). The ligands were reacted with most of the transition metal 
acetates in presence of Cl
-
, Br
-
, I
-
 and SCN
-
 ions derived from hydrochloric acid (HCl), 
potassium bromide (KBr), sodium iodide (NaI) and sodium thiocyanate (NaSCN) 
respectively. For the set of the complexes, the respective ligands were mixed in different 
ratios in ethanol and refluxed for 2-3hours. In most of the complexes an in situ method was 
used in which the ligands were not isolated and the ethanolic solutions of metal acetates 
and chlorides with different salts were used. The ligands and complexes were characterized 
by elemental analysis, spectroscopic techniques such as IR, NMR, UV/Visible and X-Ray 
crystallography. 
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3.1 Physico-Chemical properties of the compounds 
Table 3.1: Physical properties for 2-morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine (LMA) and metal complexes. 
Compound  Mol.W. 
(g/mol) 
 Melting 
Point 
 Yield 
(%) 
 Color Elemental Percentage (%) Calculated (Found) 
    C H  N  
LMA (Liq) 
  
233.31 - 62 Orange 66.92 8.21  18.01 
[Mn(LMA)Cl2] 359.15 >350 82 Brown 43.47(43.74) 5.33(5.34) 11.70(11.70) 
[Mn(LMA)(NCS)2.H2O] 
 
422.43 >380 86 Reddish 42.65(42.64) 5.01(5.05) 16.58(16.58) 
[Co(LMA)Cl2] 363.15 >370 60 Brownish 43.00(43.10) 5.27(5.44) 11.57(12.07) 
[Co(LMA)(N3)3] 418.30 >400 95 Brown 41.85(40.65) 5.67(5.60) 28.16(28.32) 
[Co(LMA)(NCS)2.H2O] 426.42 >400 78 Pink 42.25(42.55) 4.96(5.06) 16.42(16.42) 
[Ni(LMA)NCS2.H2O] 426.18 >400 80 Green 42.27(42.31) 4.97(4.98) 16.43(16.43) 
[Cu(LMA)Cl2] 367.76 >360 90 Greenish 42.46(42.19) 5.21(5.11) 11.43(11.39) 
[Cu(LMA)(NCS)2.H2O] 413.02 >365 82 Blue 43.62(43.61) 4.64(4.64) 16.96(16.99) 
[Zn(LMA)Br2] 458.51 >400 85 Milky 30.89(30.79)  3.79(3.49) 8.31(8.28) 
[Zn(LMA)Cl2] 369.61 >370 90 White 42.24(42.24) 5.18(5.18) 11.37(11.37) 
[Zn(LMA)I2] 552.51 >400 55 Brown 28.26(29.26) 3.47(3.67) 7.61(7.51) 
[Zn(LMA)(NCS)2] 414.86 >375 81 White 43.43(43.45) 4.62(4.62) 16.88(16.54) 
[Zn(LMA)(N3)2] 382.74 >355 88 White 40.80(40.88) 5.00(5.10) 32.94(32.98) 
[Cd(LMA)Br2] 416.63 >400 81 White 37.48(37.28) 4.60(4.45) 10.09(10.19) 
[Cd(LMA)Cl2] 505.53 >400 76 Milky 34.85(34.92) 4.27(4.17) 9.38(9.77) 
[Cd(LMA)(N3)2.H2O] 447.78 >375 90 White 34.87(34.88) 4.73(4.74) 28.15(28.17) 
65 
 
Table 3.2: Physical properties for 2-(1-(2-morpholinoethylimino)ethyl)phenol (LMH) and metal complexes. 
Compound  Mol. Weight 
(g/mol) 
 Melting 
Point(
o
C) 
  
Yield 
(%) 
Color Elemental Percentage (%) 
Theory (Experimental) 
    C H  N  
LMH (Liq.) 
 
248.15  55 Yellow 67.71 8.12 11.28 
[Mn(LMH)Br] 382.15 >400 65 Brown 44.00(43.97) 5.01(5.17) 7.33(7.40) 
[Mn(LMH)Cl] 337.70 >385 73 Reddis
h 
49.79(48.99) 5.67(5.54) 8.30(8.40) 
[Ni(LMH)Br] 385.91 >400 68 Greeni
sh 
43.57(44.00) 4.96(5.01) 7.26(7.28) 
[Ni(LMH)Cl] 341.46 >365 76 Green 49.24(49.25) 5.61(5.63) 8.20(8.50) 
[Cu(LMH)Br] 390.76 >360 78 Brown 43.03(43.19) 4.90(4.11) 7.17(7.29) 
[Cu(LMH)Cl] 346.31 >350 83 Blue 48.55(48.49) 5.53(5.71) 8.09(8.39) 
[Zn(LMH)Br] 392.61 >355 87 Milky 42.83(42.94) 4.88(4.88) 7.14(7.24) 
[Zn(LMH)Cl] 348.16 >400 82 White 48.30(48.48) 5.50(5.79) 8.05(8.98) 
LPA (Liq.) 232.17 - 40.3 Orange 67.21 8.68 24.12 
[Zn3(LPA)2Cl4] 891.55 >400 68 White 35.03(35.21) 4.75(4.88) 12.57(12.60) 
LPiA (Liq.) 231.34 - 49 Orange    
[Zn(LPiA)Cl2] 367.63 >360 75 White 45.74(45.75) 5.76(5.81) 11.43(11.46) 
[Zn(LPiA)(NCS)
2] 
 >365 69 Yellow    
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Table 3.3: Physical properties for N1,N1-dimethyl-N2-(1-(pyridin-2-yl)ethylidene)ethane-1,2-diamine (LNA) and complexes 
Compound  Mol. Weight 
(g/mol) 
 Melting 
Point 
 
 Yield 
(%) 
Color Elemental Percentage (%) 
Theory (Experimental) 
    C H  N  
LNA (Liq.) 191.27  54 Orange 69.87 8.80 13.58 
[Mn(LNA)Cl2] 327.57 >350 82 White 40.33(40.63) 5.23(5.43) 12.83(13.03) 
[Cu(LNA)(NCS)2] 372.83 >385 68 White 35.27(35.17) 4.57(4.67) 11.22(11.21) 
[Zn(LNA)Cl2] 370.98 >400 62 Green 42.09(41.99) 4.62(4.62) 18.88(18.87) 
[Zn(LNA)(NCS)2] 384.15 >375 72 Green 40.65(40.85) 4.99(5.00) 18.23(18.82) 
[Zn(LNA)(N3)2] 458.50 >350 61 White - - - 
[Cd(LNA)Cl2] 374.59 >400 74 White 35.27(35.36) 4.57(4.64) 11.22(11.22) 
[Cd(LNA)(NCS)2] 317.12 >350 84 Brown 41.66(41.68) 5.40(5.41) 13.25(13.25) 
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Table 3.4: Physical properties for 2-(1-(2-(dimethylamino)ethylimino)ethyl)phenol (LNH) and complexes 
Compound  Mol.Weight 
(g/mol) 
 Melting 
Point (
o
C) 
 Yield (%) Color Elemental Percentage (%) 
Theory (Experimental) 
    C H  N  
LNH (Liq.) 206.28 - 59 Yellow 69.87 8.80 13.58 
[Mn(LNH)Br] 340.12 >400 65 Brown 42.38(42.97) 5.04(5.17) 8.24(8.40) 
[Mn(LNH)Cl] 295.67 >385  73 Reddish 48.75(48.99) 5.80(5.84) 9.47(9.50) 
[Ni(LNH)Br] 343.87 >400  68 Brown 41.91(42.00) 4.98(5.01) 8.15(8.28) 
[Ni(LNH)Cl] 299.42 >365 76 Green 48.14(49.25) 5.72(5.73) 9.36(9.50) 
[Cu2(LNH)2Br2] 715.47 >400  85 Blue 40.29(40.88) 5.07(5.20) 7.83(7.93) 
[Cu(LNH)Br] 348.73 >360  80 Brown 41.33(42.19) 4.91(4.91) 8.03(8.29) 
[Cu(LNH)Cl] 304.28 >360 72 Green 47.37(48.19) 5.63(6.11) 9.21(9.39) 
[Zn(LNH)Br] 350.57 >355 87 Yellow 41.11(42.94) 4.89(4.98) 7.99(7.99) 
 
In summary Tables 3.1, 3.2, 3.3 and  and 3.4 above presented physical properties of the synthesized compounds which includes; molecular 
weight, melting points, percentage yield, colors and elemental analysis data for ligands and their respective metal complexes. The calculated 
values for the elemental analysis (CHN analysis) are in a good agreement with the experimental value found. 
68 
 
3.2 Infrared Spectral analysis for the compounds 
Aromatic compounds show useful characteristic infrared bands in five regions of the mid-
infrared spectrum. The v(C–H) stretching bands of aromatic compounds appear in the 
3100–3000 cm−1 range, so making them easy to differentiate from those produced by 
aliphatic v(C–H) groups which appear below 3000 cm-1. In the 2000–1700 cm−1 regions, a 
series of weak combination and overtone bands appear and the pattern of the overtone 
bands reflects the substitution pattern of the benzene ring. Skeletal vibrations, representing 
v(C=C) stretching, absorb in the 1650–1430 cm−1 range. The v(C–H) bending bands appear 
in the regions 1275–1000 cm−1 (in-plane bending) and 900–690 cm−1 (out-of plane 
bending). The bands of the out-of-plane bending vibrations of aromatic compounds are 
strong and characteristic of the number of hydrogen in the ring, and hence can be used to 
give the substitution pattern. 
The IR spectra of transition metal complexes were recorded in 4000–400 cm−1 range. The 
characteristic IR stretching frequencies of the metal complexes along with their proposed 
assignments are summarized in Table 3.5 below. There are similarities in the IR spectrum 
of the metal complexes to each other, except for some slight variations in the shifts and 
intensities of few vibration peaks caused by different metal(II) ions, indicating that the 
metal complexes had similar structure. However, there were some significant differences 
between the metal(II) halides complexes and that of the azides and thiocyanate complexes, 
as expected.  
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Table 3.5. Some of the important IR bands in (cm
-1
) for 2-morpholino-N-(1-(pyridin-2-
yl)ethylidene)ethanamine (LMA) and metal complexes. 
Compound (C-H) (NCS/N3) (C=N) (C-C) (C-N) (M-N) 
LMA 
  
2972 - 1642 1451 1113 - 
[Mn(LMA)Cl2] 2938 - 1650 1464 1109 555 
[Mn(LMA)(NCS)2H2O] 
 
2974 2082 1651 1442 1165 568 
[Co(LMA)Br2] 3033 - 1654 1438 1121 557 
[Co(LMA)Cl2] 3106 - 1652 1441 1107 516 
[Co(LMA)(N3)3] 2944 1992 1646 1428 1112 572 
[Co(LMA)(NCS)2H2O] 2880 2071 1650 1435 1110 563 
[Ni(LMA)NCS2 
H2O] 
2880 2082 1652 1441 1107 516 
[Cu(LMA)Br2] 2980 - 1652 1441 1107 516 
[Cu(LMA)Cl2] 2949 - 1655 1443 1144 577 
[Cu(LMA)N3] 2979 2066 1659 1446. 1145 573 
[Cu(LMA)(NCS)2H2O] 2964 2086 1656 1444 1115 523 
[Zn(LMA)Br2] 2959 - 1649 1439 1114 561 
[Zn(LMA)Cl2] 3069 - 1654 1438 1121 557 
[Zn(LMA)I2] 2956 - 1652 1433 1119 558 
[Zn(LMA)(NCS)2] 2874 2070 1654 1433 1118 566 
[Zn(LMA)(N3)2] 2965 2069 1657 1461 1114 565 
[Cd(LMA)Br2] 2957 - 1652 1433 1119 558 
[Cd(LMA)Cl2] 2962 - 1650 1458 1115 556 
[Cd(LMA)(N3)2H2O] 2951 2045 1649 1438 1110 552 
 
 
 
70 
 
The IR spectra of LMA ligand and series of complexes (Figure 3.2.1 - 3.2.4) and Table 3.5 
possess characteristic absorption bands in the region of 1665-1640 cm
-1 
which is attributed 
to the v(C=N) stretching vibration of the Schiff base imino functional group (Yusnita, 
2009; Raman and Khan, 2011). The characteristics frequencies appeared in the spectra of 
all complexes in the region of 3110-2874 cm
-1
 assignable to ν(C-H/NH) group. The v(OH) 
stretching frequency appeared in the spectra of the ligand as broad bands in wave number 
of 3340cm
-1
. This is due to the presence of water molecules, located outside the 
coordination sphere (Maeda, 1999).  For thiocyanates and azide complexes chemical shifts 
were observed in the region of 2090-1990 attributable to metal coordination (Banerjee and 
Chattopadhyay, 2005). The spectra for the complex showed v(M–N) bands at a lower 
wavelength in the range of 580-515 cm
-1
 (Mohamed, 2009; Shahabadi, 2010).   
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Figure 3.2.1: IR spectra of  [Mn(LMA)Cl2] 
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Figure 3.2.2: IR spectra of [Co(LMA)(N3)3] 
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Figure 3.2.3: IR spectra of  [Co(LMA)(NCS)2H2O] 
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Figure 3.2.4: IR spectra of  [Cu(LMA)(NCS)2] 
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Table 3.6: Some of the important IR bands (cm
-1
) for 2-(1-(2-
morpholinoethylimino)ethyl)phenol (LMH) and metal complexes. 
Compound (C-H) (C=N) (C-C) (C-N) (M-N) (M-O) 
LMH 
 
2952 1611 1448 1113 - - 
[Mn(LMH)Br] 2838 1650 1464 1109 555 462 
[Mn(LMH)Cl] 2974 1651 1442 1165 522 
2 
461 
[Ni(LMH)Br] 2980 1597 1441 1157 516 492 
[Ni(LMH)Cl] 2943 1605 1436 1102 518 474 
[Cu(LMH)Br] 3109 1664 1428 1125 531 473 
[Cu(LMH)Cl] 2972 1580 1432 1113 526 493 
3 [Zn(LMH)Br] 3076 1654 1438 1121 557 454 
[Zn(LMH)Cl] 2984 1654 1438 1115 541 453 
 
The IR spectra of the free ligand (LMH) and corresponding complexes exhibit various 
bands in the 400-4000 cm
-1
 region (Figure 3.2.6 and 3.27). The v(O-H) stretching 
frequency of the free ligand is found in the 3397.19 cm
-l
 region as expected (Figure 3.2.5). 
The coordination of the ligand to the metal center could be determined by comparing the IR 
spectra of the metal complexes with their respective ligands and are mainly elucidated by 
the disappearance of hydroxyl group of the ligand (O-H) and the formation of new metal-
oxygen (M-O) and metal-nitrogen (M-N) bands. Nonetheless, the assignment of v(M-O) 
and v(M-N) bands at the lower region seems to be due to the interference with the vibration 
signals of the ligand.  
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Figure 3.2.5: IR spectra of LMH 
The band at 1611cm
-1 
is attributed to the ν(C=N). Upon chelation, a shift to a different 
wave number in the region of 1664-1580cm
-1
, indicates a change in the bond order due to 
coordination of the metal atom to the azomethine nitrogen lone pair. This small shift of 
ν(C=N) was also reported in the previous studies (Leovac, 2008). We considered 
differences caused by the difference of the strength of the v( M-O) and v(M-N) bonding in 
the various complexes. In the complexes, the closed-shell metal ions react primarily with 
the negatively charged oxygen; the v(M-O) bonding plays a more important role than the 
v(M-N) bonding. On the other hand, transition metal ions in group complexes react 
primarily with the covalent nitrogen, the v(M-N) bonding is stronger than the v(M-O) 
bonding. That is, the v(M-N) bonding plays a more important role in the complexes. These 
results are in agreement with Pearson's soft-hard acid-base theory.
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Figure 3.2.6: IR spectra of [Cu(LMH)Cl] 
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Figure 3.2.7: IR spectra of [Ni(LMH)Br] 
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Table 3.7: Some of the important IR bands for 2-(piperazin-1-yl)-N-(1-(pyridin-2-
yl)ethylidene)ethanamine (LPA)  
Compound (C-H) V(NCS) (C=N) (C-C) (C-N) (M-N) 
LPA 2945  1640 1437 1132 - 
[Zn3(LPA)2Cl6] 2953  1654 1439 1130 576 
[Cd4(LPA)2(PA)2(Cl)8
] 
3221  1654 1438 1121 556 
 
The IR spectra of (LPA) ligand and series of complexes (Figure Appendix) possess very 
strong characteristic absorption bands in the region of 1660-1640 cm
-1 
which is attributed to 
the v(C=N) stretching vibration of the Schiff base imino functional group. The 
characteristics frequencies appeared in the spectra of all complexes at region of 3220-2950 
cm
-1
 assignable to ν(C-H/NH) group.  The spectra for the complex showed v(M–N) bands 
at a lower wavelength in the range of 570-550 cm
-1
 (Mohamed, 2009; Shahabadi, 2010).   
Table 3.8: Some of the important IR bands for 2-(piperidin-1-yl)-N-(1-(pyridin-2-
yl)ethylidene)ethanamine (LPiA) with their metal complexes. 
Compound (C-H) V(NCS) (C=N) (C-C) (C-N) (M-N) 
LPiA 2736 - 1638 1458 1116 - 
[Zn(LPiA)Cl2] 2958 2080 1626 1449 1120 566 
[Zn(LPiA)(NCS)2] 3223 2079 1624 1438 1121 556 
 
In the IR spectrum (of LPiA)  and series of complexes (Figure 3.2.8 and 3.2.9) possess the 
medium and sharp bands at 2.30 cm
−1
 assigned to thev( N-H) stretching vibration; however, 
the strong absorption bands at 1640-1660 cm
−1
 in the complexes are assigned to the 
stretching vibration of the azomethine groups (Yusnita, 2009) The intense absorptions at 
550 cm
−1
 and 580 cm
−1
 for are assigned to the stretching vibration of the v(M-N) groups 
(Mohamed , 2009; Shahabadi, 2010). 
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Figure 3.2.8: IR spectra of [Zn(LPiA)Cl2] 
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Figure 3.2.9: IR spectra of [Zn(LPiA)(NCS)2] 
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Table 3.9: Some of the important IR bands for N1,N1-dimethyl-N2-(1-(pyridin-2-
yl)ethylidene)ethane-1,2-diamine (LNA) and metal complexes. 
Compound (C-H) (NCS/N3) (C=N) (C-C) (C-N) (M-N) 
LNA 2946 - 1639 1435 1103 - 
[Mn(LNA)Cl2] 2838, - 1650 1464 1109 554 
[Ni(LNA)(NCS)2H2O] 2880 2082 1652 1441 1107 515 
[Cu(LNA)(NCS)2] 2979 2066 1659 1446 1144 573 
[Zn(LNA)Cl2] 2852 - 1661 1443 1139 575 
[Zn(LNA)(NCS)2] 2849 2070 1655 1438 1139 577 
[Cd(LNA)(NCS)2]n 2863 2116 1661 1436 1160 559 
 
The characteristic IR stretching frequencies of the ligand (LNA) (Figure 3.2.10) showed 
bands at 2946cm
-1
 assignable to v(C-H) group. The strong band of the azomethine group 
v(C=N) occurred at range of 1642 cm
-1
. In the spectra of the complexes (Figure 3.2.11 - 
13), v(C=N) band signal shifted to the different frequencies indicating that the coordination 
of the ligand to metal ion occurs through nitrogen atom of the imine group (Li, 2011). The 
IR spectrum of the metal complexes are similar to each other, except for some slight 
variations in the shifts and intensities of few vibration peaks caused by different metal(II) 
ions, indicating that the metal complexes had similar structure.  
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Figure 3.2.10: IR spectra of LNA 
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Figure 3.2.11: IR spectra of  [Zn(LNA)Cl2] 
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Figure 3.2.12: IR spectra of [Zn(LNA)(NCS)2] 
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Figure 3.2.13: IR spectra of Preparation of  [Cd(LNA)(NCS)2]n  
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The complex shows characteristic intense IR band for thiocyanate anion at 2093 cm
−1 
(Banerjee, 2005 and Chattopadhyay 2005). The bands in the region 560–505 cm−1 are 
assigned to the v(M-N) vibrations (Deoghoria, 2004; Shahabadi, 2010 and Lakshmi, 2011). 
The presences of hydrates were characterized by the exhibition of bands in the range of 
650–700 cm-1 (Chan et al., 1995).   
 
Table 3.10: Some of the important IR bands for 2-(1-(2-
(dimethylamino)ethylimino)ethyl)phenol (LNH) and metal complexes. 
Compound        
 (C-H) (C=N) (C-C) (C-N) (M-N) (M-O) 
LNH 2944 1642 1445 1183 -  
[Mn(LNH)Br] 3107 1650 1443 1109 524 461 
[Mn(LNH)Cl] 3103 1651 1449 1105 528 461 
[Ni(LNH)Br] 3058 1597 1471 1116 505 422 
[Ni(LNH)Cl] 3050 1605 1474 1112 508 423 
[Cu(LNH)Br] 2943 1605 1436 1102 518 423 
[Cu(LNH)Cl] 3105 1579 1432 1113 526 492 
[Zn(LNH)Br] 3070 1650 1428 1121 557 451 
[Zn(LNH)Cl] 3105 1654 1435 1119 531 433 
 
The IR spectra of the free ligand (LNH) and corresponding complexes exhibit various 
bands in the 400-4000 cm
-1
 region. The v(O-H) stretching frequency of the free ligand is 
found in the 3524.15 cm
-l
 region as expected (Figure 3.2.14).  
82 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 450.0
44.0
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
93.9
cm-1
%T 
3524.15
3465.11
3001.35
2947.10
2907.35
2843.53
2800.60
1978.98
1605.47
1593.89
1550.04
1474.35
1458.74
1436.35
1367.18
1342.76
1303.14
1242.59
1186.07
1156.86
1131.15
1102.37
1071.12
1056.11
1043.15
1024.76
1011.87
991.29
967.81
948.67
884.33
848.86
780.03
749.92
632.17
614.90
598.52
579.99
518.01
473.95
 
Figure 3.2.14: IR spectra of  LNH 
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Figure 3.2.15: IR spectra of [Zn(LNH)Cl] 
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The sharpness of the signals reveals that no intramolecular or intermolecular hydrogen 
bonding interaction occurs (Pouralimardan, 2007). In the spectra of the complexes, v(C=N) 
band signal shifted to the different frequencies ranging from 1650 cm
-1
 to 1575 cm
-1
 
indicating that the coordination of the ligand to metal ion occurs through nitrogen atom of 
the imine group. Two new weak bands appears at lower frequencies range of 505 cm
-1 
and 
560 cm
-1 
assigned to v(M-N) (Bagihalli, 2008), are observed in metal complexes spectra 
also v(M-O) bands in the range of 490 cm
-1
- 420 cm
-1
 are observed in metal complexes 
spectra but not in the spectra of the ligand which is consistent with the formation of the 
desired metal complexes. Nonetheless, the assignment of v(M-O) and v(M-N) bands at the 
lower region seems to be due to the interference with the vibration signals of the ligand.  
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Figure 3.2.16: IR spectra of Preparation of  [Cu2(LNH)2Br2] 
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In general the difference just noted suggests that a fundamental difference in the structure 
of some sort may exist between the two groups of complexes. We considered differences 
caused by the difference of the strength of the v(M-O) and v(M-N) bonding in the various 
complexes. In the complexes like (Figure 3.2.15), the metal ions react primarily with the 
negatively charged oxygen; the v( M-O) bonding plays a more important role than the M-N 
bonding. On the other hand, transition metal ions in group complexes (Figure 3.2.16) react 
primarily with the covalent nitrogen, the v(M-N) bonding is stronger than the v(M-O) 
bonding. That is, the v(M-N) bonding plays a more important role in the complexes. These 
results are in agreement with Pearson's soft-hard acid-base theory. 
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3.3 
1
H-NMR Spectral analysis of the compounds 
The 
1
H and 
13
C NMR spectra of the ligand and complexes (Figure 3.3.1-3.3.8) were 
recorded using a Bruker Apex 600MHz; FT-NMR spectrometers chemical shifts are given 
in δ values (ppm) using TMS as the internal standard. Deuterated dimethylsulphoxide 
(DMSO-d6) was used as solvent. 
 
Table 3.11: 1H-NMR- Spectra for 2-morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine 
(LMA) and metal complexes. 
Compound 
1
H-NMR (600 MHz, δ, DMSO-d6) 
(H
1 
- H
3
) Ar-H 
H
2 
H
3 
H
4 
H
5 
H
6
 H
7
 
LMA 8.59 - 7.73 
8.27, 8.22  
7.73 
3.92 3.83 2.81 2.61 
[Zn(LMA)Br2] 8.78 - 7.89 
8.30, 8.25 
7.89 
3.89 3.85 2.91 2.62 
[Zn(LMA)Cl2] 8.70 - 7.86 
8.28, 8.24 
7.86 
3.92 3.84 2.82 2.61 
[Zn(LMA)I2] 8. 0 - 7.85 
8.28, 8.24 
7.85 
3.92 3.84 2.82 2.61 
[Zn(LMA)(N3)2] 8.6  - 7.93 
8.36, 8.29 
7.93 
3.70 3.68 2.76 2.62 
[Zn(LMA)(NCS)2] 8.69 - 7.96 
8.35, 8.31 
7.96 
3.85 3.81 2.80 2.61 
[Cd(LMA)Br2] 8.76 - 7.87 
8.28, 8.22 
7.87 
3.87 3.83 2.89 2.66 
[Cd(LMA)Cl2] 8 69 - 7.85 
8.29, 8.25 
7.85 
3.93 3.73 2.82 2.55 
[Cd(LMA)(N3)2H2O] 8 68 - 7.85 
8.28, 8.23 
7.85 
3.79 3.74 2.79 2.53 
[Cd2(LMA)2(NCS)4] 8.81 - 7.87 
8.30, 8.25 
7.87 
3.81 3.70 2.80 2.51 
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Figure 3.3.1: 1H-NMR spectra of LMA 
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Figure 3.3.2: 1H-NMR spectra of  [Zn(LMA)Br2] 
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Figure 3.3.3: 1H-NMR spectra of [Cd(LMA)Cl2] 
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Figure 3.3.4: 1H-NMR spectra of  [Cd(LMA)(N3)2(H2O)] 
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Figure 3.3.5: 1H-NMR spectra of LNA 
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Figure 3.3.6: 1H-NMR spectra of [Cd(LNA)(SCN)2]n and n=Polymer 
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Figure 3.3.7: 1H-NMR spectra of [Cd(LNA)Cl2] 
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Figure 3.3.8: 1H-NMR spectra of [Zn(LNA)(SCN)2] 
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3.4 
13
Carbon NMR spectra of the ligands and complexes 
In the 
13
C NMR spectra of the metal complexes, the signal at region of 165.00 ppm-170.00 
can be assigned to the azomethine (C=N) carbon atoms for complexes (Shahabadi et. al., 
2010). Aromatic ring carbon atoms of the ligands were determined in the region of 120.00-
160.00 ppm (Ali et. al., 2008).  
Table 3.12: 
13
C-NMR- Spectra for 2-morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine 
(LMA) and metal complexes. 
Compound 
13
C-NMR (600 MHz, δ, DMSO-d6)
 
C
1
 (C
2 
- C
6
) Ar-C 
C
3
 
C
4 
C
5
 
C
6 
C
7 
C
8 
C
9
 C
10
 C
11
 
LMA 168.54 148.46 - 123.81 63.45 56.09 53.68 
 
44.22 15.83 
[Zn(LMA)Br2] 168.38 146.49 - 124.05 62.88 54.55 52.09 44.12 15.86 
[Zn(LMA)Cl2] 168.54 148.46 - 123.81 63.45 56.09 52.67 44.22 15.82 
[Zn(LMA)I2] 165.22 149.58 - 124.85 65.99 58.62 53.99 - 15.85 
[Zn(LMA)(N3)2] 169.11 148.63 - 124.52 63.90 57.30 53.42 53.11 15.86 
[Zn(LMA)(NCS)2] 168.42 147.85 - 124.47 63.72 56.93 53.07 43.79 15.77 
[Cd(LMA)Br2] 169.18 149.22 - 124.55 65.36 63.94 57.35 53.14 15.91 
[Cd(LMA)Cl2] 166.90 149.13 - 124.42 64.65 53.49 36.00 30.67 15.95 
[Cd(LMA)(N3)2H2O] 164.66 149.02 -  
- 
65.43 58.06 53.44 44.46 15.29 
[Cd2(LMA)2(NCS)4] 165.80 149.24 - 127.68 64.76 53.44 44.36 21.98 15.77 
 
FT-NMR for the coordinated complexes have been summarized in Table 3.1.1 and 3.12. 
The proton NMR chemical shift in the region 8.70-7.80 ppm, were observed for zinc 
complexes respectively and they were assigned to the aromatic ring protons (Ali et. al., 
2008). The other single peaks appeared in the region 2.60 ppm-2.90 ppm respectively were 
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attributed to δ(CH3) indicating the methyl on the carbonyl group in the complexes (Ali et. 
al., 2008). In the 
13
C NMR spectra of the metal complexes, the signal at region of 165.00 
ppm-170.00 can be assigned to the azomethine (C=N) carbon atoms for complexes. 
Aromatic ring carbon atoms of the ligands were determined in the region of 120.00-160.00 
ppm (Ali et. al., 2008).  
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Figure 3.4.1: 13C-NMR spectra of LMA 
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Figure 3.4.2: 13C-NMR spectra of Preparation of  [Zn(LMA)Br2] 
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Figure 3.4.3: 13C-NMR spectra of [Cd(LMA)Cl2] 
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Figure 3.4.4: 13C-NMR spectra of [Cd(LMA)(N3)2(H2O)] 
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Figure 3.4.5: 13C-NMR spectra of [Cd(LMA)Br2] 
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Figure 3.4.6: 13C-NMR spectra of LMH 
 
102 
 
 
Figure 3.4.7: 13C-NMR spectra of  [Zn(LMH)Cl] 
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Figure 3.4.8: 13C-NMR spectra of LNA 
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Figure 3.4.9: 13C-NMR spectra of [Cd(LNA)Cl2] 
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Figure 3.4.10: 13C-NMR spectra of [Cd(LNA)(SCN)2]n 
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 3.5 UV-Visible spectroscopy 
The isolated benzene ring exhibits three characteristic absorptions all assigned to n→π* 
type transitions. The substitutions on the ring by auxochromes and chromophores shift this 
band to the red. The band occurring for the ligands assigned as n→π* transition involving 
molecular orbitals of the C=N chromophore and the benzene. The remainder of the 
observed bands in all the ligands are assigned as n→π* type transitions involving molecular 
orbitals located essentially on the phenolic chromophore. Electron donating group on the 
aromatic ring generally caused a bathochromic shift in all the observed bands. 
The electronic spectra for the free ligands were obtained and showed absorption band in 
two distinct regions. The first region is characteristic for the electronic inter-ligand π→π* 
transitions (Chen, 2010), while the second characteristic wavelength is the inter ligand 
n→π transition of the C=C and C=N chromophores (Creaven, 2010). Another distinct 
region in the complexes is the characteristic for the charge transfer from metal to ligand 
(C.T.M→L) or  ligand to metal charge transfer (LMCT) from the nitrogen atom to the 
transition metal centre (Ali, 2008). The last distinct region is the characteristic for inter 
metal d→d* transition (Ali, 2008). 
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Table 3.13 (a): UV-Visible spectroscopy for 2-morpholino-N-(1-(pyridin-2-yl) ethylidene) 
ethanamine (LMA) with its manganese and cobalt metal complexes. 
Compound Wavelength (nm) 
λmax Absorb. εmax(Lmol-
1
cm
-1
) 
Assignment 
LMA 
  
488 0.250 500.00 n→ π* 
[Mn(LMA)Cl2] 272 2.591 5182.00 C.T. M → L 
603 0.065 130.00 
6
A1 → 
4
E(D) 
813 0.094 188.00  
[Mn(LMA)(NCS)2H2O]     
486 3.470 82.14 
6
A1g → 
4
A1g(E) 
327 23.724 561.61 
6
A1g→
4
T2g(E) 
641 15.397 364.49 
6
A1g → 
4
T1g(E) 
[Co(LMA)Br2]     
356 0.258 516.00 
4
T1g(F)→
4
A2g(F)(ν2) 
603 0.095 190.00 
4
T1g(F) →
4
T1g(D) (ν3) 
 821 0.103 206.00 
4
T1g(F) →
4
T2g(F) (ν1) 
 [Co(LMA)Cl2] 275 20.096 553.00 
4
T1g(F) → 
4
A2g(F) (ν2) 
309 18.730 525.73  
525 3.072 84.59 
4
T1g(F) →
4
T1g(D) (ν3) 
 569 2.765 76.14  
635 3.063 84.35 
4
T1g(F) →
4
T2g(F) (ν1) 
 [Co(LMA)(N3)3] 
 
    
395 3.135 6270.00 
1
A1g→
3
A1g; 
416 3.311 6622.00  
1
A1g→
3
T2g; 
596 1.434 2868.00 
1
Aig→
5
T2g 
[Co(LMA)(NCS)2H2O] 286 0.106 212.00    
4
T1g(F) → 
4
A2g(F) (ν2) 
658 0.127 254.00 
4
T1g(F)→
4
T1g(P) (ν3) 
 668 0.127 254.00  
803 0.106 212.00 
4
T1g(F) → 
4
T2g(F) (ν1) 
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Another factor to be considered in the assignment of these transitions for the free ligand is 
its absence in the spectrum of the corresponding metal(II) complexes as shown in Table 
3.13 (a-c).  The n→π* type transition due the C=N chromophore shifts to different energies 
on complexation. In general, the A+X* type transition due to the aromatic ring undergoes a 
similar smaller shift. The deconvolution of the visible portion of the optical absorption 
spectrum yields extra peaks. 
The electronic spectra of Mn
2+
 ion d
5
 complex Mn(LMA)Cl2 exhibited bands at 272, 603 
and 813 corresponding to 
6
A1 → 
4
E(D) in distorted square bipyramidal geometry.  
Mn(LMA)(NCS)2(H2O) with a transitions of 
6
A1 → 
4
E(D) and 
6
A1 → 
4
T2(D) can be 
attributed to the band at 203, 486, 327, and 641 nm indicates that they have tetrahedral 
geometries. 
The Co(II) ion with its d
7 
configuration for  Co(LMA)Cl2 and Co(LMA)Br2 exhibits 
absorption bands at 275, 309, 525, 569, 635 and 240, 356, 603, 821 nm respectively 
assigned to the transition 
4
T1g(F) → 
4
T2g(P) (V3), 
4
Tlg(F) → 
4
A2g(F)(V2) and 
4
T1g(F) → 
4
T2g(F) 
(V1) in octahedral geometry (Carlin 1968). The Co(II) complex in 
[Co(LMA)(NCS)2(H2O)] exhibited bands at 286, 658, 668, 803 which is attributed to the 
electronic transitions of 4T1g(F) →4A2g(F), 4T1g(F) →4T1g(P). These transitions correspond to Co(II) as a 
distorted octahedral complex. The d-d peaks on the spectrum (Figure 3.5.4) are transitions 
for the d
6
 cobalt(III) complex in [Co(LMA)(N3)3] bands at 240, 395, 416, 596 nm 
attributable to 
1
A1g→
3
A1g; 
1
Aig→
3
T2g and 
1
Aig→
5
T2g Judging by the Tanabe-Sugano 
diagram for d
6 
complexes, the ground state 5D would be split into a 
5
T2g and a 
5
Eg. The 
stronger of the two peaks is most likely the transition between these two states. The weaker 
peak may be a spin-forbidden transition, which cannot be accurately predicted. The 
complex is most likely weak field, with four unpaired electrons.  
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Figure 3.5.1: UV-Visible spectrao of [LMA] 
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Figure 3.5.2: UV-Visible spectra of [Mn(LMA)(NCS)2H2O] 
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Figure 3.5.3: UV-Visible spectra of [Co(LMA)Cl2] 
 
Figure 3.5.4: UV-Visible spectra of Co(LMA)N3 
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Table 3.13 (b): UV-Visible spectroscopy for 2-morpholino-N-(1-(pyridin-2-yl)ethylidene) 
ethanamine (LMA) with its nickel and copper metal complexes. 
Compound Wavelength (nm) 
λmax Absorb. εmax(Lmol-
1
cm
-1
) 
Assignment 
LMA 
  
488 0.250 500.00 n→ π* 
[Ni(LMA)N3]Polymer 279 3.215 6430.00 
3
A2g(F)→ 
3
T2g(F) 
307 1.372 2744.00 
3
A2g(F) →
3
T1g(P) 
628 0.116 232.00  
 712 0.114 228.00 
3
A2g(F) →
3
T1g(P) 
[Ni(LMA)(NCS)2H2O] 276 18.978 445.30  
301 19.021 446.31 
3
A2g(F)→ 
3
T1g(P) 
323 19.361 454.29 
3
A2g(F)→ 
3
T1g(F) 
578 4.166 97.75 
3
A2g(F)→ 
3
T2g(P) 
[Cu(LMA)Br2] 275 19.406 424.96 C.T. M → L  
316 19.916 436.12  
375 17.925 392.52 
2
Eg(D) → 
2
Tg(D) 
636 13.800 302.19 
2
Eg2(D) →
2
b1g(D)( ν1) 
 [Cu(LMA)Cl2] 288 14.596 396.88 C.T. M → L 
309 14.441 392.67 C.T. M → L 
337 14.206 386.28 
2
A1g(D) →
2
B1g(D)( ν3) 
 645 2.889 78.56 
2
Eg(D) →
2
B1g(D)( ν1) 
 [Cu(LMA)(N3)2] 279 16.245 426.49 C.T. M → L 
316 16.293 427.75 C.T. M → L 
689 16.355 429.38 
2
Eg2(D) →
2
B1g(D)( ν2) 
 707 16.469 432.37 
2
Eg2(D) →
2
B1g(D)( ν1) 
 722 16.386 430.19  
[Cu(LMA)(NCS)2] 290 20.401 493.95 C.T. M → L 
315 20.227 489.734 C.T. M → L 
544 5.435 131.59 
2
B2g(D) → 
2
B1g(D) 
591 5.527 133.82  
601 5.550 134.38 
2
E2g(D) →
2
B1g(D)( ν1) 
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Nickel(II), which has d
8 
configuration, commonly exhibits octahedral, square planar and 
tetrahedral coordination geometries. Octahedral geometry generally occurs for nickel(II) 
with a coordination number of six. The electronic spectra of Ni(II) complexes 
[Ni(LMA)(N3)3] showed d-d transitions in the region of 279, 307, 628 and 712. These are 
assigned to the transitions 
3
T1(F) → 
3
A2(F), 
3
T1(F) → 
3
T1(P) and 
3
T1(F) → 
3
T2(F) consistent with 
distorted octahedral geometry (Cotton  and Wilkinson 1998).  The electronic spectra of 
Ni(II) complex [Ni(L2)(NCS)2(H2O)] shows an absorption band at 276, 301, 323 and 578 
corresponding to the transitions 
3
A2g(F) →  
3
T2g(F), 
3
A2g(F)→ 
3
T1g(F) and 
3
A2g(F)→ 
3
T1(P) 
respectively. These assignments correspond for Ni(II) as an octahedral complex with the 
coordinated water molecule complete the geometry (Lever, 1968). 
Cu(II) is usually found in tetragonal coordination environment, with four short equatorial 
bonds and one or two axially elongated bonds due to the Jahn-Teller effect, though some 
four coordinate tetrahedral and planar complexes are known. 
The spectrum of Cu(II) complexes Cu(LMA)Cl2 and Cu(LMA)Br2 showed bands in the 
visible region at 288, 309, 337, 645 nm and 275, 316, 375, 636nm respectively. These are 
assigned to the transitions 
2
B1g→ 
2
B2g, 
2
B1g→ 
2
A1g and 
2
B1g→ 
2
Eg respectively consistent 
with distorted square planar geometry (Shayma, 2010). Also spectra of Cu(LMA)(NCS)2 
complex exhibits three broad bands in the region of 290, 315, 544, 591 and 601,  likewise  
Cu(LMA)(N3)2 complex exhibits bands at 279, 316, 689, 707 and 722 all corresponding to 
the d-d transitions 
2
B1→ 
2
A1, 
2
B1 → 
2
B2 and 
2
B1→ 
2
E (Shayma Shaker, 2009). Therefore, 
these transitions confirmed that the Cu(II) complex has a distorted octahedral geometry. 
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Figure 3.5.5: UV-Visible spectra of [Cu(LMA)Cl2] 
 
Figure 3.5.6: UV-Visible spectra of [Cu(LMA)(NCS)2] 
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Table 3.13 (c): UV-Visible spectroscopy for 2-morpholino-N-(1-(pyridin-2-yl)ethylidene) 
ethanamine (LMA) with its zinc and cadmium metal complexes. 
Compound Wavelength (nm) 
λmax Absorb. εmax(Lmol-1 
cm
-1
) 
Assignment 
LMA 
  
488 0.250 500.00 n→ π* 
[Zn(LMA)Br2] 272 18.145 395.74 π→ π* 
312 16.115 351.46 C.T. M → L  
[Zn(LMA)Cl2] 279 16.570 448.31 π→ π* 
476 0.094 2.54 C.T. M → L  
[Zn(LMA)I2]     
274 8.570 155.11 C.T. M → L  
[Zn(LMA)(N3)2] 289 3.402 6804.00 π→ π* 
492 0.079 158.00 C.T. M → L  
 [Zn(LMA)(NCS)2] 271 17.324 417.59 π→ π* 
315 15.661 377.50 C.T. M → L 
506 0.116 2.79 C.T. M → L 
[Cd(LMA)Br2] 275 3.436 6872.00 π→ π* 
291 3.524 7048.00 C.T. M → L  
[Cd(LMA)Cl2] 279 2.364 4728.00 π→ π* 
403 0.095 19.10 C.T. M → L 
 [Cd(LMA)(N3)2] 272 16.437 367.08 π→ π* 
793 0.464 10.36 C.T. M → L  
 [Cd2(LMA)2(NCS)4] 277 3.436 6872.00 π→ π* 
288 3.524 7048 C.T. M → L  
    
 
Lastly the electronic spectra for Zn(II) and Cd(II) complexes with an electronic 
configuration of d
10
 did not presented any d-d transitions. Instead the absorption bands 
observed were due to charge transfer transitions which suffered from blue shift with hyper 
chromic effect (Shayma, 2009). Coordination of the free ligand to Zn(II) and Cd(II) ions, is 
supported by the appearance of three main bands. Both π →π* and n→π* transition bands 
experience bathochromic shift and appear at the shorter wavelength of 220-250 nm and 
115 
 
280-370 nm respectively. The exhibition of the new LMCT band centered at 3920-580 nm 
is associated with the (LMCT) charge transfer in the spectra of metal complexes supported 
the formation of the zinc(II) and cadmium(II) complexes. All these absorptions for the free 
ligands and their corresponding metal complexes have been fully assigned in [Table 3.1.3 
(c)]. 
In summary the difference observed in the visible spectra of the copper(II), cobalt(II/III), 
manganese(II) and nickel(II) complexes when compared with the spectra of the 
corresponding free ligand is the appearance of a broad low-intensities band in the ranges of 
200-850 nm. This band is attributed to the d-d transitions of the metal(II/III) ions. These 
bands are of low molar absorptivity, E, being Laporte "forbidden" transition. Another 
important characteristic is the absence of the n→π* band. The formation of the metal 
nitrogen bond stabilizes the electron pair on the nitrogen atoms, i.e., the energy of the 
nonbonding n orbital is lowered and the transition occurs at a lower wavelength. The 
absorption peak from approximately 400 nm to 600 nm means that the compound absorbs 
light in the violet-blue-green range. The sum of the non-absorbed, or reflected, wavelengths 
gives the products different colors.  
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Table 3.14: UV-Visible spectroscopy for 2-(1-(2-morpholinoethylimino)ethyl)phenol 
(LMH) and metal complexes. 
Compound Wavelength (nm) 
λmax Absorb. εmax (Lmol
-1
cm
-1
) Assignment 
LMH 321 2.817 5634.00 n→ π* 
396 0.749 1498.00 n→ π* 
[Mn(LMH)Br]     
307 1.068 2136.00 
6
A1→
4
E(D) 
712 0.112 224.00 
6
A1→
4
T2(D) 
[Mn(LMH)Cl] 277 2.672 5344.00  
307 1.068 2056.00 
6
A1→
4
E(D) 
628 0.114 228.00 
6
A1→
4
T2(D) 
728 0.126 252.00  
745 0.078 156.00  
[Ni(LMH)Br]     
372 2.635 5270.00 
3
T1(F) →
3
A2(F) 
597 0.332 664.00 
3
T1(F) → 
3
T1(P) 
778 0.063 126.00 
3
T1(F) → 
3
T2(F) 
[Ni(LMH)Cl]     
574 0.374 748.00 
3
T1(F) → 
3
T1(P) 
845 0.224 448.00 
3
T1(F) → 
3
T2(F) 
[Cu(LMH)Br]     
403 3.215 6430.00 
1
A1g→
1
B1g 
596 0.734 1468.00 
1
A1g→
1
A2g 
778 0.090 180.00 
1
A1g→
1
Eg 
[Cu(LMH)Cl] 
 
279 1.551 3102.00  
358 1.470 2942.00 
1
A1g→
1
B1g 
594 0.231 462.00 
1
A1g→
1
A2g 
726 0.162 324.00 
1
A1g→
1
Eg 
744 0.110 220.00  
[Zn(LMH)Br]     
307 1.068 2136.00 C.T. M → L 
[Zn(LMH)Cl]     
322 0.645 1290.00 C.T. M → L 
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The electronic spectra for the free ligands were obtained and showed absorption band in 
two distinct regions. The first region is characteristic for the electronic inter-ligand π→π* 
transitions (Chen, 2010) while the second characteristic wavelength is the second inter 
ligand n→π transition of the C=C and C=N chromophores (Creaven, 2010).  The electronic 
spectra of Mn(LMH)Cl and Mn(LMH)Br indicate that they have tetrahedral geometries. 
The 
6
A1 → 
4
E(D) and 
6
A1 → 
4
T2(D) can attributed to the band at 307, 628, 745 and  307, 
712 nm respectively (Shayma, 2010). 
 
 
Figure 3.5.7: UV-Visible spectra of  LMH 
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Figure 3.5.8: UV-Visible spectra of  [Ni(LMA)Br] 
 
Figure 3.5.9: UV-Visible spectra of  [Cu(LMA)Cl] 
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Figure 3.5.10: UV-Visible spectra of [Cu(LMA)Br] 
 
Figure 3.5.11: UV-Visible spectra of [Zn(LMA)Cl] 
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The electronic spectra of Ni(II) complexes Ni(LMH)Cl and Ni(LMH)Br showed d-d 
transitions in the region of 265, 574, 845 and 261, 372, 597, 778nm respectively. These are 
assigned to the transitions 
3
T1(F) → 
3
A2(F), 
3
T1(F) → 
3
T1(P) and 
3
T1(F) → 
3
T2(F) consistent with 
tetrahedral geometry (Shayma Shaker 2010; Cotton and Wilkinson 1998). 
The spectrum of Cu(II) complexes Cu(LMH)Cl and Cu(LMH)Br showed three bands in the 
visible region at 594, 726, 744 nm and 403, 596, 778 respectively. These are assigned to the 
transitions 
1
A1g→
1
B1g; 
1
A1g→
1
A2g; 
1
A1g→
1
Eg respectively consistent with distorted square 
planar geometry (Shaker, 2010). Lastly the electronic spectra for Zn(II) and Cd(II) 
complexes with an electronic configuration of d
10
 did not presented any (d-d) transitions. 
Instead the absorption bands observed were due to charge transfer transitions which 
suffered from blue shift with hyper chromic effect (Shayma, 2009). All these absorptions 
for the free ligands and their corresponding metal complexes have been fully assigned in 
(Table 3.14). 
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Table 3.15: UV-Visible spectroscopy for N1,N1-dimethyl-N2-(1-(pyridin-2-
yl)ethylidene)ethane-1,2-diamine (LNA) and metal complexes. 
Compound Parameters 
λmax Absorb. εmax (Lmol
-1 
cm
-1
) 
Assignment 
LNA     
487 0.058 116.00 n→ π* 
[Mn(LNA)Cl2] 272 2.591 5182.00 C.T. M → L 
603 0.065 130.00 
6
A1g  → 
4
A1g 
813 0.094 188.00 
6
A1g  → 
4
Eg, 
4
A1g 
[Ni(LNA)(NCS)2H2O] 
 
270 2.061 4042.00 
3
A2g(F) → 
3
T1g(P) 
364 0.900 1800.00 
3
A2g(F) → 
3
T1g(F) 
807 0.109 218.00 
3
A2g(F) → 
3
T2g(F) 
[Cu(LNA)(NCS)2] 281 2.696 5392.00 C.T. M → L 
643 0.125 250.00 2E2g(D) → 2B1g(D) 
 [Zn(LNA)Cl2]     
284 3.675 7350.00 C.T. M → L 
603 0.084 168.00 C.T. M → L 
[Zn(LNA)(NCS)2] 280 2.285 4570.00 π→ π* 
606 0.064 128.00 C.T. M → L 
[Cd(LNA)Cl2]     
279 0.285 570.00 C.T. M → L 
407 0.089 178.00 C.T. M → L 
[Cd(LNA)(NCS)2]n 280 2.767 5534.00 π→ π* 
467 0.055 110.00 C.T. M → L 
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The electronic spectra of Mn
2+
 ion Mn(LNA)Cl2 exhibited bands at 272, 603 and 813 
corresponding to   
6
A1 → 
4
E(D) in distorted square bipyramidal geometry.  
Mn(LMA)(NCS)2(H2O) with a transitions of 
6
A1 → 
4
E(D) and 
6
A1 → 
4
T2(D) can be 
attributed to the band at 203, 486, 327, and 641 nm indicates that they have tetrahedral 
geometries. The electronic spectra of Ni(II) complexes Ni(LMA)(NCS)2 showed d-d 
transitions in the region of 270, 364 and 807. These are assigned to the transitions 
3
A2g(F) 
→ 3T1g(P), 
3
A2g(F) → 
3
T1g(F) and 
3
A2g(F) → 
3
T2g(F) consistent with distorted octahedral 
geometry (Lever, 1968). The spectrum of Cu(II) complex Cu(LNA)(NCS)2 complex 
exhibits broad bands in the region of 28190 and 643 corresponding to the d-d transition 2e2g 
(D) → 2b1g(D). Therefore, these transitions confirmed that the Cu(II) complex has a distorted 
square pyramidal geometry. 
Coordination of the free ligand to Zn(II) and Cd(II) ions, is supported by the appearance of 
three main bands. Both π →π* and n→π* transition bands experience bathochromic shift 
and appear at the shorter wavelength of 220-250 nm and 280-370 nm respectively. The 
exhibition of the new LMCT band centered at 392-580 nm is associated with the (LMCT) 
charge transfer in the spectra of metal complexes supported the formation of the Zinc(II) 
and Cadmium(II) complexes. All these absorptions for the free ligands and their 
corresponding metal complexes have been fully assigned in (Table 3.15). 
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Figure 3.5.12: UV-Visible spectra of  (LNA) 
 
      
 
Figure 3.5.13: UV-Visible spectra of  [Cu(LNA)(NCS)2] 
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Table 3.16: UV-Visible spectroscopy for 2-(1-(2-(dimethylamino)ethylimino)ethyl)phenol 
(LNH) and metal complexes. 
 
Compound λmax Absorb. εmax (Lmol-1 cm-1) Assignment 
LNH 272 3.612 7224.00 π→ π* 
364 1.823 3646.00 n→ π* 
[Cu2(LNH)2Br2]     
276 3.612 7224.00 C.T. M → L 
307 1.379 2758.00 C.T. M → L 
364 2.107 4214.00 
2
B2g(D) → 
2
B1g(D) 
606 0.166 332.00  
726 0.147 294.00 
2
E2g (D) →
2
B1g(D) 
 
743 0.095 190.00  
778 0.090 180.00  
 
 
The electronic spectrum of Cu2(LNH)2Br2 presented bands in the region of  276, 307, 364, 
606, 726, 743 and 778 which correspond to the transition of 
2
B2g(D) → 
2
B1g(D) and 2E2g (D) 
→2B1g(D). All these absorptions for the free ligand and corresponding metal complex have 
been fully assigned in (Table 3.16). 
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Figure 3.5.14: UV-Visible spectra of LNH 
 
Figure 3.5.15: UV-Visible spectra of [Cu2(LNH)2Br2. H2O] 
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3.6 X-ray crystallographic structures of the complexes 
3.6.1 Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene] ethanamineκ 
3N,N’,N”}Mn(II) 
 
Figure 3.6.1: Crystal structure for [Mn(LMA)Cl2] 
The brown colored crystal compound is isostructure to the recently reported Cd(II) complex 
(Ikmal Hisham, 2010). The Mn(II) ion is five-coordinated by the Schiff base 2-morpholino-
N-[1-(2-pyridyl)ethylidene]ethanamine and two Cl atoms in a distorted square-pyramidal 
environment (τ = 0.22). The Mn-Cl and Mn-N bond lengths in the present structure is 
similar to those in [MnCl2(C24H25N3)], the structurally closest Mn(II) complex (Schmiege, 
2007). In the crystal structure, intermolecular C-H···Cl hydrogen bonds link the adjacent 
molecules into a three-dimensional network. An intramolecular C-H···Cl hydrogen bonding 
has also been observed. 
In summary, the Mn(II) ion is pentacoordinated in a distorted square-pyramidal geometry. 
The coordination environment is defined by the N,N’,N”-tridentate Schiff base ligand and 
one Cl atom in the basal positions and one Cl atom in the apical position. 
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3.6.2 Aqua{2-morpholino-N-[1-(2-pyridyl)-ethylidene]ethanamine-κ3N,N’,N”}-bis 
(thiocyanato-κN)manganese(II) 
 
 
Figure 3.6.2: Crystal structure for [Mn(LMA)(NCS)2(H2O)] 
The crystal of the title compound is iso structural with the previously reported Co(II) 
complex (Gwaram, 2011). The metal center is coordinated by the N,N',N"-tridentate Schiff 
base, two N-donor thiocyanates and one water O atom in a distorted octahedral geometry. 
In the crystal, the molecules are linked through O-H···O and O-H···S hydrogen bonds into 
layers parallel to the ac plane and these are connected into a three-dimensional network via 
C-H···S interactions. Moreover, intramolecular C-H···O hydrogen bonding is observed. 
In summary, the Schiff base acts as an N,N’,N"-tridentate ligand, forming two five-
membered chelating rings with the Mn(II) atom. The distorted octahedral geometry around 
the metal atom is completed by two cis-positioned N-bound thiocyanate ligands and one 
water molecule. In the crystal, adjacent molecules are linked through O-H---O, O-H---S 
and C-H---S hydrogen bonds into a three-dimensional supra-molecular structure (Figure 
3.6.3). An intramolecular C-H---O hydrogen bond also occurs. 
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Figure 3.6.3: Packing structure for [Mn(LMA)(NCS)2(H2O)] 
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Table 3.17: Crystal data and structure refinement for  [Mn(LMA)Cl2] & 
[Mn(LMA)(NCS)2(H2O)] complexes 
Identification code  [Mn(LMA)Cl2] [Mn(LMA)(NCS).H2O] 
Empirical formula  C13H19Cl2MnN3O  C15H21MnN5O2S2  
Formula weight  359.15  422.43  
Temperature/K  373(2)  373(2)  
Crystal system  monoclinic  monoclinic  
Space group  P21/n  P21/c  
a/Å  9.6117(6)  7.1837(13)  
b/Å  13.8507(8)  22.408(4)  
c/Å  12.1330(7)  12.112(2)  
α/°  90.00  90.00  
β/°  106.7380(10)  91.149(3)  
γ/°  90.00  90.00  
Volume/Å
3
  1546.82(16)  1949.3(6)  
Z  4  4  
ρcalcmg/mm
3
  1.542  1.439  
m/mm
-1
  1.197  0.910  
F(000)  740.0  876.0  
Crystal size/mm
3
  0.40 × 0.35 × 0.25  0.19 × 0.16 × 0.08  
2Θ range for data collection  4.58 to 55°  3.64 to 54.58°  
Index ranges  -12 ≤ h ≤ 12, -16 ≤ k ≤ 17, -
15 ≤ l ≤ 15  
-9 ≤ h ≤ 9, -28 ≤ k ≤ 15, -13 
≤ l ≤ 15  
Reflections collected  15613  12085  
Independent reflections  3543[R(int) = 0.0188]  4358[R(int) = 0.0403]  
Data/restraints/parameters  3543/0/182  4358/2/233  
Goodness-of-fit on F
2
  1.108  1.040  
Final R indexes [I>=2σ (I)]  R1 = 0.0195, wR2 = 0.0520  R1 = 0.0378, wR2 = 0.0842  
Final R indexes [all data]  R1 = 0.0206, wR2 = 0.0526  R1 = 0.0602, wR2 = 0.0964  
Largest diff. peak/hole/e Å
-3
  0.33/-0.23  0.38/-0.47  
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3.6.3 Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamineκ3N,N’,N”} 
cobalt(II) 
 
Figure 3.6.4: Crystal structure for [Co(LMA)Cl2] 
The reddish brown colored crystal compound is isostructural to the Mn(II) complex (Ikmal 
Hisham, 2010). The Co(II) ion is five-coordinated by the Schiff base 2-morpholino-N-[1-
(2-pyridyl)ethylidene]ethanamine and two Cl atoms in a distorted square-pyramidal 
environment (τ = 0.21). The Co-Cl and Co-N bond lengths in the present structure is similar 
to those in [MnCl2(C24H25N3)], the structurally closest Mn(II) complex (Schmiege, 2007). 
In the crystal structure, intermolecular C-H···Cl hydrogen bonds link the adjacent 
molecules into a three-dimensional network. An intramolecular C-H···Cl hydrogen bonding 
has also been observed. 
In summary, the Co(II) ion is pentacoordinated in a distorted square-pyramidal geometry. 
The coordination environment is defined by the N,N’,N”-tridentate Schiff base ligand and 
two Cl atoms that completed the five coordinated geometry. 
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3.6.4. Aqua{2-morpholino-N-[1-(2-pyridyl)-ethylidene]ethanamine-κ3N,N’,N”}-bis 
(thiocyanato-κN)cobalt(II) 
 
Figure 3.6.5: Crystal structure for [Co(LMA)(NCS)2(H2O)] 
The crystal structure of the Co(II) complex is isostructural with the previously reported 
Ni(II) complex (Gwaram, 2011). The Schiff base, prepared in situ, acts as an N,N',N''-
tridentate ligand towards the Co(II) ion to form two five membered chelate rings with the 
metal atom. Two cis-located isothiocyanate and one water molecule complete a distorted 
octahedral geometry around the Co(II) center. A similar arrangement was observed in a 
related Co(II) complex (Sun, 2007). In the crystal, the adjacent molecules are connected via 
O-H···O, O-H···S, C-H···S hydrogen bonds into infinite layers parallel to the ac plane. The 
layers are further linked into a three-dimensional polymeric structure through an S···S 
interaction [3.5546 (18) Å] between S1 and S2 of the symmetry related molecule at –x+1, y 
- 1/2, -z + 3/2. 
In summary, the Co(II) ion is six-coordinated by the N,N’,N”-tridentate Schiff base, the N 
atoms of two thiocyanate ligands and one water molecule in a distorted octahedral 
geometry. Intramolecular C-H---N and C-H---O hydrogen bonds occur (Figure 3.6.6). 
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Figure 3.6.6: Packing Structure Co(LMA)(NCS)2(H2O) along c-axis 
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3.6.4 Cobalt(III)tris(azido-κN){2-Morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-
κ3N,N’,N”} 
 
 
Figure 3.6.7: Crystal structure for [Co(LMA)(N3)3] 
The crystal structure of Co(III) compound as depicted in (Figure 3.6.7) and selected bond 
lengths and angles are listed in Table 3.19. In the compound, the Schiff base molecule acts 
as an N,N’,N”-tridentate ligand to form two five-membered chelate rings with the Co(III) 
atom. Three meridionally arranged nitrogen atoms from three azide ligands complete a 
distorted octahedral geometry around the metal center. The distortion from an ideal 
octahedron is evident from the cisoid [82.45(5)-96.03(5)⁰] and transoid [168.62(5)-
177.62(5)⁰] angles. The azide groups are almost linear [175.65(15)-179.22(14)⁰] whereas 
the Co-N-N-N linkages are significantly bent [114.33(9)-123.13(9)⁰]. The Co-N bond 
lengths are similar to those observed in a similar structure (Rahman, 2005). 
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Table 3.18: Crystal data and structure refinement for  cobalt complexes 
Identification code  [Co(LMA)Cl2] [Co(LMA)(NCS)] [Co(LMA)(N3)3] 
Empirical formula  C13H19Cl2CoN3O  C16H21ClCoN5O2S2  C13H19CoN12O  
Formula weight  363.14  438.43  418.33  
Temperature/K  373(2)  373(2)  373(2)  
Crystal system  monoclinic  monoclinic  monoclinic  
Space group  P21/n  P21/c  P21/c  
a/Å  9.6620(5)  7.1554(3)  10.0164(2)  
b/Å  13.6941(7)  22.1870(10)  12.6221(3)  
c/Å  11.9927(6)  12.1297(5)  13.7134(3)  
α/°  90.00  90.00  90.00  
β/°  107.0790(10)  91.115(3)  91.1770(10)  
γ/°  90.00  90.00  90.00  
Volume/Å
3
  1516.81(13)  1925.31(14)  1733.39(7)  
Z  4  4  4  
ρcalcmg/mm
3
  1.590  1.513  1.603  
m/mm
-1
  1.482  1.129  1.024  
F(000)  748.0  908.0  864.0  
Crystal size/mm
3
  0.32 × 0.25 × 0.15  0.18 × 0.10 × 0.08  0.27 × 0.21 × 0.18  
2Θ range for data collection  4.64 to 54°  3.68 to 51.98°  4.06 to 54°  
Index ranges  
-12 ≤ h ≤ 11, -16 ≤ k 
≤ 17, -12 ≤ l ≤ 15  
-8 ≤ h ≤ 8, -27 ≤ k ≤ 
26, -14 ≤ l ≤ 14  
-12 ≤ h ≤ 12, -16 ≤ k 
≤ 15, -17 ≤ l ≤ 17  
Reflections collected  7632  11529  15495  
Independent reflections  
3291[R(int) = 
0.0229]  
3782[R(int) = 
0.0622]  
3783[R(int) = 
0.0199]  
Data/restraints/parameters  3291/0/182  3782/2/233  3783/0/245  
Goodness-of-fit on F
2
  1.028  1.049  1.102  
Final R indexes [I>=2σ (I)]  
R1 = 0.0277, wR2 = 
0.0584  
R1 = 0.0579, wR2 = 
0.1352  
R1 = 0.0223, wR2 = 
0.0545  
Final R indexes [all data]  
R1 = 0.0350, wR2 = 
0.0613  
R1 = 0.0842, wR2 = 
0.1480  
R1 = 0.0253, wR2 = 
0.0557  
Largest diff. peak/hole / e Å
-3
  0.32/-0.23  0.87/-0.60  0.34/-0.28  
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3.6.5 Aqua{2-morpholino-N-[1-(2-pyridyl)-ethylidene]ethanamine-κ3N,N’,N”}-bis 
(thiocyanato-κN)nickel(II) 
 
Figure 3.6.8: Crystal structure for [Ni(LMA)(NCS)2(H2O)] 
The mixed-ligand nickel(II) complex was obtained by following a similar synthetic 
procedure as for its analogous copper(II) complex (Gwaram, 2011). However, compared to 
the square-pyramidal environment around the Cu(II) ion, afforded by the tridentate Schiff 
base and the N atoms of two SCN
-
, the Ni(II) ion is coordinated by one additional water 
ligand to have an octahedral geometry. 
 
Figure 3.6.9: Packing structure for [Ni(LMA)(NCS)2(H2O)] 
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 The Ni-N and Ni-O bond lengths in this complex are comparable to those in the similar 
structures (Chiumia, 1999; Zhao, 2008). In the crystal, the adjacent molecules are linked 
together through O-H···S, O-H···O and C-H···S hydrogen bonds into layers parallel to the 
ac plane (Figure 3.6.9). An S···S interaction [3.5276 (7) Å] between S1 and S2 of the 
symmetry related molecule at -x, y + 1/2, -z + 3/2, connects the layers into a three-
dimensional network. Intramolecular C-H···N and C-H···O hydrogen bonding are also 
observed. 
In summary, the Ni(II) ion is six-coordinated by the N,N’,N”-tridentate Schiff base, the N 
atoms of two thiocyanate ligands and one water O atom in a distorted octahedral geometry. 
 
3.6.6 Nickel(II)poly(azido-κN){2-Morpholino-N-[1-(2-pyridyl)ethylidene] ethanamine-
κ3N,N’,N”} [Ni2(LMA)2(N3)2(H2O)2] 
 
 
Figure 3.6.10: Crystal structure for [Ni2(LMA)2(N3)2(H2O)2] 
 
137 
 
In the compound, the Ni(II) atom is octahedrally coordinated by the N,N’,N”-tridentate 
Schiff base ligand and one terminal azide N atom. In the crystal, adjacent Ni(II) ions are 
linked by the azide N:N-bridges into polymeric chains along the c axis. 
The azide ions act as either bridging or terminal ligands. However, different from the 
doubly bridged dimeric structure of the former, in the present structure the bridging azide 
ligands singly bridge the adjacent metal centers into infinite chains along the c axis. Within 
this coordination polymer, Two azide N:N-bridges, one terminal azide N atom and the 
Ni(II) ion is coordinated by one additional water ligand to have an octahedral geometry. 
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Table 3.19: Crystal data and structure refinement for [Ni(LMA)(NCS)(H2O)] and 
[Ni2(LMA)2(N3)2(H2O)2] complexes 
Identification code  [Ni(LMA)(NCS)(H2O)] [Ni2(LMA)2(N3)2(H2O)2] 
Empirical formula  C15H21N5NiO2S2  C13HN9ONi  
Formula weight  426.20  357.94  
Temperature/K  373(2)  373(2)  
Crystal system  monoclinic  triclinic  
Space group  P21/c  P1  
a/Å  7.18810(10)  10.4169(4)  
b/Å  21.9708(3)  15.0746(6)  
c/Å  12.1438(2)  20.7751(9)  
α/°  90.00  90.00  
β/°  91.4120(10)  90.00  
γ/°  90.00  90.00  
Volume/Å
3
  1917.27(5)  3262.3(2)  
Z  4  8  
ρcalcmg/mm
3
  1.477  1.458  
m/mm
-1
  1.248  1.209  
F(000)  888.0  1424.0  
Crystal size/mm
3
  0.35 × 0.32 × 0.22  0.19 × 0.11 × 0.05  
2Θ range for data collection  5 to 50.5°  1.96 to 60.08°  
Index ranges  
-8 ≤ h ≤ 8, -26 ≤ k ≤ 26, -14 ≤ 
l ≤ 14  
-14 ≤ h ≤ 14, -20 ≤ k ≤ 20, -29 
≤ l ≤ 28  
Reflections collected  14240  34671  
Independent reflections  3474[R(int) = 0.0228]  30044[R(int) = 0.0553]  
Data/restraints/parameters  3474/4/233  30044/3/753  
Goodness-of-fit on F
2
  1.093  1.828  
Final R indexes [I>=2σ (I)]  R1 = 0.0254, wR2 = 0.0568  R1 = 0.1362, wR2 = 0.3318  
Final R indexes [all data]  R1 = 0.0288, wR2 = 0.0582  R1 = 0.1667, wR2 = 0.3515  
Largest diff. peak/hole /e Å
-3
  0.45/-0.36  8.48/-2.13  
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3.6.7. Dichlorido{2-(morpholin-4-yl)-N-[1-(pyridin-2-yl)ethylidene]ethanamineκ3, 
N’,N”} copper(II)monohydrate 
 
 
Figure 3.6.11: Crystal structure for [Cu(LMA)Cl2 .H2O] 
 
The asymmetric unit of the title compound consists of a copper(II) complex and one 
molecule of water. Like the CdCl2 complex of the Schiff base, 2-morpholino-N-[1-(2-
pyridyl)ethylidene]ethanamine, (Ikmal Hisham, 2010) the metal ion in the present structure 
is five-coordinated by the N,N',N"-tridentate Schiff base ligand and two Cl atoms in a 
distorted square-pyramidal geometry, the τ value (Addison, 1984) being 0.15. The Cu-Cl 
and Cu-N inter atomic distances are comparable to the values reported in the literature 
(Saleh Salga, 2010; Wang, 2009). In the crystal, the adjacent metal complexes and water 
molecules are linked into a three-dimensional network via O-H···Cl, C-H···Cl and C-H···O 
interactions. In addition, intramolecular C-H···Cl hydrogen bonding is observed. 
In summary the crystal system of the complex, tridentate Schiff base ligand and the two Cl 
atoms complete distorted square-pyramidal coordination geometry around the Cu(II) ion in 
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which the three N atoms and one Cl atom are located in the basal plane and the other Cl 
atom is at the apical position. In the crystal, O-H---Cl hydrogen bonds link the complex 
molecules and the uncoordinated water molecules into infinite chains along the a-axis. The 
chains are further connected into a three-dimensional network via C-H---O and C-H---Cl 
interactions. 
3.6.8 2-Morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-κ3,,N’,N”-bis(thiocyanato-
κN) copper(II) 
 
 
Figure 3.6.12: Crystal structure for [Cu(LMA)(NCS)2] 
The title compound is a mixed-ligand copper(II) complex with isothiocyanate and the 
Schiff base 2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine. The geometry of the 
complex is slightly distorted square-pyramidal (τ = 0.05) with the N,N',N"-tridentate Schiff 
base and one NCS ligand at the basal positions, while the apical position is occupied by a 
second NCS ligand. This arrangement has been observed in some other mixed-ligand 
copper(II) complexes (Drew, 2009; You, 2006; Yue, 2005). In the crystal structure, the C-
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H···N, C-H···O and C-H···S interactions within the range for normal hydrogen bonds link 
the adjacent molecules into layers parallel to the ac plane (Fig. 2). An intramolecular C-
H···N hydrogen bonding is also observed. Moreover, the aromatic rings of each two 
molecules related by the symmetry -x + 2, -y, -z + 1, are arranged in an anti parallel manner 
with centroid-centroid separation of 3.9412 (9) Å, indicative of a weak π–π interaction. 
In summary, the Cu(II) ion is five-coordinated by the N,N’,N”-tridentate Schiff base and 
the N atoms of two isothiocyanate ligands in a square pyramidal geometry. In the crystal, 
C-H---N, C-H---O and C-H---S interactions link adjacent molecules into layers parallel to 
the ac plane. 
 
    
Figure 3.6.13: Packing structure for along c-axis for [Cu(LMA)(NCS)2] 
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Table 3.20: Crystal data and structure refinement for [Cu(LMA)(NCS)2] 
Identification code   [Cu(LMA)(NCS)2] 
Empirical formula  C15H19CuN5Os2  
Formula weight  413.01  
Temperature/K  373(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.69120(10)  
b/Å  14.0350(2)  
c/Å  12.2530(2)  
α/°  90.00  
β/°  92.2030(10)  
γ/°  90.00  
Volume/Å
3
  1837.22(4)  
Z  4  
ρcalcmg/mm
3
  1.493  
m/mm
-1
  1.428  
F(000)  852.0  
Crystal size/mm
3
  0.41 × 0.39 × 0.08  
2Θ range for data collection  4.42 to 54°  
Index ranges  -13 ≤ h ≤ 13, -17 ≤ k ≤ 17, -15 ≤ l ≤ 15  
Reflections collected  16491  
Independent reflections  4007[R(int) = 0.0242]  
Data/restraints/parameters  4007/2/218  
Goodness-of-fit on F
2
  1.078  
Final R indexes [I>=2σ (I)]  R1 = 0.0234, wR2 = 0.0592  
Final R indexes [all data]  R1 = 0.0271, wR2 = 0.0607  
Largest diff. peak/hole / e Å
-3
  0.37/-0.26  
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3.6.9 Dibromido{2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamineκ3,N,N’,N”} 
zinc(II) 
 
 
Figure 3.6.14: Crystal structure for [Zn(LMA)Br2] 
The compound [Zn(LMA)Br2] was obtained upon the reaction of 2-morpholino-N-[1-(2-
pyridyl) ethylidene]ethanamine with Zn(II) ion in the presence of potassium bromide. 
Similar to the structure of the analogous ZnCl2 complex (Hisham, 2011), the metal center is 
five-coordinated by the N,N',N"-tridentate Schiff base ligand and two halogen atoms. The 
geometry of the complexes can be determined by using the index τ = (β-α)/60, where β is 
the largest angle and α is the second one around the metal center. For an ideal square-
pyramid τ is 0, while it is 1 in a perfect trigonal-bipyramid (Addison, 1984). The τ value in 
the present structure is calculated to be 0.30, indicative of a distorted square-pyramidal 
geometry. The Zn-Br and Zn-N bond lengths in the complex are in agreement with the 
values reported in the literature (You, 2006; Zakrzewski, 1970).  
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In summary, the Zn(II) ion in the compound, is five-coordinated by the N,N',N"-tridentate 
Schiff base ligand and two Br atoms in a distorted square-pyramidal geometry. The three 
Zn-N bond lengths are given as Zn(1)-N(1) 2.243(3), Zn(1)-N(2) 2.076(2), Zn(1)-N(3) 
2.331(2), and two Zn–Br bond lengths are Zn(1)-Br(1) 2.4036(4) (18), Zn(1)-Br(2) 
2.4172(4). In the crystal, intermolecular C---H...Br hydrogen bonds link the adjacent 
molecules into infinite chains along the crystallographic axis. An intramolecular C---H...Br 
interaction is also observed. 
3.6.10 Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamineκ3N,N’,N”} 
zinc(II) 
 
 
Figure 3.6.15: Crystal structure for [Zn(LMA)Cl2] 
The title compound is isostructural with the analogous Cd(II) complex (Ikmal Hisham, 
2010). The Schiff base, 2-morpholino- N-[1-(2-pyridyl)ethylidene]ethanamine and two Cl 
atoms coordinate the Zn(II) ion in a distorted square-pyramidal geometry (τ = 0.22). The 
Zn-Cl and Zn-N bond lengths in the structure are in agreement with the values reported in 
the literature (Chattopadhyay, 2009; Sun, 2005). In the crystal structure, intermolecular C-
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H···Cl hydrogen bonding and long range C-H···O and C-H···Cl interactions link the 
adjacent molecules into a three-dimensional network. An intramolecular C-H···Cl 
hydrogen bonding has also been observed. 
In summary, the Schiff base ligand acts as an N,N’,N”-tridentate chelating agent, making 
two five-membered rings with the Zn(II) ion. The metal atom is five-coordinated by the 
Schiff base ligand and two Cl atoms in a distorted square-pyramidal geometry. 
3.6.11 Diiodido{2-(morpholin-4-yl)-N-[1-(2-pyridyl)ethylidene]ethanamineκ3N,N’,N”} 
zinc(II) 
 
Figure 3.6.16: Crystal structure for [Zn(LMA)I2] 
The above compound was obtained via the complexation of Zn(II) ion with the in situ 
prepared Schiff base, 2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine, and two iodide 
ions. Similar to what was observed in an analogous ZnCl2 complex (Ikmal Hisham, 2011), 
the Schiff base acts as an N,N',N''-tridentate chelate ligand, along with two halide ligands, 
make a distorted square-pyramidal geometry around the metal ion τ = 0.24, (Addison, 
1984). The Zn-I and Zn-N interatomic distances (Table 1) are comparable to the values 
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reported for similar structures (Drew & Hollis, 1978; Yousefi, 2010). In the crystal, a pair 
of the molecules, related by a symmetry operation -x + 1, -y + 2, -z + 2, are linked through 
C-H···O hydrogen bonds into a centrosymmetric dimer (Table). 
In summary, the compound, the Zn(II) ion is five coordinated in a distorted square-
pyramidal geometry, in which the basal plane is defined by three N atoms from the Schiff 
base ligand and one iodide ion. A second iodide ligand, situated in the apical position, 
completes the coordination geometry. 
2.6.12 2-Morpholino-N-[1-(2-pyridyl)-ethylidene]ethanamine-κ3N,N’,N”-
bis(thiocyanato-κN) zinc(II) 
 
 
Figure 3.6.17: Crystal structure for [Zn(LMA)(NCS)2] 
Owing to the presence of several donor atoms and the flexibility of the morpholine ring, 
this Schiff base can, in principle, show ambidentate coordination behavior toward metal 
ions. On the other hand, thiocyanate is known to bind metal ions in different modes: N-
donor, S-donor or N:S-bridging mode. The title compound is a mixed-ligand zinc(II) 
complex with the two ambidentate ligands. In the crystal, two geometrically slightly 
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different molecules exist. The weighted root mean square (r.m.s.) fit for the superposition 
of the non-H atoms in both molecules is 1.5267 Å. The Schiff base ligand in the molecules 
acts as an N,N',N"-tridentate chelate, along with the N atoms of two isothiocyanate ligands 
this makes pentacoordinated zinc(II) complexes. Similar coordination environment has 
been reported in related mixed-ligand zinc(II) complexes (Cai, 2009; Chen, 2005). The 
geometry of the two present complexes can be determined by using the index τ = (β-α)/60, 
where β is the largest angle and α is the second one around the metal center. For an ideal 
square-pyramid τ is 0, while it is 1 in a perfect trigonal-bipyramid (Addison, 1984). The τ 
values in the two molecules are 0.14 for the Zn1 complex and 0.33 for the Zn2 complex, 
indicating distorted square-pyramidal geometries. The NCS groups are almost linear [178.3 
(2)° and 179.9 (3)° in the Zn1 complex; 179.1 (2)° and 179.1 (2)° in the Zn2 complex], 
whereas the Zn-N-CS linkages are somewhat bent [158.34 (19)° and 165.19 (18)° in the 
Zn1 complex; 145.54 (17)° and 169.54 (18)° in the Zn2 complex]. The morpholine rings in 
both molecules adopt a chair conformation. The crystal structure is stabilized by 
intermolecular C-H···S and an intramolecular C-H···N hydrogen bond (Table). 
In summary, the asymmetric unit of the title compound contains two crystallographically 
independent molecules. In each molecule, the Zn(II) ion is five-coordinated by the N,N’,N"-
tridentate Schiff base and the N atoms of two thiocyanate ligands in a distorted square-
pyramidal geometry. The two molecules differ mainly in the deviations from the ideal 
geometry, with τ values of 0.14 and 0.33. In the crystal, intermolecular C-H---S hydrogen 
bonds are observed. An intramolecular C-H---N hydrogen bond occurs in one of the 
independent molecules. 
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3.6.13 2-Morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-κ3N,N’,N”}bis(azido-
κN)zinc(II) 
 
Figure 3.6.18: Crystal structure for [Zn(LMA)(N3)2] 
The compound above is a square-pyramidal zinc(II) complex in which the metal center is 
coordinated by the N,N’,N”-tridentate Schiff base and the N atoms of two azide ligands. 
The CH2N(CH3)2 fragment is disordered over two sets of sites in a 0.53(4):0.471 (4) ratio. 
Like the structure of the zinc(II) thiocyanate complexes of similar Schiff bases (Cai, 2009); 
Chen, 2005), the present structure is a mononuclear square-pyramidal metal complex, the τ 
value being 0.35. In contrast, the cadmium(II) thiocyanate complex of the same Schiff base 
(Gwaram, 2011), showed a polymeric structure wherein the metal centers are linked by the 
N:N-bridging azide ligands. In the crystal structure of the title compound, C---H...N 
interactions connect a pair of molecules, related by symmetry −x+1, −y, −z, around a center 
of inversion. The zinc atom is bonded to three donor nitrogen atoms of the ligand and two 
azides bonded through the nitrogen atoms ending. 
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Table 3.21: Crystal data and structure refinement for zinc(II) complexes 
Identification code  [Zn(LMA)Br2] [Zn(LMA)Cl2] [Zn(LMA)I2] 
Empirical formula  C13H19Br2N3OZn  C13H19Cl2N3OZn  C13H19I2N3OZn  
Formula weight  458.50  369.58  552.48  
Temperature/K  373(2)  373(2)  373(2)  
Crystal system  monoclinic  monoclinic  triclinic  
Space group  P21/n  P21/n  P-1  
a/Å  9.8290(2)  9.5737(12)  8.8874(3)  
b/Å  14.0218(2)  13.7064(17)  10.3117(4)  
c/Å  12.1371(2)  12.0766(15)  10.3643(4)  
α/°  90.00  90.00  68.881(2)  
β/°  106.9180(10)  106.643(2)  81.959(2)  
γ/°  90.00  90.00  66.399(2)  
Volume/Å
3
  1600.35(5)  1518.3(3)  811.91(5)  
Z  4  4  2  
ρcalcmg/mm
3
  1.903  1.617  2.260  
m/mm
-1
  6.527  1.968  5.314  
F(000)  904.0  760.0  524.0  
Crystal size/mm
3
  0.33 × 0.25 × 0.11  0.35 × 0.21 × 0.05  0.17 × 0.13 × 0.09  
2Θ range for data 
collection  
4.56 to 54°  4.6 to 52°  4.22 to 53.98°  
Index ranges  
-12 ≤ h ≤ 12, -17 ≤ k ≤ 
17, -14 ≤ l ≤ 15  
-11 ≤ h ≤ 11, -16 ≤ k ≤ 
16, -14 ≤ l ≤ 14  
-11 ≤ h ≤ 11, -13 ≤ k ≤ 
13, -13 ≤ l ≤ 13  
Reflections collected  12535  13693  7292  
Independent 
reflections  
3496[R(int) = 0.0351]  2979[R(int) = 0.0474]  3517[R(int) = 0.0128]  
Data/restraints/param
eters  
3496/0/182  2979/0/182  3517/0/182  
Goodness-of-fit on 
F
2
  
1.028  1.080  1.048  
Final R indexes 
[I>=2σ (I)]  
R1 = 0.0271, wR2 = 
0.0595  
R1 = 0.0336, wR2 = 
0.0866  
R1 = 0.0182, wR2 = 
0.0438  
Final R indexes [all 
data]  
R1 = 0.0360, wR2 = 
0.0624  
R1 = 0.0411, wR2 = 
0.0912  
R1 = 0.0205, wR2 = 
0.0451  
Largest diff. 
peak/hole / e Å
-3
  
0.68/-0.47  1.03/-0.39  0.85/-1.23  
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Table 3.22: Crystal data and structure refinement for zinc(II) complexes 
Identification code  [Zn(LMA)(NCS)] [Zn(LMA)(N3)2] 
Empirical formula  C15H19N5Os2Zn  C13H19N9OZn  
Formula weight  414.84  382.74  
Temperature/K  373(2)  373(2)  
Crystal system  triclinic  monoclinic  
Space group  P-1  P21/c  
a/Å  9.9203(2)  10.7118(19)  
b/Å  13.5659(2)  9.2241(16)  
c/Å  14.6957(2)  17.110(3)  
α/°  112.7020(10)  90.00  
β/°  91.4710(10)  105.719(2)  
γ/°  94.3560(10)  90.00  
Volume/Å
3
  1815.97(5)  1627.4(5)  
Z  4  4  
ρcalcmg/mm
3
  1.517  1.562  
m/mm
-1
  1.594  1.531  
F(000)  856.0  792.0  
Crystal size/mm
3
  0.42 × 0.33 × 0.25  0.25 × 0.06 × 0.05  
2Θ range for data collection  4.12 to 52°  4.94 to 52.82°  
Index ranges  -12 ≤ h ≤ 12, -16 ≤ k ≤ 16, -
17 ≤ l ≤ 18  
-13 ≤ h ≤ 13, -11 ≤ k ≤ 11, -
21 ≤ l ≤ 18  
Reflections collected  15354  8625  
Independent reflections  7118[R(int) = 0.0203]  3323[R(int) = 0.0582]  
Data/restraints/parameters  7118/5/435  3323/0/218  
Goodness-of-fit on F
2
  1.042  1.011  
Final R indexes [I>=2σ (I)]  R1 = 0.0278, wR2 = 0.0756  R1 = 0.0459, wR2 = 0.0870  
Final R indexes [all data]  R1 = 0.0345, wR2 = 0.0797  C13H19N9OZn  
Largest diff. peak/hole/e Å
-3
  0.62/-0.30  382.74  
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3.6.14 Dibromido{2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-κ3N,N’,N”}-
cadmium 
 
Figure 3.6.19: Crystal structure for [Cd(LMA)Br2] 
The white colored crystal compound [Cd(LMA)Br2] was obtained upon the reaction of 2-
morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine with Cd(II) ion in the presence of 
potassium bromide. Similar to the structure of the analogous CdCl2 complex (Ikmal 
Hisham, 2010), the metal center is five-coordinated by the N,N',N"-tridentate Schiff base 
ligand and two halogen atoms. The geometry of the complexes can be determined by using 
the index τ = (β-α)/60, where β is the largest angle and α is the second one around the metal 
center. For an ideal square-pyramid τ is 0, while it is 1 in a perfect trigonal-bipyramid 
(Addison, 1984). The τ value in the present structure is calculated to be 0.18, indicative of a 
distorted square-pyramidal geometry. The Cd-Br bond lengths in the complex are in 
agreement with the values reported in the literature (Bermejo, 1999; Bermejo, 2003). In the 
crystal, the adjacent molecules are connected together via C-H···O and C-H···Br hydrogen 
bonds, forming infinite layers parallel to the ab plane. Moreover an intramolecular C-
H···Br occurs. The Cd(II) ion, is five-coordinated by the N,N’,N”-tridentate Schiff base 
ligand and two Br atoms in a distorted square-pyramidal geometry. 
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3.6.15 Dichlorido{2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine-κ3N,N’,N”}-
cadmium 
 
Figure 3.6.20: Crystal structure for [Cd(LMA)Cl2] 
The crystal of this compound has been obtained via the complexation of cadmium(II) 
chloride by the N,N’,N”-tridentate ligand, 2-morpholino-N-[1-(2-
pyridyl)ethylidene]ethanamine, which had itself been prepared from the condensation of 4-
(2-aminoethyl)morpholine and 2-acetylpyridine. The geometry of the complex can be 
defined as distorted square-pyramidal (τ = 0.18) with one of the chloride ligands in the 
apical position. Like the similar structures reported in the literature (Ikmal Hisham, 2009; 
Cai, 2009), the morpholine ring in the present complex adopts a chair conformation. In the 
crystal structure, the molecules are linked together through C-H···Cl interactions into a 
three dimensional network. 
In summary, the Cd(II) ion is five-coordinate, with the N,N’,N”-tridentate Schiff base 
ligand 2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine and two Cl atoms in a 
distorted square-pyramidal geometry. 
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3.6.16 Di-l-thiocyanato-j2N:S;k2 S:N-bis ({2-morpholino-N-[1-(2-pyridyl)ethylidene]-
Ethanamine-k
3N,N’,N”} (thiocyanatokN)cadmium) Aqua{2-Morpholino-N-[1-(2-
pyridyl)ethylidene] ethanamine-κ3N,N’,N”} bis(azido-κN) cadmium(II) 
 
 
 Figure 3.6.21: Crystal structure for [Cd2(LMA)2(NCS)4] 
In the title complex, [Cd2(LMA)2(NCS)4], the two Cd(II) ions are bridged by a pair of 
thiocyanate N:S-bridging ligands around an inversion center. One terminal thiocyanate N 
atom and one N,N’,N”-tridentate Schiff base ligand complete a distorted CdN5S octahedral 
geometry about each Cd
II
 atom. In the crystal, the Schiff base aromatic rings of adjacent 
molecules are arranged above each other into infinite chains along the a-axis with alternate 
centroid–centroid separations of 3.5299 (13) and 3.7857 (13) A ° . For the structure of the 
Cu(II) complex with the same Schiff base and thiocyanate, see: (Gwaram, 2011). For the 
structures of similar cadmium complexes, see: (Banerjee, 2005); You, 2006). 
In summary, the title compound is a mixed-ligand cadmium(II) complex with thiocyanate 
and the Schiff base 2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine. Unlike the 
mononuclear square-pyramidal structure of the analogous copper(II) complex (Suleiman,  
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2011), the present structure represents a dinuclear metal complex with a distorted 
octahedral geometry around the cadmium atoms. Each two Cd(II) centers are linked by a 
pair of thiocyanate N:S bridges around an inversion center to form an eight-membered 
Cd2(μ2-NCS)2 ring. The resulting ring has a chair conformation, the displacement of Cd1 
out of the (NCS)2 plane being 0.635 (2) Å. Within this double bridged dimer, the Cd···Cd 
distance [5.9380 (3) Å] is similar to those observed in the related complexes (Banerjee, 
2005; You, 2006). The distorted octahedral geometry about the metal cadmium is 
completed by one terminal thiocyanate N atom and one N,N',N"-tridentate Schiff base 
ligand. In the crystal, the molecules are connected into infinite chains along the a axis via 
π-π interactions formed by the Schiff base aromatic ring and its symmetry related 
counterparts at (-x + 1, -y, -z and –x + 2, -y, -z) with centroid separations of 3.5299 (13) Å 
and 3.7857 (13) Å respectively. 
 
3.6.17 Structure of Aqua{2-morpholino-N-[1-(2-pyridyl)- ethylidene]ethanamine-
k
3N,N’,N”}bis(thiocyanato-kN)cadmium(II) [Cd(LMA)(N3)2(H2O)] 
 
Figure 3.6.22: Crystal structure for [Cd(LMA)(N3)2(H2O)] 
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In the compound, the Cd(II) atom is octahedrally coordinated by the N,N’,N”-tridentate 
Schiff base ligand and two terminal azide N atom. The adjacent Cd(II) ions are coordinated 
by one additional water ligand to have complete distorted octahedral geometry. 
3.6.18 Chlorido(2-{1-[(2-morpholinoethyl)-imino]ethyl}phenolato-κ3N,N’,O)-
copper(II) 
 
Figure 3.6.23: Crystal structure for [Cu(LMH)Cl] 
The title compound was obtained through the reaction of the Schiff base ligand, prepared in 
situ, with copper(II) chloride. Upon complexation, the Schiff base loses its phenolic 
hydrogen to chelate the Cu(II) ion as an anionic tridentates ligand. One chloride atom 
completes the distorted square-planar geometry of the complex. The deviation from the 
regular geometry is evident from the disposition of the metal atom 0.0494 (15) Å out of the 
N1-N2-O1-Cl1 coordination plane.  
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Figure 3.6.24: Packing structure for [Cu(LMH)Cl] 
The Cu-N, Cu-O and Cu-Cl bond lengths in the present complex are comparable with those 
in similar structures (Elias, 1982; Ikmal Hisham, 2009; Wang & You, 2007). In the crystal, 
C-H···Cl and C-H···O interactions within the range for normal hydrogen bonds, link 
adjacent molecules into two-dimensional networks parallel to the bc plane (Figure 3.6.23). 
In addition, intramolecular C-H···Cl hydrogen bonds occurs. 
In summary, the Cu(II) ion is four-coordinated by one deprotonated N,N’,O-tridentate 
Schiff base and one chloride ion in a distorted square-planar geometry. 
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3.6.19 Hexachloridobis{-2-2-(piperazin-1-yl)-N-[1-(2-pyridyl)ethylidene]ethanamine}-
trizinc dihydrate 
 
 
Figure 3.6.25: Crystal structure for [Zn3(LPA)2Cl6].2H2O 
It has been shown that ligands having piperazine ring, depending on the ring conformation 
(chair or boat), may display ambidentate ligation behavior (Mukhopadhyay, 2003; Xu, 
2008). The title compound was obtained upon the reaction of the in situ prepared Schiff 
base, 2-piperazino-N-[1-(2-pyridyl)ethylidene]ethanamine, with zinc(II) chloride. As 
shown in Fig. 3.6.25, the compound contains three unique metal centers. One Schiff base 
ligand chelates each of the two terminal zinc atoms via three N atoms. The piperazine rings 
assume chair conformations and their nitrogen atoms, N4 and N5, which stay away from 
chelation, are coordinated to the central zinc atom. Within the resulting trinuclear zinc 
complex, the metal atoms are separated by 5.8498 (7) Å (Zn1···Zn2) and 7.0153 (7) Å 
(Zn2···Zn3).  
The coordination environment around each metal center is completed by two Cl atoms, 
resulting in a tetrahedral geometry for the central Zn(II) ion and square-pyramidal 
geometries for the terminal zinc atoms τ = 0.39 and 0.26 for Zn1 and Zn3 centers, 
respectively, (Addison, 1984). The crystal structure contains intra- and intermolecular C-
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H···Cl interactions. The latter connect the adjacent metal complexes into a three-
dimensional network. The complex is N-H···O and C-H···O hydrogen bonded to two 
molecules of water, one of which being disordered between two sites. 
In summary, the trinuclear title compound, each terminal Zn(II) atom is coordinated by an 
N3 donor set from the Schiff base ligands and two Cl atoms in a distorted square-pyramidal 
geometry. The central Zn(II) atom is tetrahedrally coordinated by two piperazine N atoms 
from two Schiff base ligands and two Cl atoms. The piperazine rings adopt chair 
conformations. 
3.6.20 Octachloridobis[l2-2-(piperazin-1-yl)-N-1-(2-pyridyl)ethylidene ethanamine-bis-
4-(2-aminoethyl)piperazine]-tetracadminic Cd4(LPA)2(PA)2(Cl)8] 
 
Figure 3.6.26: Crystal structure for Cd4(LPA)2(PA)2(Cl)8] 
In the crystal system of the complex, Cd(II) ion in the adjacent ligands is five-coordinate, 
with the N,N’,N”-tridentate Schiff base ligand 2-piperazino-N-[1-(2-pyridyl)ethylidene] 
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ethanamine and two Cl atoms in a distorted square-pyramidal geometry. 
Also the Cl and Cd(II) atoms are located on a twofold rotation axis and the Cd(II) atom is 
octahedrally coordinated by two N,N’-bidentate 2-(piperazino-4-yl)ethanamine ligands and 
two trans-located Cl atoms. The chloride ions act as either bridging or terminal ligands.The 
piperazine rings adopt chair conformations. However, different from the doubly bridged 
dimeric structure of the former, in the present structure the bridging chlorine ligands doubly 
bridged the adjacent metal centers into chains along the axis. Within this coordination 
polymer, the central Cd(II) atom is octahedrally coordinated by two piperazine N atoms 
from two Schiff base ligands and four Cl atoms from the two N,N’-bidentate 2-(piperazino-
4-yl)ethanamine ligands.  
3.6.21 Dichlorido-2-(piperidin-1-yl)-N-[1-(2-pyridyl)ethylidene]ethanamineκ3N,N’,N”} 
zinc(II) 
 
Figure 3.6.27: Crystal structure for [Zn(LPipA)Cl2] 
The crystal of this compound has been obtained via the complexation of zinc(II) chloride 
by the N,N’,N”-tridentate ligand, 2-piperodino-N-[1-(2-pyridyl)ethylidene]ethanamine, 
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which had itself been prepared from the condensation of 4-(2-aminoethyl)piperidine and 2-
acetylpyridine. Schiff base, 2-piperidino-N-[1-(2-pyridyl)ethylidene]ethanamine and two Cl 
atoms coordinate the Zn(II) ion in a distorted square-pyramidal geometry (τ = 0.22). The 
Zn-Cl and Zn-N bond lengths in the structure are in agreement with the values reported in 
the literature (Chattopadhyay, 2009; Sun, 2005) with one of the chloride ligands in the 
apical position. Like the similar structures reported in the literature (Ikmal Hisham, 2009; 
Cai, 2009), the morpholine ring in the present complex adopts a chair conformation. 
 In the crystal structure, intermolecular C-H···Cl hydrogen bonding and long range C-
H···O and C-H···Cl interactions link the adjacent molecules into a three-dimensional 
network. An intramolecular C-H···Cl hydrogen bonding has also been observed. 
3.6.22 Dithiocyanate-2-(piperidin-1-yl)-N-[1-(2-pyridyl)ethylidene]ethanamineκ3N,N’,N”} 
zinc(II) 
 
Figure 3.6.28: Crystal structure for [Zn(LPipA)(NCS)] 
Thiocyanate is known to bind metal ions in different modes: N-donor, S-donor or N:S-
bridging mode. The title compound is a mixed-ligand zinc(II) complex with the two 
ambidentate ligands. In the crystal, two geometrically slightly different molecules exist. 
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The asymmetric unit of the title compound, contains two independent penta coordinate 
Zn(II) complex molecules. In each molecule, the metal atom is coordinated by an N,N’,N”-
tridenate Schiff base and two N-bound thiocyanate ligands in a distorted square-pyramidal 
geometry. The two molecules differ little in their geometry, but more in their 
intermolecular interactions. In the crystal, adjacent molecules are connected via C-H---N 
interactions into a three dimensional supra molecular structure. The network is 
supplemented by π–π* interactions formed between the aromatic rings of pairs of the 
symmetry-related molecules.  
3.6.23 Dichlorido{N,N-dimethyl-N’-[1-(2-pyridyl)ethylidene]ethane-1,2-diamineκ3 
N,N’,N”} manganese(II) 
 
 Figure 3.6.29: Crystal structure for [Mn(LNA)Cl2] 
The title compound was obtained upon complexation of the Schiff base, N,N-dimethyl-N'-
[methyl(2- pyridyl)methylene]ethane-1,2-diamine, with MnCl2. Similar to its analogous 
copper(II) complex (Saleh Salga, 2010), the metal center is five-coordinated by the 
N,N',N"-tridentate Schiff base and two Cl atoms. Two geometrically different molecules 
exist in the crystal structure. In both molecules, the Mn(II) ions are in a square-pyramidal 
coordination environment with different degrees of distortion from the ideal geometry as 
revealed by the τ values of 0.101 for Mn1 complex and 0.035 for Mn2 complex. The 
weighted r.m.s. fit for the superposition of the non-H atoms in both molecules is 0.0868 Å. 
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The Mn-Cl and Mn-N bond lengths in the two molecules are comparable with those in the 
related structures (Gibson, 2003; Reardon, 2002). In the crystal, the adjacent molecules are 
connected via C-H···Cl hydrogen bonds into a three-dimensional polymeric structure. The 
crystal structure contains void spaces with the size of 54.00 Å-3 within which there is no 
evidence for included solvent. 
In summary, the asymmetric unit of the compound contains two crystallographically 
independent molecules with slightly different geometries. In each molecule, the Mn(II) ion 
is five coordinated by the N,N’,N”- tridentate Schiff base and two Cl atoms in a distorted 
square pyramidal geometry. 
3.6.24 Aqua{N,N-dimethyl-N’-[1-(2-pyridyl)-ethylidene]ethane-1,2-diamineκ3N,N’,N”} 
bis (thiocyanato-κN)nickel(II) 
 
 
Figure 3.6.30: Crystal structure for [Ni(LNA)(NCS)2(H2O)] 
The title mixed-ligand complex was obtained via the treatment of nickel(II) ion with the 
Schiff base N,N-dimethyl-N'- [methyl(2-pyridyl)methylene]ethane-1,2-diamine, prepared in 
situ, and the thiocyanate salt. The Schiff base acts as an N,N',N"-tridentate chelate and the 
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two thiocyanate ions behave in an N-donor fashion towards the Ni(II) ion. The geometry 
around the metal center is completed by one water O atom. This arrangement is similar to 
what was observed in the nickel(II) thiocyanate complex of a similar Schiff base (Gwaram, 
2011). In contrast, the metal ions in the nickel(II) thiocyanate complex of N,N-dimethyl-N'-
(2-pyridylmethylene)ethane-1,2-diamine (Diao, 2007) and N,N-diethyl- N'-[methyl(2-
pyridyl)methylene]ethane-1,2-diamine (Bhowmik, 2010) are doubly bridged into dimers by 
N:S-bridging thiocyanate ligands. 
 
Figure 3.6.31: Packing crystal structure for [Ni(LNA)(NCS)2(H2O)] 
 In the present structure, the adjacent molecules are connected into 2-D arrays in ac plane 
via O-H···S interactions (Figure 3.6.31). A C-H···π interaction connects the layers into a 
three-dimensional structure. 
In summary, the Ni(II) ion is six-coordinated by the N,N’,N"-tridentate Schiff base N 
atoms, two cis-positioned N-bound isothiocyanate groups and one water molecule. In the 
crystal, O-H---S hydrogen bonds link adjacent molecules into infinite layers parallel to the 
ac plane. The layers are further connected into a three dimensional network via C-H---
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interactions. The-CH2-N(CH3)2 fragment is disordered over two sets of sites in a 0.556 
(5):0.444 (5) ratio. 
3.6.24 N,N-Dimethyl-N’-[1-(2-pyridyl)ethylidene]ethane-1,2-diamine-κ3N,N’,N”}bis 
(thiocyanato-κN)copper(II) 
 
Figure 3.6.32: Crystal structure for [Cu(LNA)(NCS)2] 
The title compound was obtained upon the reaction of the Schiff base, N,N-dimethyl-N'-
[methyl(2-pyridyl)methylene]ethane-1,2-diamine, with Cu(II) ion in the presence of 
thiocyanate anion. There are two geometrically slightly different molecules in crystal 
structure. The weighted r.m.s. fit for the superposition of the non-H atoms in both 
molecules is 0.296 Å. Each metal ion is five-coordinated by the three N atoms from the 
Schiff base and two N-donor thiocyanate ligands. Similar arrangements are observed in the 
structures of related mixed-ligand copper(II) complexes (Xue, 2010; Yue, 2005). Different 
from those, in the cadmium(II) thiocyanate complex of the same Schiff base (Gwaram, 
2011), N:S bridging thiocyanates connect the metal ions into an octahedral polymeric 
structure. The Addison τ values (Addison, 1984) of 0.13 for Cu1 complex and 
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0.14 for Cu2 complex (τ = 0 for an ideal square pyramid and τ = 1 for an ideal trigonal 
bipyramid) imply distorted square-pyramidal geometries of the molecules. In the crystal, 
the adjacent molecules are bonded via C-H···S and C-H···N interactions into layers parallel 
to the ac plane. Moreover, intramolecular C-H···N hydrogen bonding occurs. 
In summary, asymmetric unit of the title compound consists of two crystallographically 
independent molecules. In each molecule, the Cu(II) ion is five-coordinated in a distorted 
square-pyramidal geometry wherein the basal plane is defined by the N,N',N"-tridentate 
Schiff base and one N-bound thiocyanate ligand. The second N-donor thiocyanate group, 
located at the apical site, completes the coordination environment. 
3.6.25 Dibromido{N,N-dimethyl-N’-[1-(2-pyridyl)ethylidene]ethane-1,2-diamineκ3 
N,N’,N”}zinc 
 
Figure 3.6.33: Crystal structure for [Zn(LNA)Br2] 
The zinc(II) ion is penta-coordinated by the N,N',N"-tridentate Schiff base ligand and two 
Br atoms in a distorted square-pyramidal geometry, the τ value (Addison, 1984) being 0.17. 
This arrangement is similar to what was observed in the structure of [ZnBr2(C10H15N3)], the 
closest analogous cadmium complex (Bian, 2003). In the crystal, pairs of the molecules, 
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related by symmetry -x, -y, -z + 1, are bonded into centrosymmetric dimers via C7-
H7B···Br2 interaction. 
 3.6.26 Dichlorido{N,N-dimethyl-N’-[1-(2-pyridyl)ethylidene]ethane-1,2-diamineκ3 
N,N’,N”}zinc 
 
Figure 3.6.34: Crystal structure for [Zn(LNA)Cl2] 
The crystal structure of the title Zn(II) complex is isomorphous with that of the Mn(II) 
analogue (Ikmal Hisham, 2011). The asymmetric unit consists of two geometrically slightly 
different molecules; the weighted r.m.s. fit for the superposition of the non-H atoms in both 
molecules (after inversion) being 0.078 Å. The metal centers are five-coordinate in 
distorted square-pyramidal geometries, the apical positions being occupied by a chlorine 
atom. The Addison τ values (Addison, 1984) for Zn1 and Zn2 molecules are 0.103 and 
0.168, respectively. The Zn-Cl and Zn-N bond lengths are comparable to those reported for 
similar complexes (Gourbatsis, 1999, Sun, 2005). In the crystal, the molecules are linked 
through C-H···Cl interactions into a three-dimensional polymeric structure and this is 
consolidated by π–π interactions formed between pairs of molecules [Cg1···Cg1i = 3.6255 
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(10) Å; Cg2···Cg2ii = 3.7073 (10) Å, where Cg1 and Cg2, are the centroids of the rings 
N1/C1-C5 and N4/C12-C16, for i: -x, -y + 1, -z; ii: -x + 1, -y + 1, -z + 1]. The lattice contains 
void spaces with the size of 52 Å
3
 within which there is no evidence for included solvent. 
In summary, the asymmetric unit of the title compound, contains two independent penta 
coordinate Zn(II) complex molecules. In each molecule, the metal atom is coordinated by 
an N,N’,N”-tridenate Schiff base and two Cl atoms in a distorted square-pyramidal 
geometry. The two molecules differ little in their geometry, but more in their 
intermolecular interactions. In the crystal, adjacent molecules are connected via C-H---Cl 
interactions into a three dimensional supra molecular structure. The network is 
supplemented by π–π* interactions formed between the aromatic rings of pairs of the 
symmetry-related molecules [centroid-centroid distances = 3.6255 (10) and 3.7073 (10) Å]. 
The crystal lattice contains void spaces with a size of 52 Å
3
. 
3.6.27 N,N-Dimethyl-N’-[1-(2-pyridyl)ethylidene]ethane-1,2-diamine-κ3N,N’,N”-bis 
(thiocyanato-κN)zinc(II) 
 
Figure 3.6.35: Crystal structure for [Zn(LNA)(NCS)2] 
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The compound Zn(LMA)(NCS)2, is a mixed-ligand Zn(II) complex with the in situ 
prepared Schiff base and thiocyanate ligands. Like the structure of the zinc(II) thiocyanate 
complexes of similar Schiff bases (Gwaram, 2011 and Ikmal, 2011), the present structure is 
a mononuclear square-pyramidal metal complex, the τ value being 0.35 (Addison,, 1984). 
In contrast, the cadmium(II) thiocyanate complex of the same Schiff base (Gwaram, 2011), 
showed a polymeric structure wherein the metal centers are linked by the N:S-bridging 
thiocyanate ligands. In the crystal structure of the title compound, C---H...S interactions 
connect a pair of molecules, related by symmetry -x+1, -y, -z, around a center of inversion. 
 In summary, the zinc atom is bonded to three donor nitrogen atoms of the ligand and two 
thiocyanates both bonded through the nitrogen atoms. The five Zn–N bond lengths as 
apparent from figure 3.6.35 are given as Zn(1)-N(1) 2.1752(18), Zn(1)-N(2) 2.0752(18), 
Zn(1)-N(3) 2.217(2), Zn(1)-N(4) 1.9681(18), Zn(1)-N(5) 1.9698(19). The compound, 
[Zn(NCS)2(C11H17N3)], is a square-pyramidal zinc(II) complex in which the metal center is 
coordinated by the N,N',N”-tridentate Schiff base and the N atoms of two thiocyanate 
ligands. In the crystal structure, pairs of molecules are connected into centrosymmetric 
dimer. The CH2N(CH3)2 fragment is disordered over two sets of sites in a 0.529 (4):0.471 
(4) ratio. 
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3.6.28 Dichlorido{N,N-dimethyl-N’-[1-(pyridin-2-yl)ethylidene]ethane-1,2-diamineκ3 
N,N’,N”}cadmium(II) 
 
Figure 3.6.36: Crystal structure for [Cd(LNA)Cl2] 
The title compound was obtained via the complexation of CdCl2 by N,N-dimethyl-N'-
[methyl(2-pyridyl)methylene]ethane-1,2-diamine. Similar to the structure of the analogous 
copper(II) complex (Saleh Salga, 2010), the cadmium(II) ion is penta-coordinated by the 
N,N',N"-tridentate Schiff base ligand and two Cl atoms in a distorted square-pyramidal 
geometry, the τ value (Addison, 1984) being 0.17. This arrangement is similar to what was 
observed in the structure of [CdCl2(C10H15N3)], the closest analogous cadmium complex 
(Bian, 2003). In the crystal, pairs of the molecules, related by symmetry -x, -y, -z + 1, are 
bonded into centrosymmetric dimers via C7-H7B···Cl2 interaction. 
In summary, the Schiff base acts as an N,N’,N”-tridentate ligand towards the Cd(II) ion. 
Two Cl atoms complete a distorted square-pyramidal geometry around the metal atom. 
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3.6.29 Catena-Poly[[{N,N-dimethyl-N’-[1-(pyridin-2-yl)ethylidene]ethane-1,2-diamine-
κ3N,N’,N”} (thiocyanato-κN)-cadmium]-l-thiocyanato-κ2S:N]  
 
Figure 3.6.37: Crystal structure for [Cd(LNA)(NCS)2]n 
Thiocyanate anion is known to bind the cadmium ion in different modes: terminal N-bound, 
terminal S-bound (Nfor, 2006) or N:S-bridging ligand. As a bridging ligand, it may give 
rise to a singly bridged (Bose et al. 2004), doubly bridged or triply bridged (Chen, 2002) 
cadmium complex. The title compound is a mixed-ligand cadmium complex with 
thiocyanate and the Schiff base N,N-dimethyl-N'-[methyl(2-pyridyl)methylene]ethane-1,2-
diamine. Similar to what was observed in the cadmium thiocyanate adduct of the similar 
Schiff base, N,N-diethyl-N'-[methyl(2-pyridyl)methylene]ethane-1,2-diamine (Banerjee, 
2005), the thiocyanate ions act as either bridging or terminal ligands. However, different 
from the doubly bridged dimeric structure of the former, in the present structure the 
bridging thiocyanate ligands singly bridge the adjacent metal centers, related by symmetry 
x, –y+1/2, z - 1/2, into infinite chains along the c axis. Within this coordination polymer, 
the Cd(II) ions are separated by the distance of 8.0234 (9) Å. Two thiocyanate N:S-bridges, 
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one terminal thiocyanate N atom and the N,N',N"-tridentate Schiff base make a distorted 
octahedral geometry around the Cd(II) atoms. 
In summary, the Cd(II) atom is octahedrally coordinated by the N,N’,N”-tridentate Schiff 
base ligand and one terminal thiocyanate N atom. Two trans- N:S-bridging thiocyanates 
complete the N5S donor set around the Cd atom. In the crystal, adjacent Cd(II) ions are 
linked by the thiocyanate N:S-bridges into polymeric chains along the c axis. 
3.6.30 Bis(l-2-{1-[2-(dimethylamino)ethylimino]ethyl}phenolato)bis[bromidocopper(II)] 
monohydrate 
 
Figure 3.6.38: Crystal structure for [Cu2(LNH)2Br2]H2O 
The title dimeric copper(II) complex was synthesized through the reaction of the in situ 
prepared Schiff base, N,N-dimethyl- N'-[methyl(2-phenolyl)methylene]ethane-1,2-diamine, 
with copper(I) bromide. Under the reaction conditions, the Cu(I)ion was oxidized to Cu(II) 
and chelated by the deprotonated N,N',O-tridentate Schiff base. Pairs of metal centers are 
doubly bridged via the phenoxide O atoms around centers of inversion. Within the formed 
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dimer, the Cu···.Cu distance [2.9935 (8) Å] is comparable to those reported for similar 
structures (Li, 2000; Rigamonti, 2008; Suo, 2008). The square-pyramidal geometry (τ = 
0.11, Addison, 1984) around each Cu(II) ion is completed by one apically positioned Br 
atom. The dimeric complex is cocrystallized with one molecule of water whose oxygen 
atom is situated on a 2-fold rotational axis. In the crystal, the water molecules link the 
dimers into infinite chains along the b axis via O-H···Br and-H···O interactions. 
 
In the centrosymmetric dinuclear copper(II) title complex, each Cu(II) ion is five 
coordinated in a square-pyramidal geometry by the N,NO,O-tridentate Schiff base, one Br 
atom and the bridging O atom of the centrosymmetrically related Schiff base. In the crystal, 
the water molecules link the complex molecules into infinite chains along the b-axis via O-
H---Br and C-H---O hydrogen bonds. 
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BIOLOGICAL APPLICATIONS 
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4. Experimental 
4.1 Anti ulcer Activities 
Omeprazole: In this research, omeprazole obtained from the University of Malaya Medical 
Centre (UMMC) Pharmacy was used as the reference anti-ulcer drug. The drug was 
dissolved in 10% Tween 20 (Merck Schuchardt OHG, 85662 Hohenbrunn, Germany). A 
10% v/v dilution of Tween 20 was used as the vehicle for rat dosing (5 ml/kg) and 
administered orally to the rats in doses of 20 mg/kg body weight (5 ml/kg) according to 
(Mahmood 2010). 
4.1.1 Acute toxicity testing and experimental animals 
Adult, healthy male and female Sprague-Dawley rats (6-8 weeks old) were obtained from 
the Animal House, Faculty of Medicine, University of Malaya, Kuala Lumpur (Ethics No. 
PM/27/07/2010/MAA (R)). The rats weighed between 150-180 g. The animals were given 
standard rat pellets and tap water Ad libitum. The acute toxicity study was used to 
determine a safe dose for the zinc(II) complex. Thirty-six rats (18 males and 18 females) 
were divided equally into three groups that were administered the vehicle only (10% Tween 
20) and 1 or 2 g/kg of the prepared compound. The animals were fasted overnight (with 
water) prior to dosing, and food was withheld for a further 3 to 4 hours after dosing. The 
animals were observed for 0.5, 2, 4, 8, 24 and 48 hours after administration for the onset of 
clinical or toxicological symptoms. Mortality, if any, was observed over a period of two 
weeks. The animals were sacrificed on day fifteen. The histology, hematological and serum 
biochemical parameters were determined according to the Guideline for testing (OECD, 
2005). This study was approved by the ethics committee for animal experimentation, 
Faculty of Medicine, University of Malaya, Malaysia. All of the animals received humane 
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care according to the criteria outlined in the “Guide for the Care and Use of Laboratory 
Animals” prepared by the National Academy of Sciences and published by the National 
Institutes of Health.  
4.1.2 Ethanol-induced gastric ulcer formation 
Prior to the experiment, the rats were fasted for 24 hours according to our published method 
(Mahmood, 2010). And they were allowed free access to drinking water until 2 hours 
before the experiment. Gastric ulcer formation was induced by orogastric intubation of 
absolute ethanol (5 ml/kg) as described by (Abdulla 2010). Both the negative control rats 
(Group 1) and the ulcer control rats (Group 2) were orally administered 10% Tween 20 (5 
ml/kg). The reference group (Group 3) received oral doses of 20 mg/kg omeprazole in 10% 
Tween 20 (5 ml/kg) as a positive control. The experimental groups were orally 
administered the zinc(II) compound dissolved in 10% Tween 20 (5 ml/kg) at 50 and 100 
mg/kg (Groups 4 and 5, respectively). One hour after this pretreatment, (Group 1) were 
orally administered distilled water in 5 ml/kg 10% Tween 20, whereas (Group2, 3, and 4)  
were orally administered absolute ethanol (5 ml/kg) to induce gastric ulcer formation. The 
rats were euthanized sixty minutes later (Mahmood, 2010) with an overdose of xylazine 
and ketamine anesthesia, and their stomachs were immediately excised. 
4.1.3 Gastric wall mucus determination 
The glandular segments of the stomach were removed, weighed and assessed for gastric 
wall mucus content. Each segment was transferred immediately into a 1% Alcian blue 
solution (in sucrose solution buffered with sodium acetate at pH 5), and the excess dye was 
removed with a sucrose solution rinse. The dye complexed with the gastric wall mucus was 
extracted with a magnesium chloride solution. A 4-ml aliquot of the blue extract was then 
shaken with an equal volume of diethyl ether. The resulting emulsion was centrifuged, and 
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the absorbance of the aqueous layer was recorded at 580 nm. The quantity of Alcian blue 
extracted per gram of glandular tissue (net) was then calculated. 
4.1.4 Gross gastric lesion evaluation 
Ulcers of the gastric mucosa appear as elongated bands of hemorrhagic lesions parallel to 
the long axis of the stomach. The gastric mucosa of each rat was thus examined for 
damage. The length and width of the ulcer (mm) were measured with a planimeter (10 × 10 
mm
2
 = ulcer area) under a dissecting microscope (1.8x). The ulcerated area was measured 
by counting the number of small squares (2 mm × 2 mm) covering the length and width of 
each ulcer band. The sum of the areas of all lesions for each stomach was applied in the 
calculation of the ulcer area (UA), wherein the total number of small squares × 4 × 1.8 = 
UA (mm
2
) according to (Zahra et al. 2009). The inhibition percentage (I%) was calculated 
using the following formula according to (Abdulla, 2010). 
(I%) = [(UAcontrol − UAtreated)  UAcontrol] × 100%. 
 
4.1.5 Histological evaluation of the gastric lesions  
The gastric wall specimens were fixed in 10% buffered formalin and processed in a paraffin 
tissue-processing machine (Leica, Germany). Sections of the stomach were prepared at a 
thickness of 5 µm and stained with hematoxylin and eosin for histological evaluation 
(Behmer, 1976). 
4.1.7 Preparation of the homogenates 
The gastric tissue was washed thoroughly with ice-cold saline. A 10% (w/v) homogenate 
was prepared using a Teflon homogenizer (Polytron, Heidolph RZR 1, Germany) in ice-
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cold 50 mM phosphate buffer pH 7.4 containing mammalian protease inhibitor cocktail. 
The homogenate was centrifuged at 10,000 g for 30 min at 4
°
C. The supernatant was used 
in the assays for antioxidant activity/level and lipid peroxidation. 
4.1.8 The measurement of superoxide dismutase (SOD) activity 
SOD activity was measured according to (Sun, 1988). The activity of the enzyme was 
evaluated by measuring its capacity to inhibit the photochemical reduction of nitro-blue 
tetrazolium (NBT). In this assay, the photochemical reduction of riboflavin generates O
2−
 
that reduces the NBT to produce formazan salt, which absorbs light at a wavelength of 560 
nm. In the presence of SOD, the reduction of the NBT is inhibited because the enzyme 
converts the superoxide radical to peroxide. The results are expressed as the quantity of 
SOD necessary to inhibit the rate of reduction of the NBT by 50% in units of the enzyme 
per gram of protein. The homogenates (10% of the tissue in phosphate buffer) were 
centrifuged (10 min, 3,600 rpm, 4°C), and the supernatant was removed and centrifuged a 
second time (20 min, 12,000 rpm, 4 °C). The resulting supernatant was assayed. In a dark 
chamber, 1 mL of the reactant (50 mM phosphate buffer, 100 nM EDTA and 13 mM l-
methionine, pH 7.8) was mixed with 30 μL of the sample, 150 μL of 75 μM NBT and 300 
μL of 2 μM riboflavin. The tubes containing the resulting solution were exposed to 
fluorescent light bulbs (15 W) for 15 minutes and then read using a spectrophotometer at 
560 nm. 
4.1.9 The measurement of reduced glutathione 
To assess changes in the amount of gastric mucosal GSH, which is a non-protein sulfhydryl 
compound, the GSH content was measured according to (Sedlak and Lindsay 1968). The 
glandular segment from each stomach was homogenized in an ice-cold solution of 0.02 M 
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EDTA (at 10%). Aliquots (400 μL) of the tissue homogenate were mixed with 320 μL of 
distilled water and 80 μL of 50% (w/v) trichloroacetic acid in glass tubes and centrifuged at 
3,000 rpm for 15 min. Subsequently, the supernatants (400 μL) were mixed with 800 μL 
Tris buffer (0.4 M, pH 8.9), and 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB; 0.01 M) was 
added to the mixture. After the reaction mixture was shaken for 3 minutes, its absorbance 
was measured at 412 nm within 5 minutes of the addition of DTNB against a blank with no 
homogenate. The absorbance values were extrapolated from a glutathione standard curve, 
and the GSH content was expressed in μg GSH/g of protein. The protein concentration was 
measured using the Bradford method (Varley, 1980). 
4.1.10 The measurement of membrane lipid peroxidation 
The rate of lipoperoxidation in the gastric mucous membrane was estimated by measuring 
the malondialdehyde (MDA) content with the thiobarbituric acid reactive substances 
(TBARS) test. The stomachs were washed with buffered saline to minimize the effect of 
hemoglobin on the free radicals and to remove the blood adhered to the mucous membrane. 
The stomachs were homogenized with 10% of the tissue in potassium phosphate buffer. A 
250-μL aliquot of the homogenate was removed and stored at 37°C for 1 hour, after which 
400 μL of 35% perchloric acid was added, and the mixture was centrifuged at 14,000 rpm 
for 20 minutes at 4°C. The supernatant was removed, mixed with 400 μL of 0.6% 
thiobarbituric acid and incubated at 95–100 °C for 1 hour. After cooling, the absorbance 
was measured at 532 nm. A standard curve was generated using 1,1,3,3-tetrametoxy 
propane. The results were expressed as nM of MDA/mg of protein. The concentration of 
the proteins was measured using the Bradford method (Bradford, 1976). The measurement 
of the total protein content in the stomach samples after ethanol-induced lesion formation 
was based on the interaction of the Coomassie Blue G250 dye with protein.  
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At the pH of the reaction, the interaction between proteins of high molecular weight and the 
dye causes a shift in the dye to the anionic form, which absorbs strongly at 595 nm. 
Solutions containing an albumin standard, distilled water, buffer and each sample were 
added to the wells. For sample preparation, 2 μL of a sample and 38 μL of buffer were 
added to each well. Then, 200 μL of Bradford's solution (diluted 5×) was added to each 
well. After 5 minutes, a reading was obtained at a wavelength of 595 nm. 
4.2 IN VITRO ANTIOXIDANT ACTIVITY 
4.2.1 Ferric Reduction Antioxidant Power (FRAP) assay 
The determination of the total antioxidant activity (FRAP assay) of the compounds is a 
modified method of (Choi, 2002). The stock solutions included 300 mM acetate buffer (3.1 
g C2H3NaO2·3H2O and 16 ml C2H4O2), pH 3.6, 10 mM TPTZ (2, 4, 6-tripyridyl-s-triazine) 
solution in 40 mMHCl, and 20 mM FeCl3·6H2O solution. The fresh working solution was 
prepared by mixing 25 ml acetate buffer, 2.5 ml TPTZ, and 2.5 ml FeCl3·6H2O. The 
temperature of the solution was raised to 37 °C before use. CLG (10 μL) was allowed to 
react with 300 μl of the FRAP solution in the dark.  Readings of the colored product 
(ferrous tripyridyltriazine complex) were taken at 593 nm. The standard curve was linear 
between 100 and 1000 μM FeSO4. Results are expressed in μM Fe (II)/g dry mass and 
compared with that of ascorbic acid and BHT. 
4.2.2 DPPH (1,1-Diphenyl-2-picrylhydrazyl) radical scavenging activity 
The scavenging activity of the compounds on DPPH was determined using the method 
described in (Benzie, 1999). Compounds were tested at final concentrations ranging from 
0-25µg/mL in methanol. One milliliter of 0.3 mM DPPH ethanol solution was added to 2.5 
mL of sample solution of different concentrations to make the test solutions; while 1 mL of 
methanol was added to 2.5 mL of samples to make the blank solutions. The negative 
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control (blank) consisted of 1 mL DPPH solution plus 2.5 mL of methanol. These solutions 
were allowed to react at room temperature for 30 minutes in the dark. The absorbance 
values were measured at 518 nm and converted into percentage antioxidant activity 
according to the equation: % Inhibition = [(AB-AA)/AB] X 100. 
Where: AB: absorption of blank sample; AA: absorption of tested samples. The IC50 as well 
as the kinetics of DPPH scavenging activity was determined. Ascorbic acid was used as a 
positive control in this assay. 
4.3 IN VITRO ANTI-CANCER STUDIES 
4.3.1 MTT - Culture of cells and cytotoxicity assay 
The MCF-7 cells (human breast cancer cells) were seeded into 96 well plates at an initial 
cell density of approximately 5x10
5
 cells cm
-3
. After 24 hours incubation for cell 
attachment and growth, the medium was removed and replaced with fresh medium 
containing varying concentrations of the compounds. The compounds added were first 
dissolved in DMSO at the required concentration. Subsequent 6 desirable concentrations 
was prepared using growth medium. Control wells received only DMSO. Each 
concentration of the compound under study was assayed in six replicates. The assay was 
terminated after 48 hours incubation period. Again, the medium was removed and cell 
viability was determined after further 4 hours with 5 mg cm-3 MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium]bromide; also named thiazol blue. DMSO 
was then added per well and the dissolving formazan precipitate was read by using Elisa 
plate reader, Dynatech MR5000 at 570 nm. Comparison was made with positive control 
tamoxifen.   
4.3.2 Soft-agar Colony Formation Assay (Clonogenic Assay) 
A two-layer technique was used, with a base layer consisting of 1% agar (Promega), and a 
181 
 
second layer containing cells with 0.7% agar. The base agar containing 1% agar was melted 
in a microwave oven and cooled to 40˚C in a water bath. 2X RPMI 1640 with 20% FCS 
were warmed at 40˚C in a water-bath and for 30 minutes. Then, equal volumes of the two 
solutions were mixed to obtain 0.5% agar and 1X RPMI 1640 with 10% FCS. After that, 
1.5 ml of mixed solutions was added to a petri dish (35 mm). The second layer, the top agar 
containing 0.7% agar, was melted in a microwave oven and cooled to 40˚C in a water-bath. 
Also, 2X RPMI 1640 with 20% FCS were heated at the same temperature. 
Cells were trypsinised and counted to a ratio of 5 × 10
3
 cells per plate. Then, 3 ml of 2X 
RPMI 1640 (20% FCS) and 3 ml of 0.7% agar were added to a centrifuge tube and mixed 
gently, after which 1.5 ml was added to each petri dish (35 mm) that was covered with base 
agar. Incubated assays were performed at 37˚C with 5% CO2 in a humidified incubator for 
9 days. After that, plates were stained with 0.5 ml of 0.005% crystal violet for 
approximately 2 hrs; then colonies were counted using an inverted microscope Nikon 
Eclipse Ti camera. Also, the cloning efficiency was calculated as the number of colonies 
divided by the number of cells added to each plate. 
4.3.3 DNA Fragmentation Assays 
DNA fragmentation assay was performed using the Suicide Track™ DNA Ladder Isolation 
Kit (Calbiochem, CA), according to manufacturer's instructions. Briefly, 1 × 10
6 
MCF-7 
cells were cultured in a T-25 flask and treated with different concentration of compounds 
for 24 hours. Floating and trypsinized-adherent of treated and untreated cells were collected 
by centrifuging at 1500 × g for 5 min. Cell pellets were then resuspended in 500 μl of 
extraction buffer following incubation on 4°C for 30 min. The suspensions were then 
centrifuged at 16, 000 × g for 5 min at room temperature. The resulting supernatant were 
transferred to a clean tube, followed by the addition of 20 μl of RNase A solution and 
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incubated at 37°C for 1 h. DNA isolation buffer was added and further incubated at 50°C 
for overnight. Then, 2 μl of Pellet Paint® Co-precipitant was added to the suspension 
together with 60 μl of 3 M sodium acetate and 662 μl of 2-propanol. Samples were mixed 
by inversion for 2 min and then centrifuged at 16, 000 × g for 5 min. The resulting pellets 
were washed with 500 µl of 70% and 100% ethanol, respectively. The small apoptotic 
DNA fragments were separated from intact chromatin and were then air-dried and 
resuspended in 50 μl of resuspension buffer (10 mM Tris, 1 mM EDTA). Finally, purified 
fragments were analyzed on a 1.5% (w/v) agarose gel electrophoresis and stained with 0.5 
µg/ml ethidium bromide. Fragmentation of DNA was observed under UV illumination and 
visualized using a gel documentation system (UVP Biospectrum HR410). Positive control 
was supplied by Calbiochem which consist of 1 × 10
6 
HL-60 cells treated with 0.5 mg/ml 
Actinomycin D for 19 h. 
4.4 IN VITRO ANTI-MICROBIAL STUDIES 
4.4.1 Antimicrobial Testing 
The synthesized compounds were first screened for potential antibacterial activity by 
testing against two randomly selected strains from each bacterial species, using disc 
diffusion assay (CLSI, 2011).   Briefly, a loopful of an overnight bacterial culture of each 
strain was suspended in sterile 0.85% saline (BDH) to the concentration of approximately 
“108” cfu/ml (equivalent to 0.5 Mc Farland units) before inoculated evenly on the entire 
surface of Mueller Hinton agar (Oxoid) with a sterile cotton swab. Sterilized paper discs 
(Thermo Fisher, 6mm diameter), impregnated with 30 µg of respective synthetic Schiff 
compound, and was placed on the inoculated agar plate. DMSO disc was used as a negative 
control in the test. The diameter of inhibition zone around the impregnated paper disc was 
measured after 18 hour of incubation at 37˚C. All tests were performed in duplicate. 
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Synthetic Schiff compounds, in which inhibition zone was observed in any one of the four 
species tested, were selected for MIC and MBC determination with broth micro-dilution 
assay. Only compounds with MIC and MBC value lesser than “10 µg/mL,” is considered 
potentially active against the corresponded bacterial species; and further tested against the 
entire collection of the corresponded bacterial species with disc diffusion assay. This was to 
determine the variation in the susceptibility responses to the tested compound within the 
bacterial species tested. The two selected strains for each species in the initial screening 
were: MRSA 0804-25 and MRSA 0807-7 for MRSA; AC 0612-7 and AC 0903-21 for A. 
baumannii; KB 71 and KB 83 for K. pneumonia; and PA45 and PA104 for P. aeruginosa.  
4.4.2 MIC determination 
Minimum inhibition concentration (MIC) was determined with 96-well broth micro-
dilution assay. The inoculum was prepared by suspending an overnight culture in a sterile 
0.85% saline (BDH) to approximate 10
8
 cfu/ml (equivalent to 0.5 McFarland units) and 
further diluted in cation adjusted Mueller Hinton broth (CMHB; BD) to the concentration 
of 10
6
 cfu/ml. Two-fold serial dilutions of the tested compound were prepared in CMHB 
across the 96-well microtiter plate with the highest concentration starting from 750 ppm 
(750 µl/ml) in duplicate rows. The prepared suspension of the bacteria was added to each 
well except the negative control wells of the microtitre plate in a 1:1 ratio with final 
bacteria concentration of approximately “5 x 105” cfu/ml. The inoculated microtitre plates 
were incubated at 37˚C for 24 hour.  
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Figure 4.4.2.1: Photograph showing the antibacterial (MRSA 0804-25-A,B,C) and (MRSA 
0807-7- a,b,c) screening 
The MIC was determined as the lowest concentration of the test compound that exhibits no 
visible growth. A further confirmative test was done by adding 30 µl of MTT dye (Sigma) 
to each well. Wells with color changes within 30 - 60 minutes incubation at room 
temperature were scored as positive growth. The lowest concentration of the tested 
compound that exhibits no color changes (yellow) is determined as the MIC value.  
4.4.3 MBC determination 
Before MTT dye was added to each well, 0.1ml was removed from each turbid well and 
inoculated onto Mueller Hinton agar (MHA) plate. It was then incubated at 37C for 24 
hour before result was read. The minimal bactericidal concentration (MBC) was determined 
as the lowest concentration of the tested compound that exhibits no viable microorganism 
growth on the MHA plate. The antimicrobial compound is regarded as bactericidal if the 
MBC is not more than four times the MIC. 
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4.5 ANTIBACTERIAL EVALUATION  
Nosocomial infections caused by multidrug resistant bacteria are an increasing medical 
problem worldwide, particularly among immunocompromised patients and those 
hospitalized in intensive care units. Both Gram positive and Gram negative bacteria have 
developed high level resistance to multiple classes of antibacterial agents. These include 
methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, 
Acinetobacter baumannii, Escherichia coli and vancomycin resistant enterococci (VRE) 
(Guidos, 2010). Few available drugs such as linezolid and some newer glycopeptides, and 
tigecycline are active against MRSA and VRE, but their success rates are variable 
(Esposito, 2007). As such, there is a need to explore other sources of effective antibacterial 
compounds to augment the limited choice of drugs for therapeutic treatment. 
A series of Schiff bases derived from 2-acetylpyridne and their metal complexes were  were 
screened for anti-bacterial activity against Methicillin-resistant Staphylococcus aureus 
(MRSA), Acinetobacter baumanni (AC), Klebsiella pneumonie (KB) and Pseudomonas 
aeruginosa (PA) using the disc diffusion and micro broth dilution assays. Based on the 
overall results, the complexes showed the highest activities against MRSA while a weak 
antibacterial activity was observed against A. baumanii and P. Aeruginosa, while no 
activity was observed in K. pneumonie.  
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Scheme 1. Reaction pathway for the coordinated complexes. 
 
Pharmacology: Bacterial Strains: The antibacterial activities of the investigated 
compounds were tested against a panel of multi-drug resistant nosocomial bacterial 
pathogens, consisted of ten (10) isolates of methicillin-resistant Staphylococcus aureus 
(MRSA)–MRSA 0804-25, MRSA 0805-21, MRSA 0806-1, MRSA 0807-1, MRSA 0807-7, 
MRSA 0807-19, MRSA 0808-35, MRSA 0809-15, MRSA 0809-24, MRSA 0809-38; two (2) 
isolates of Acinetobacter baumannii(AC)–AC 0612-7, AC 0903-21, two (2) isolates of 
Klebsiella pneumonia (KB)–KB 71, KB 83, and two (2) isolates of Pseudomonas 
aeruginosa (PA)–P. aeruginosa. All tested bacterial strains of MRSA were of clinical origin 
and have shown resistance to at least four antibiotics. For each bacterial species, six to ten 
strains were included in the antibacterial study to capture possible drug resistance variation 
within species. All bacterial strains that used in this study were obtained from the bacteria 
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culture collection of Biomedical Science Laboratory, Institute of Graduate Studies 
University of Malaya, Kuala Lumpur, Malaysia.  
4.6 RESULTS AND DISCUSSION 
Antibacterial Activity Results: A total of ten Schiff-base compounds were synthesized and 
screened for potential antibacterial activity against the emerging multi-drug resistance 
nosocomial bacterial pathogens in hospital settings, namely, methicillin-resistant 
Staphylococcus aureus, A. baumanii, K. pneumonia and P. aeroginosa. In the first level 
antibacterial screening with the disc diffusion assay, all compounds under study were tested 
against eight clinical strains, two from each bacterial species. Inhibition zones were 
observed in the Schiff base compounds. However, no inhibition zone was observed in any 
of the compounds tested against K. pneumonia (Table 4.1). All compounds were strongly 
inhibitive against MRSA, while they showed weak antibacterial activity against A. 
baumanii and P. aeroginosa in the disc diffusion test (Table 4.1). This higher antimicrobial 
activity of the metal complexes 4–10, compared with that of Schiff base ligands 1–3, is 
perhaps due to the change in structure as a result of coordination, as chelating tends to 
make metal complexes act as more powerful and potent bacteriostatic agents, thus inhibiting 
the growth of the microorganisms (Chohan, 2006 & Chohan, 2003). These seven compounds 
were then analyzed further for the MIC and MBC value using broth micro-dilution assay 
(Table 4.2). The result from broth micro-dilution assay was in total analogue to the disk 
diffusion screening. The test showed that, all of the seven compounds were most active 
against MRSA, with MIC value ranged from 0.7–2.9 µg/mL; MBC value ranged from 2.9–
46.9 µg/mL (Table 4.2). Both A. baumanii and P. aeroginosa were resistant to the tested 
compounds at concentration lower than 93.8 and 187.0 µg/mL, respectively (Table 4.2). 
Therefore, it was concluded that these seven compounds were highly inhibitive only against 
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the Gram positive bacterium MRSA. Further antibacterial tests were conducted against 
eight clinical strains of multi-drug resistant MRSA (Table 4.3) showing varying responses 
towards the seven selected Schiff-based compounds in the disc diffusion assay (scheme 1), 
however, they demonstrated twenty percent of resistance rate (two strains out of ten were 
resistant to the seven tested compounds). The broth micro-dilution assay resulted in similar 
findings, in which all, but MRSA 0807-1 and MRSA 0808-35, were inhibited at MIC 
ranging from “1.5 to 11.7” µg/mL. Both, MRSA 0807-1 and MRSA 0808-35, were only 
inhibited at MIC ranging from “209.7 to 419.4” µg/mL. (Table 4.4) presented the 
antibiogram of ten clinical strains of MRSA used in this antibacterial analysis with some 
known antibacterial drugs in which MRSA either showed resistant (R), susceptible (S) or 
intermediate resistant (I) towards them. 
Table 4.1: First level antibacterial screening Disc diffusion assay. 
Compound 
MRSA 
0804-25 
MRSA 
0807-7 
AC 
0612-7 
AC 0903-
21 
KB 71 
KB 
83 
PA 
45 
PA 
104 
1 6 6 0 0 0 0 5 6 
2 5 5 0 0 0 0 5 5 
3 0 0 0 0 0 0 0 0 
4 21 22 7 7 0 0 8 8 
5 24 23 9 8 0 0 11 19 
6 22 23 9 8 0 0 10 10 
7 23 22 10 10 0 0 8 8 
8 21 20 10 9 0 0 9 9 
9 23 23 9 8 0 0 10 9 
10 22 22 7 7 0 0 10 9 
Control 
(DMSO) 
0 0 0 0 0 0 0 0 
 
Table 4.2: Second level antibacterial screening. 
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Minimum inhibitory concentration (MIC; µg/mL)/minimum bactericidal concentration (MBC; 
µg/mL) 
 
MRSA 
0804-25 
MRSA 
0807-7 
AC  
0612-7 
AC  
0903-21 
KB 71 KB 83 PA 45 PA 104 
1-3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
4 0.7/2.9 1.5/2.9 93.8/750 93.8/750 375/750 375/750 187.5/750 187.5/750 
5 0.7/2.9 0.7/2.9 93.8/750 93.8/750 187.5/750 187.5/750 187.5/750 187.5/750 
6 1.5/5.9 1.5/5.9 93.8/375 93.8/375 375/750 375/750 187.5/750 187.5/750 
7 1.5/5.9 1.5/5.9 93.8/375 93.8/375 187.5/750 187.5/750 187.5/750 187.5/750 
8 1.5/5.9 1.5/2.9 93.8/750 93.8/750 375/750 375/750 187.5/750 187.5/750 
9 1.5/5.9 1.5/23.4 187.5/750 187.5/750 375/750 375/750 187.5/750 187.5/750 
10 2.9/46.9 2.9/46.9 187.5/750 187.5/750 375/750 375/750 187.5/750 187.5/750 
DMSO 375/>375 375/>375 375/>375 375/>375 375/>375 375/>375 375/>375 375/>375 
 
n.d. = not determined. 
Table 4.3: Varying responses of the eight MRSA clinical strains towards the seven selected 
Schiff-base complexes in the disc diffusion assay. 
Compounds 
MRSA 
0805-
21 
MRSA 
0806-1 
MRSA 
0807-1 
MRSA 
0807-
19 
MRSA 
0808-
35 
MRSA 
0809-
15 
MRSA 
0809-
25 
MRSA 
0809-
38 
4 23 24 0 23 0 22 22 21 
5 23 24 0 25 0 23 23 23 
6 24 22 0 22 0 21 21 22 
7 24 20 0 21 0 19 20 20 
8 25 23 0 24 0 21 21 22 
9 23 23 0 22 0 23 24 23 
10 22 22 0 22 0 22 22 22 
(DMSO) 0 0 0 0 0 0 0 0 
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Figure 4.6.1: Histogram for the 10 MRSA clinical strains of Schiff-base complexes. 
 
 
Table 4.4: Antibiogram of the ten clinical strains of MRSA used in the antibacterial 
analysis. 
Strain No E CN LZD MUP RD DA TEC CIP NET TE VA FD OX SXT 
MRSA 0805-21 R R S S S S S R R R S S R R 
MRSA 0806-1 R R S S S S S R R R S S R R 
MRSA 0807-1 R R S S S S S R R R S S R R 
MRSA 0807-19 R R S S S S S R I S S S R S 
MRSA 0808-35 R R S S S S S I I R S S R R 
MRSA 0809-15 R R S S S S S R R R S S R R 
MRSA 0809-24 R R S S S S S R R R S S R R 
MRSA 0809-38 R R S S S S S R R R S S R S 
MRSA 0807-7 R R S S S S S R I R S S R R 
MRSA 0804-25 R R S S S S S R S S S S R S 
 
E = erythromycin; GN = gentamycin; LZD-linozolid acid; MUP = muciprocin; RD- rifampicin;  
DA = clindamycin; TEC = teicoplanin; CIP = ciproflozaxin; NET = netilmycin; TE = tetracycline;  
VA = vancomycin; FD = fusicidic acid; OX = oxacilin; SXT = Trimethoprim-sulfamethaxazole; R = 
resistant; S = sensitive; I = intermediate resistant. 
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4.7 ANTICANCER STUDIES  
Schiff base compounds derived from morpholine are completely stable in biological 
systems, allowing rigorous long-term applications as they constitute a radical re-design of 
DNA (Summerton., 2007); these important factors are considered in designing this 
morpholine derived ligands and their metal complexes for their potential antibacterial and 
anticancer applications. First row transition metals play major roles in various biological 
activities because of the exceptionally wide range of reactivity available and have been 
particularly attractive (Petrovic., 1996). In this part, metal complexes of some newly 
synthesized N,N’N” and N’N”O donor Schiff base ligands from the reaction of 4-(2-
aminoethyl)morpholine with either 2-acetylpyridine or 2-hydroxyacetophenone in presence 
of Cl
-
, N3
-
, and SCN
- 
ions (scheme 1), were examined for potential anti-cancer applications. 
4.7.1: RESULTS AND DISCUSSION 
MTT assay: MTT assay was used to determine the metal complexes cytotoxicity against 
human breast cancer cells MCF-7. This assay served as an index used to determine 
cytotoxicity of the metal complex to stimulate or inhibit cell viability and growth by 
detecting the reduction of tetrazolium salt to blue formazan by mitochondrial enzyme 
activity of succinate dehydrogenase in living cells. MCF-7 cells were treated with varying 
concentrations of the complexes for 48 h, and the cells viabilities were measured by MTT 
assay. The metal complexes were found to inhibit the growth of MCF-7 cells in a dose-
dependent manner (Table 4.5). The free ligand MTT assay showed no significant inhibition 
activities at a concentration even higher than the complex which confirmed that chelation 
of ligand with metal ions was significance for the activity of this novel compounds.  
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Table 4.5: EC50 values in µg/ml of the tested compounds on WRL68 and MCF-7 cell lines 
 
 
 
 
 
 
 
 
 
 
Clonogenic assay: Clonogenic assay is used f or studying the effectiveness of 
specific agents on the survival and proliferation of cells. In this study we determine the 
effectiveness for the cytotoxicity of Cobalt(III) compound to inhibit growth of MCF-7 
cells. Cells were trypsinised and counted to a ratio of 5 × 10
3
 cells per plate. The number 
of cells that formed colony was reduced after exposure to the Cobalt compound at 
concentrations of 2.80, 3.72 and 4.53 µg/ml as compared to the untreated MCF-7 (control) 
(Figure 4.7.1). No colony was observed at the concentration of higher than 8.56 µg/ml, 
indicating the Cobalt(III) compound showed toxicity and inhibited the proliferation of 
MCF-7 cell. Toxicity of compound was further supported by clonogenic efficiency (CE) 
which is the number of colonies divided by the number of cells added to each plate (Table 
4.6). This result is consistent with the result of the MTT assay (IC50). 
 
 
 
 
 
  
Cpd. 
EC50 µg/ml 
 
  
Cpd. 
EC50 ug/ml 
 
 WRL68 MCF-7  WRL68 MCF-7 
1 L1 n.d. n.d. 10 L2 n.d. n.d. 
2 Cu(L1)Cl 41.15 37.58 11 Cu(L2)Cl2 47.80 64.24 
3 Cu(L1)Br 
 
23.28   4.25 12 Cu(L2)Br2 31.09 57.18 
4 Zn(L1)Br 52.26 33.09 13 Cu(L2)(N3)2   3.84   2.51 
5 Zn(L1)Cl 32.69 10.94 14 Mn(L2)Cl2 34.29 >100 
6 Ni(L1)Cl 
 
13.05   8.15 15 Mn(L2)(SCN)2 30.25 26.45 
7 Ni(L1)Br 64.53 27.64 16 Ni(L2)(SCN)2   2.68   1.82 
8 Mn(L1)Cl 
 
44.25 24.54 17 Zn(L2)I2 
 
39.25 34.55 
9 Mn(L1)Br   4.65   5.93 18 Cisplatin -    2.50 
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Table 4.6: MTT assay for cobalt(III) complex 
 
 
 
 
 
                                                      Where CE*= Colonogenic efficiency 
 
 
Figure 4.7.1: Clonogenic assay by treatment of the Cobalt(III) on MCF-7 cell lines at 14 
days after seeding.  Panels A and B represent in vitro growth inhibition of MCF-7 by 
Cobalt(III) at concentrations of 2.80±0.02 and 3.72±0.05 µg/ml. White arrows indicate 
reduced apoptotic colonies. Panel C shows untreated MCF-7 as control. The colonies which 
is defined to consist of at least 50 cells were counted and photographed. Magnification 20×. 
 
 
 
 
 
 
Compound Concentrations 
(µg/ml-IC50) 
Number 
of 
Cells/Plat 
Number of  
Apoptotic 
colonies  
Total colony 
number before 
treatment 
CE* 
Co(III) 2.80±0.02  5×10
3
 250 500 0.050 
Co(III) 3.72±0.05 5×10
3
 290 500 0.042 
Co(III) 4.53±0.03 5×10
3
 340 500 0.032 
Co(III) 8.56±0.02 5×10
3
 500 500 0 
Co(III) 12.45±0.03 5×10
3
 500 500 0 
Control - 5×10
3
 10 500 0.098 
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Multiparameter cytotoxicity analysis: The multiparameter cytotoxicity analysis identifies 
the changes in nuclear morphology, size, and membrane permeability status, cytochrome C 
level and mitochondrial damage caused by compound toxicity. In this study, treated MCF-7 
cells with Cobalt(III) compound induced reduction of nuclear morphology size, cell density 
and increased cell membrane permeability, which highlights better activity than Tamoxifen 
(standard drug). However, cytochrome C release by Tamoxifen was rather higher than by 
the Cobalt compound (Figure 4.7.2). The decline in mitochondrial membrane together with 
simultaneous nuclear fragmentation, increased cell permeability and cytochrome C release 
confirmed the mode of cell death as apoptosis (S. Syam, 2012). 
 
Figure 4.7.2: Multiparameter cytotoxicity analysis 
The nuclear morphological changes of treated MCF-7 cells using Hoechst 33342 staining 
were examined to show nuclear condensation and fragmentation for 48 hrs, which is the 
hallmark for apoptosis. Our results were in agreement with previous studies which showed 
that the treated cells that underwent apoptosis exhibited characteristic morphological 
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changes, such as cell shrinkage, membrane blebbing, chromatin condensation, and nuclear 
fragmentation (Kerr., 1991). Mitochondrial membrane potential, which is important for 
ATP formation and cell survival, showed a significant reduction of fluorescence intensity 
(Figure 4.7.3) on treated MCF-7 cells with Cobalt(III) compound for 48 hrs. In particular, 
Cobalt(III) compound disrupted mitochondrial membrane potentials in MCF-7 cells, 
indicating increased mitochondrial membrane permeability (Figures 4.7.3). The cell 
permeability was also increased subsequently upon treatment with the compound. An 
apoptotic stimulus which triggers the release of cytochrome C from the mitochondria into 
the cytosol by binding to Apaf-1, plays an important role in apoptosis (Liu. 2011). 
Cobalt(III) compound significantly triggered the MCF-7 cells to translocate the cytochrome 
C from the mitochondria into the cytosol during apoptosis. In this study, cytochrome C was 
released even at the concentration of 2 µg/ml. These effects occurred more rapidly, and 
followed a dose-response pattern.  
 
 
Figure 4.7.3: Graph of Multiparameter cytotoxicity analysis 
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DNA Fragmentation Assays: Apoptotic DNA fragmentation is a key feature of apoptosis, a 
type of programmed cell death (Syam, 2011). Apoptosis is characterized by the activation 
of endogenous endonucleases with subsequent cleavage of chromatin DNA into 
internucleosomal fragments. Degradation of nuclear DNA into nucleosomal units is one of 
the hallmarks of apoptotic cell death (Figure 4.7.4). It occurs in response to various 
apoptotic stimuli in a wide variety of cell types. The enzyme responsible for apoptotic 
DNA fragmentation is the Caspase-Activated DNase (CAD) that is normally inhibited by 
the Inhibitor of Caspase Activated DNase (ICAD). However, during apoptosis, the 
apoptotic effector caspase, caspase-3, cleaves ICAD and thus causes CAD to become 
activated.
 
At 2 µg/ml concentration the Cobalt(II) compound was capable in producing 
DNA ladder, the ladder formation increased with increase in concentration of the 
compound used. 
 
Figure 4.7.4: Apoptotic DNA fragmentation showing degradation of nuclear DNA into 
nucleosomal units 
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Roles of caspase-3 in compound-induced apoptosis in MCF-7 cells: To further confirm the 
Cobalt compound induced apoptosis in MCF-7 cells, we performed calorimetric 
measurement of the caspase activity and mechanisms involved after treatment with 1.5, 3 
and 4.5 µg/ml Cobalt compound for 48 h. The activity of caspase-3 increased remarkably in 
MCF-7 cells after administration of cobalt compound via the intrinsic mitochondrial 
apoptotic pathway in caspase-3 activity, which confirmed the apoptosis of MCF-7 cells 
induced by Cobalt compound (Figure 4.7.5). The importance of caspase-3 is well discussed 
elsewhere (Porter, 1999) as it has a role in DNA fragmentation and other morphological 
changes in relation to apoptosis. 
 
Figure 4.7.5: Histology of the Result of caspase-3 relative activity vs concentration in uM 
Molecular Docking: Caspase-3 (pdb id: 1PAU) is a member of the cysteine-aspartic acid 
protease (caspase) family (Alnemri., 1996). Sequential activation of caspase-3 plays a 
central role in the execution-phase of cell apoptosis. The catalytic site of caspase-3 involves 
the sulfohydryl group of Cys-285 and the imidazole ring of His-237. His-237 stabilizes the 
carbonyl group of the key aspartate residue, while Cys-285 attacks to ultimately cleave the 
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peptide bond. Cys-285 and Gly-238 also function to stabilize the tetrahedral transition state 
of the substrate-enzyme complex through hydrogen bonding (Lavrik., 2005). 
 
Figure 4.7.6 (a) Surface Connolly representation of the molecular model of the complex 
formed between cobalt(III) and Caspase-3 (1PAU) (at the binding site).  
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Figure 4.7.6 (b). 3D representation of the ligand-enzyme binding interactions. Cobalt(III) 
compound is represented as balls and sticks, the surrounding residues as sticks and 
hydrogen bonds as green dashed lines.  
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Figure 4.7.6 (c). 2D schematic representation of the hydrogen bonding and hydrophobic 
interactions between the Cobalt(III) compound and the residues at the binding site of 
Caspase-3. 
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The residues involved in the interactions of Cobalt(III) compound are Asn 342, Asp 345, 
Asp 502, Gln 351, Glu 379, Glu 380, Glu 381, Phe 380, Phe 381, Ser 381, and Trp 348 
[Figure 4.7.6 (a)]. The complex formed between cobalt(III) compound and caspase-3 showed 
that the ligand does not bind to the active-site gorge. And  the caspase-3 zymogen (pdb id: 
1PAU) has virtually no activity until it is cleaved by an initiator caspase after apoptotic 
signaling events have occurred (Walters., 2009), therefore, the introduction of cobalt(III) 
compound can activate caspase-3 initiator into cells targeted for apoptosis (Katunuma, 
2001). This extrinsic activation then triggers the hallmark caspase cascade characteristic of 
the apoptotic pathway, in which caspase-3 plays a dominant role (Perry., 1997). The 
decline in mitochondrial membrane potential leads to release of cytochrome C (both 
confirmed by high content screening) and this could eventually lead to caspase-3 activation 
and hence apoptosis. Thus it is not the cobalt(III) compound that directly binds to capsase-3 
which resulted the increase in caspase-3 after the treatment, rather, the mitochondria 
mediated apoptotic signaling cascade which leads to the increase in level (Syam, 2012, 
Narula, 1999).  In intrinsic activation, cytochrome C from the mitochondria works in 
combination with ATP to process procaspase-3 (Katunuma., 2001; Porter., 1999, Li, 2004). 
A closer inspection of the interactions [Figure 4.7.6 (b)] showed the presence of hydrogen 
bond between the oxygen attached to the morpholine group with Gln 351 (B), π-π and 
cation-π stacking involving between nitrogen atoms from the azide groups and Glu 379(A), 
Glu 381(B), Phe 380, Ser 381 and Asp 502(C). Furthermore, hydrophobic interactions 
[Figure 4.7.6(c)] between ligand and caspase-3 residues [Phe 380, Asp 345 (B), Phe380 
(B), Trp 348 (B) and Asn 342(B)] was observed which enables the morpholine oxygen to 
form a hydrogen bond with Gln 351(B) and  azide groups to form a cluster of networking 
hydrogen bonds with Gln351(B). 
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4.8 ANTI-ALZHEIMER AND ANTI-OXIDANT ACTIVITIES  
Over view: The chemistry of hydrazones is an intensive area of study and numerous Schiff 
base ligands and their complexes of this type have been synthesized and their biological 
applications reported (da Silva, 2011, Creaven, 2010, Ceyhan, 2011, Qiao, 2011 and Xu, 
2008). The major antioxidants currently used in foods are monohydroxy or polyhydroxy 
phenol compounds with various ring substitutions. These compounds have low activation 
energy for hydrogen donation (Rice-Evans., 1999). Alzheimer’s disease (AD) is the most 
common form of dementia among older people and the pathogenesis of this disease is 
associated with oxidative stress. Acetylcholinesterase inhibitors with antioxidant activities 
are considered potential treatments for AD. Some novel ketone derivatives of gallic 
hydrazide-derived Schiff bases were synthesized and examined for their antioxidant 
activities and in vitro and in silico acetyl cholinesterase inhibition. The compounds were 
characterized using spectroscopy and X-ray crystallography.  Mainly from in vitro studies, 
polyphenols have been reported to have antioxidant (Clemetso., 1966, Sun-Waterhouse, 
2009), anti-cancer (Kuhn, 2005 and Samoylenko., 2011) and cardioprotecive activities 
(Claudine, 2005) 
Researchers have recently investigated the potential health benefits of polyphenols in 
organic product (Bourn, 2002). Increased consumption of polyphenols has been associated 
with a reduced risk of cardiovascular disease and possibly cancer and stroke. Laboratory 
findings have shown that oxidative stress may play an important role to the pathogenesis of 
AD. Therefore, the risk of AD disease might be decreased by intake of antioxidants that 
neutralize the unfavorable effects of oxidative stress (Arts, 2005). The present work reports 
the synthesis, characterization, antioxidants activities and X-ray crystal structures of Schiff 
bases derived from the condensation reaction of gallic hydrazide with pyridine and 
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acetophenone derivatives, together with their acetylcholinesterase inhibition and 
antioxidant activity (Scheme 1). 
Scheme 1. Reaction pathways. 
 
4.8.0: Synthesis of Gallic Hydrazide (1) 
 
(Yield 70%), melting point = 290 °C, elemental analysis theory: C (45.6%); H (4.3%); N 
(15.2%); found: C (45.2%); H (5.04%); N (15.04%), %, FT-IR spectra (KBr); 3,429 cm
−1
 
(νAr-OH), 3,299 cm−1 (νN-H), 1,654 cm−1 (νC=O), 1,344cm−1 (νC-O), 1,103 cm−1 (νN-N), 
1
H-NMR (DMSO-d6): 9.35 ppm [δ(Ar-OH), 1H s], 9.13 ppm, 9.05 ppm [δ(Ar-OH), 2H, d], 
8.65 ppm [δ(NH), 1H, brd], 6.79 ppm, 6.82 ppm [δ(Ar-H), 2H s], 4.37 ppm [δ(NH2), 2H s]. 
204 
 
13
C-NMR (DMSO-d6): 166.39 ppm [δ(CONH), 1C], 145.37 ppm [δ(aromatic), 1C-OH], 
136.10, 136.42 ppm [δ(aromatic), 2C-OH], 124.00 ppm [δ(aromatic), 1C], 106.43 ppm 
[δ(aromatic), 2C = C] ppm. 
4.8.1 N-(1-(5-Bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide (2) 
 
(Yield 75%), elemental analysis: theory C (47.50); H (3.89); N (7.32); found C (47.26); H 
(3.44); N (7.35); IR spectra (KBr); 3,558 cm
−1
 (νAr-OH), 3,235 cm−1 (νN-H), 1,604 cm−1 
(νC=N), 1,658 cm−1 (νC=O), 1,242 cm−1 (νC-O), 953 cm−1 (νN-N), 1H-NMR (DMSO-d6): 
13.57 ppm [δ(OH), 1H, s], 11.10 ppm [δ(OH), 1H, s], 9.05 ppm [δ(OH), 2H, brd], 6.79–7.73 
ppm [δ(aromatic), 5H, m], 4.34 ppm [δ(NH), 1H, s], 1.24 ppm [δ(-CH3 ), 3H, s]. 
13
C-NMR 
(DMSO-d6): 166.39 ppm [δ(C=N)], 164.43 ppm [δ(C=O)], 145.53 ppm, 145.36 ppm 
[δ(aromatic), 2C-OH], 137.41 ppm [δ(aromatic), 1C-OH], 137.40, 136.10 ppm, 
[δ(aromatic), 2C], 130.31 ppm [δ(aromatic), 1C], 123.51 ppm, 122.35 ppm, 121.52 ppm, 
119.50 ppm [δ(aromatic), 4C], 107.54 ppm, 106.42 ppm [δ(aromatic), 2C=C], 13.92 ppm 
[δ(CH3)] ppm. 
4.8.2 N-(1-(5-Chloro-2-hydroxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide (3) 
 
(Yield 75%) respectively, elemental analysis: theory C (53.50); H (3.89); N (8.32); found C  
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(53.39); H (3.76); N (8.33); IR spectra (KBr); 3,568 cm
−1
 (νAr-OH), 3,225 cm−1 (νN-H), 
1,638 cm
−1
 (νC=O), 1,604 cm−1 (νC=N), 1,212 cm−1 (νC-O), 953 cm−1 (νN-N). 1H-NMR 
(DMSO-d6): 11.14 ppm [δ(OH), 1H, s], 11.13 ppm [δ(OH), 1H, s], 9.30 ppm [δ(OH), 2H, 
brd], 7.66 ppm [δ(NH), 1H, s], 7.37–6.93 ppm [δ(aromatic), 3H, m], 6.983 ppm, 6.976 ppm 
[δ(aromatic), 2H str d], 2.12 ppm [δ(-CH3), 3H, s]. 13C-NMR (DMSO-d6): 166.94 ppm 
[δ(C=N)], 164.84 ppm [δ(C=O)], 157.94 ppm [δ(aromatic) 1C], 146.10 ppm, 145.93 ppm 
[δ(aromatic), 2C-OH], 137.97 ppm [δ (aromatic), 1C-OH], 128.10 ppm, 124.08 ppm, 
122.92 ppm, 122.53 ppm, 121.48 ppm, 119.58 ppm [δ(aromatic), 6C], 108.10 ppm, 106.98 
ppm [δ(aromatic), 2C=C], 14.48 ppm [δ(CH3)] ppm. 
4.8.3 N-(1-(2-Hydroxy-5-methoxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide (4) 
 
(Yield = 65%), elemental analysis: theory C (57.83); H (4.85); N (8.43); found C (58.30); 
H (4.51); N (8.71); IR spectra (KBr); 3,467 cm
−1
 (νAr-OH), 3,308 cm−1 (νN-H), 1,650 cm−1 
(νC=O), 1,623 cm−1 (νC=N), 1,282 cm−1 (νC-O), 944 cm−1 (νN-N), 1H-NMR (DMSO-d6): 
12.89 ppm [δ(OH)], 10.98 ppm [δ(OH), 1H, s], 9.28 ppm [δ(OH), 2H, brd], 8.90 ppm 
[δ(NH)], 7.11 ppm [δ(aromatic), 2H str s], 7.11–6.83 ppm [δ(aromatic), 3H, m], 3.75 ppm 
[δ(O-CH3), 3H, s], 1.24 ppm [δ(-CH3), 3H, s]. 
13
C-NMR (DMSO-d6): 152.58 ppm 
[δ(C=N)], 151.36 ppm [δ(C=O)], 145.52 ppm [δ(aromatic), 2C-OH], 137.27 ppm 
[δ(aromatic), 1C-OH], 122.70 ppm, 122.61 ppm, 117.77 ppm, 117.39 ppm, 119.49 ppm 
[δ(aromatic), 5C], 107.44 ppm [δ(aromatic), 2C=C], 55.54 ppm [δ(O-CH3)], 13.94 ppm 
[δ(CH3)] ppm. 
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4.8.4:  3,4,5-Trihydroxybenzoic Acid [1-Pyridylethylidene] Hydrazide (5) 
 
(Yield = 65%), melting point = 253 °C, elemental analysis: theory: C (58.53%); H (4.56%); N 
(14.63%); found: C (57.99%); H (4.56%); N (14.06%), IR spectra (KBr); 3,399 cm
−1
 (νAr-
OH), 3,351 cm
−1
 (νN-H), 1,621 cm−1 (νC=N), 1,618 cm−1 (νC=O), 1,560 cm−1 (νC=N)Py, 
1,281 cm
−1
 (νC-O), 1,032 cm−1 (νN-N), 1H-NMR (DMSO-d6): 9.38 ppm [δ(OH), 1H, s], 
9.21 ppm, 9.11 ppm [δ(OH), 2H, brd], 8.14–8.07 ppm [δ(aromatic), 2H m], 7.87–7.70 ppm 
[δ(aromatic), 2H m], 7.63 ppm [δ(NH), 1H, s, brd], 6.92 ppm [δ(aromatic), 2H str s], 1.24 
ppm [δ(-CH3), 3H, s]. 13C-NMR (DMSO-d6): 162.47 ppm [δ(C=N)], 155.25 ppm 
[δ(C=O)], 148.54 ppm [δ(aromatic), pyridine], 145.85 ppm [δ (aromatic), 2C-OH], 138.70 
ppm [δ(aromatic), 1C-OH], 136.52 ppm [δ(aromatic), pyridine], 124.57 ppm [δ(aromatic), 
1C], 123.95 ppm, 122.90 ppm [δ(aromatic), pyridine], 107.55 ppm, 106.35 ppm [δ 
(aromatic), 2C=C], 22.10 ppm [δ(CH3)] ppm. 
4.8.5: N'-(1-(6-Acetylpyridin-2-yl)ethylidene)-3,4,5-trihydroxybenzohydrazide (6) 
 
(Yield 90%), elemental analysis: theory C (58.36); H (4.59); N (12.76); found: C (57.99); H 
(4.89); N (13.11); IR spectra (KBr); 3,448 cm
−1
 (νAr-OH), 3,239 cm−1 (νN-H), 1,674 cm−1 
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(νC=O), 1,610 cm−1 (νC=N), 1,511 cm−1 (νC-N)py, 1,265 cm−1 (νC-O), 955cm−1 (νN-N). 
1
H-NMR (DMSO-d6): 9.29 ppm [δ(OH), 1H, s], 8.26 ppm, 8.28 ppm [δ(OH), 2H, brd], 
8.14–8.03 ppm [δ(aromatic), 2H m], 8.01–7.90 ppm [δ(aromatic), 2H m] 6.89 ppm 
[δ(aromatic), 2H str s], 4.3 ppm [δ(NH), 1H, s], 1.19 ppm [δ(-CH3), 3H, s]. 13C-NMR (DMSO-
d6): 166.38 ppm [δ(C=N)], 164.34 ppm [δ(C=O)], 151.97 ppm [δ(aromatic), pyridine], 145.37 
ppm [δ(aromatic), 2C-OH], 137.87 ppm [δ(aromatic) 1C-OH], 136.13 ppm [δ(aromatic), 
pyridine], 123.87 ppm [δ(aromatic), 1C], 123.51 ppm [δ(aromatic), 2C=C], 121.13 ppm, 
120.26 ppm [δ(aromatic), pyridine], 199.24 ppm, 106.45 ppm [δ(C=OCH3)], 25.50 ppm 
[δ(CH3-C=O)], 18.52 ppm [δ(CH3)] ppm. 
Anti-AChE Assay: The anti-cholinesterase activities of the compounds were evaluated by 
Ellmann’s method with slight modifications, using acetylthiocholine as a substrate 
(Guilhermino, 1996) and 5,5'-dithiobis[2-nitrobenzoic acid](DTNB). Sodium phosphate 
buffer (pH 8.0, 110 μL) was added into the 96 wells followed by sample solution (20 μL), 
DTNB (0.126 mM, 50 μL) and AChE enzyme (0.6 U/mL, 20 μL). The mixture was 
incubated for 50 minutes at 37 °C. The reaction was then initiated by the addition of 
acetylthiocholine iodide (0.120 mM, 50 μL). The hydrolysis of acetylthiocholine was 
monitored by the formation of yellow 5-thio-2-nitrobenzoate anion as the result of the 
reaction of DTNB with thiocholine, released by the enzymatic hydrolysis of 
acetylthiocholine, at a wavelength of 412 nm every 30 s for 25 minutes using a 96-well 
microplate plate reader (TECAN Infinite M200, Mannedorf, Switzerland). Test compounds 
were dissolved in analytical grade DMSO. Tacrine and propidium iodide were used as 
reference standards (Laskwoski., 2001). The reactions were performed in triplicate and 
monitored with a spectrophotometer. The percent inhibition of the enzyme activity due to 
the presence of increasing test compound concentration was obtained from the expression; 
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100 − (vi/vo × 100), where vi is the initial rate calculated in the presence of inhibitors and 
vo is the enzyme activity. 
4.9 RESULTS AND DISCUSSION 
Chemistry: The reaction of gallic hydrazide (1) with selected hydroxyacetophenones and 
pyridine derivatives resulted in the formation of the corresponding polyphenolic 
compounds: N-(1-(5-Bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzohydrazide (2); N-(1-(5-Chloro-2-hydroxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzohydrazide (3); N-(1-(2-Hydroxy-5-methoxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzohydrazide (4); 3,4,5-Trihydroxybenzoic acid [1-pyridylethylidene] 
hydrazide (5); 3,4,5-Trihydroxybenzoic acid [1-(4-acetyl-pyridin-2-yl)-ethylidene] 
hydrazide (6) (Scheme 1). Their NMR, IR and UV-visible spectra were all consistent with 
the proposed structures. 
 
Figure 4.9.1. ORTEP-type view of the crystal structure of compound 4 showing the 
labeling scheme. Thermal ellipsoids are drawn at the 50% probability level. 
Anti-AChE Assay: The inhibitory activities of compounds 1–6 on human acetyl 
cholinesterase were in the range of  16–77% at 100 μM (see Table 4.7) and thus 
comparable to those of the standard drugs tacrine and propidium. 
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Table 4.7: Human AChE inhibitory effects and anti-oxidant activities for compounds 1–6. 
Cpd 
Molecular 
weight 
AChE Inhibition (%) 
 
DPPH 
(IC50, μg/mL) 
FRAP value 
(Mean ± SD) 
1 184.15 38.0 ± 1.3 1.210 ± 0.002 81,633.30 ± 0.075 
2 381.18 77.0 ± 1.8 1.140 ± 0.001 62,200.00 ± 0.083 
3 336.73 68.9 ± 1.8 1.400 ± 0.002 35,740.00 ± 0.011 
4 332.31 48.5 ± 2.5 1.220 ± 0.001 30,080.00 ± 0.054 
5 287.27 16.4 ± 1.4 1.460 ± 0.001 22,946.70 ± 0.004 
6 329.31 71.5 ± 1.7 2.300 ± 0.001 23,340.00 ± 0.021 
Propidium - 54.5 ± 1.6  - - 
Tacrine - 51.2 ± 1.6  - - 
Asc. acid - - 2.260 ± 0.001 19,400.00 ± 0.007 
BHT - - - 187.3 ± 2.6 
1: Gallic hydrazide; 2: N-(1-(5-Bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzohydrazide; 3: N-(1-(5-Chloro-2-hydroxyphenyl)-ethylidene)-3,4,5-
trihydroxybenzohydrazide; 4: N-(1-(2-Hydroxy-5-methoxyphenyl)-ethylidene)-
3,4,5-trihydroxybenzohydrazide; 5: 3,4,5-Trihydroxybenzoic acid [1-
pyridylethylidene] hydrazide, 6: 3,4,5-Trihydroxybenzoic acid [1-(4-acetyl-
pyridin-2-yl)-ethylidene] hydrazide; BHT: Butylated hydroxytoluene. 
 
Compounds 2, 3 and 6 showed the highest activities. This indicates that introduction of 
chlorine or bromine atom at position 5 of the acetophenone moiety significantly enhances 
the inhibition activity. This might be ascribed to the electron donating properties of the 
halogens by resonance, making the lone pair electrons more available to a plausible 
electron transfer. The activity of 6 could be attributed to the presence of the acetyl group on 
the pyridine ring making the lone pair electron on the pyridine nitrogen atom available for 
electron transfer, also increasing of bond dissociation enthalpy (BDE) values in phenolic 
structure contain substituent of electron withdrawing groups such as COR, COOR, CN 
(Heider, 2006) could discourage the abstraction of hydrogen. O-H bond dissociation 
enthalpy (BDE) is a theoretical parameter successfully used to measure the H-atom-donating 
ability of various antioxidants. Similar results have been reported by Kadoma (Kadoma., 
2007).  
210 
 
Molecular Docking: The crystal structure of hAChE (in complex with fasciculin-2) (pdb id: 
1B41) shows that the enzyme possesses a deep narrow gorge which penetrates halfway into 
the enzyme, where the catalytic site resides (Kadoma., 2007). The binding site of AChE 
consists of five subsites: a peripheral anionic site (PAS), an acyl binding pocket (ABP), the 
esteratic site (ES), an oxyanion hole (OH) and an anionic subsite (AS). 
 
Figure 4.9.2(a): Representations of the molecular model of the complex formed 
between compound 2 and hAChE.  3D representation of the ligand-enzyme 
binding interactions. Compound 2 is represented as a dark grey sticks and 
hydrogen bonds as green dashed lines 
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Figure. Cont. 
 
Figure 4.9.2(b): Representations of the molecular model of the complex formed 
between compound 2 and hAChE. 2D schematic representation of the hydrogen 
bonding and hydrophobic interactions. 
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The residues that have been reported to be involved in protein-ligand interactions are Tyr 
72, Asp 74, Tyr 124, Ser 125, Trp 286, Tyr 337 and Tyr 341 (PAS); Trp 236, Phe 295, Phe 
297 and Phe 338 (ABP); Ser 203, His 447 and Glu 334 (ES); Gly 121, Gly 122 and Ala 204 
(OH); and Trp 86, Tyr 133, Glu 202, Glu 448 and Ile 451 (AS) (Wiesner, 2007). The 
molecular docking simulation of the complex formed between compound 2 and hAChE (Figure 
4.9.2 a-c) showed the ligand well positioned in the active-site gorge, with the 
monohydroxyphenyl and trihydroxyphenyl moieties interacting with residues in the PAS 
and ABP, respectively. 
A closer inspection of the interactions at the PAS showed the presence of a hydrogen bond 
between the 2-hydroxyl group and Tyr 72, π-π stacking involving the monohydroxyphenyl 
ring, Trp 286 and Tyr 341 and a cation-π interaction between the protonated nitrogen atom 
of the amide and Trp 286. Furthermore, hydrophobic interactions between 2 and the rich 
aromatic residues (Asp 74, Tyr 124, Trp 286, Leu 289 and Tyr 341) along the gorge appear 
to direct the trihydroxyphenyl moiety into the ABP, thus enabling the phenolic hydroxyl 
groups to form a network of hydrogen bonds with Ser 293, Phe 295 and Arg 296.Molecular 
modeling of the complexes formed between the enzyme and compounds 3 and 6 suggested 
the involvement of a similar set of interactions as for the complex with compound 2 (see 
Figures 4.9.3 and 4.9.4). In the case of the complex with compound 3, the model showed, at 
the PAS, a hydrogen bond between the 2-hydroxyl group and Asp 74, a σ-π interaction 
between carbon 6 in the aromatic ring and Trp 286, a cation-π interaction between the 
protonated nitrogen atom of the amide and Tyr 341 and a hydrogen bond between the 
amide nitrogen atom and Tyr 124 and, in the ABP, hydrogen bonds between two of the 
hydroxyl groups in the trihydroxyphenyl moiety and Ser 293 and Arg 296. The complex 
with compound 6 showed, at the PAS, π-π stacking between the pyridinyl ring and Trp 286 
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and hydrogen bonds between the amide nitrogen atom and the carbonyl group and Arg 296 
and, in the ABP, hydrogen bonds between of the hydroxyl groups in the trihydroxyphenyl 
moiety and Tyr 337 and Phe 338. 
 
Figure 4.9.3(a). Representations of the molecular model of the complex formed 
between compound 3 and hAChE. 3D representation of the ligand-enzyme 
binding interactions. Compound 3 is represented as a dark grey sticks and 
hydrogen bonds as green dashed lines; (b) 2D schematic representation of the 
hydrogen bonding and hydrophobic interactions. 
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Figure 4.9.3(b). Representations of the molecular model of the complex formed 
between compound 3 and hAChE. 2D schematic representation of the hydrogen 
bonding and hydrophobic interactions. 
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This analysis suggests that the hAChE inhibition activity of compounds 2, 3 and 6 is 
probably due to their ability to block the active-site gorge, thus preventing the substrate, 
acetylcholine, from entering the active site. 
Antioxidant Assays: The antioxidant efficacies of the compounds 1–6 were tested and the 
results obtained (see Table 4.7) revealed different activities in the two assays. This 
indicates that two mechanisms, operating in different ways, must be responsible for the 
observed activity. The color change from deep purple to yellow at 515 nm observed in the 
DPPH assay confirmed the radical scavenging activity of the compounds. A reference 
curve of absorbance (A) against DPPH concentration in methanol was plotted and used for 
the calculation of DPPH concentration at various reaction times (R
2
 = 0.9999). The 
compounds showed IC50 values in the range of 1.1–2.3 μg/mL. All the compounds tested 
showed a lower IC50 compared to the positive control used (ascorbic acid), except for 
compound 6, which showed no significant difference with the IC50 of the positive control. 
The high activity of the compounds in the DPPH assay can be related to the resonance 
effect of the polyhydroxyl groups attached to the phenolic ring in the compounds, 
whereupon electron donating substituents increase the electron density in the aromatic ring 
making it more reactive towards electrophilic attack or mainly due to their redox properties, 
which can play an important role in the absorption and neutralization of free radicals, the 
quenching of singlet and triplet oxygen, or the decomposition of peroxides (Heo, 2007 and 
Khaledi, 2011). This presumably promotes the release of phenolic hydrogen to the (1,1-
diphenyl-2-picrylhydrazyl) free radical indicated by a color change from purple to yellow. 
The second method used for testing the antioxidant activities of these compounds was the 
FRAP assay. It is considered an accurate method for assessing “antioxidant power”. Ferric 
to ferrous ion reduction at low pH causes a colored ferrous-tripyridyltriazine complex to 
216 
 
form. FRAP values are obtained by comparing the absorbance change at 593 nm in test 
reaction mixtures with those containing ferrous ions at known concentrations. 
 
Figure 4.9.4(a). Representations of the molecular model of the complex formed 
between compound 6 and hAChE. 3D representation of the ligand-enzyme 
binding interactions. Compound 6 is represented as a dark grey sticks and 
hydrogen bonds as green dashed lines 
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Figure 4.9.4(b). Representations of the molecular model of the complex formed 
between compound 6 and hAChE.  2D schematic representation of the hydrogen 
bonding and hydrophobic interactions. 
In this study, the compounds showed FRAP values in the range 2,000–9,000 which is 
above the values shown by BHT and ascorbic acid used as standards. It was observed 
that compounds 1–5 demonstrated the highest activities in the DPPH assay while 1 and 2 
showed the highest values in the FRAP assay. This can be attributed to increased π-
electron delocalization within the pyridine ring which increases the electron density and 
causes ferric ion reduction (Stockdale. 1971). 
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4.10 ANTI-ULCER APPLICATIONS 
Peptic ulcer occurs in the parts of the digestive tract that are exposed to gastric juice 
containing acid and pepsin secreted by the H
+
/K
+
ATPase or proton pump on the parietal 
cells (oxyntic cells)of the stomach (Grossman, 1981). Gastric ulcer is one type of peptic 
ulcer other than duodenal ulcer (Patrick, 2005) and it occurs on the stomach wall. It can be 
defined as red hemorrhagic bands of erosion on the stomach lining (Patrick, 2005) and this 
disease is caused by endogenous noxious agents such as hydrochloric acid, proteolytic 
enzymes and bile. The exogenous agents however, include ingestion of non-steroidal anti-
inflammatory drugs for instance nalfon, tolectin, butazolidin, naproxen, ibuprofen and 
indomethacin (Grossman, 1981; Yamada, 1999), cigarette smoking (Yamada, 1999; Yuan, 
2007), steroid ingestion (Grossman, 1981), alcohol consumption, psychological stress, oral 
biphosphonates, potassium chloride, immunosuppressive medications and decline in 
prostaglandin levels amongst older people (Yuan, 2007). The pathogenesis pathway of the 
formation of gastric ulcer is complex and still at the crossroad to be clearly understood 
(Yuan, 2007). In this study, gastric ulcer was being induced by ethanol and it is found that 
ethanol produced gastric damage by impairing gastric defensive factors such as mucus and 
mucosa circulation (Szabo, 198). Copper(II) complexes of amino acids had been discovered 
to show potent activity in preventing the formation of gastric ulcer induced by ethanol 
(Franco, 1997).  
4.10.1 Acute toxicity study of  Zn(BzSO-HAP) 
Animals treated with Zn(BzSO-HAP) at a dose of 2 g/kg or 5 g/kg were kept under 
observation for 14 days. All of the animals remained alive and no animal manifested any 
significant sign of toxicity at these doses. There were no abnormal signs, behavioral 
changes, body weight changes, or macroscopic finding at any time of observation. There 
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was no mortality in the above-mentioned doses at the end of 14 days of observation. 
Histological examination of the liver and kidney, hematology, and serum biochemistry 
revealed no significant differences between the different groups as shown in (Figure 
4.10.1). All of the data of the acute toxicity tests are listed in Tables 4.8 and 4.9. 
Table 4.8: Acute toxicity test result of renal Function test Zn(BzSO-HAP) 
Animals 
Group 
Renal Function test 
Sodium 
(mmol/L) 
Pottasium 
(mmol/L) 
Chloride 
(mmol/L) 
CO2  
(mmol/L) 
Anion gap 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Control Grp 138.17 +2.64 5.12 +0.09 103.33 
+1.91 
23.13 +0.88 18.17 +0.60 5.73 +0.37 50.83 +1.79 
L. D(2 g/kg) 137.67 +1.65 5.30 +0.05 102.67 
+1.60 
20.42 +0.61 19.17 +0.40 4.85 +0.08 47.67 +1.22 
H. D(5 g/kg) 138.50 +1.59 4.63 +0.04 102.83 
+1.69 
22.9 +0.36 17.33 +0.42 5.98 +0.21 48.00 +1.16 
All values expressed as mean and standards error mean. There is no significant difference 
between groups 
Table 4.9: Acute toxicity test Liver function test of  Zn(BzSO-HAP) 
Animals 
Group 
Liver Function test 
Total 
protein 
(g/L) 
Albumin 
(g/L) 
Globulin 
(g/L) 
Total 
bilirubin 
(µmol/L) 
Conjugate
d bilirubin  
(µmol/L) 
AP 
(IU/L) 
ALT  
(IU/L) 
AST  
(IU/L) 
G-
Glutaml. 
Transferas
e 
 (IU/L) 
Control 
Grp 
71.17 + 
0.64 
11.33 + 
0.38 
59.83+1.10 1.81 + 0.08 0.83 + 0.02 134.83+3.0
0 
53.5 + 
0.59 
151.5 + 
2.93 
4.67 + 0.13 
L.D 
(2g/kg) 
71.50 + 
1.39 
11.67 + 
0.13 
59.50+ 
0.70 
2.17 + 0.06 1.00 + 0.09 133.17+1.8
7 
50.00 + 
1.40 
163.67+ 
2.13 
5.00 + 0.29 
HD 
(5g/kg) 
71.83 + 
0.50 
11.83 + 
0.39 
60.17 + 
0.42 
1.50 + 0.06 1.00 + 0.04 135.33+0.0
9 
52.17 + 
1.28 
155.00+ 
2.27 
5.33 + 0.10 
 
All values expressed as mean and standards error mean. There is no significant difference 
between groups 
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Figure 4.10.1: Histological sections of acute toxicity test. Figure a, b and c (20x) liver 
section in rats treated with 5 g/kg vehicle, LD and HD compound, respectively. Figure (d, e 
(20x) and f (10x)).kidney section in rats treated with 5 ml/kg vehicle. There is no 
significant differences in structures of liver and kidney between treated (LD, HD) and 
control groups. 
4.10.2 Cytoprotective activity  
The metal compound in Table 4.10 showed an important cytoprotective activity against 
ulcers induced by absolute ethanol. The values of ulcer area, percentage of ulcer inhibition 
and pH compared with those of the cimetidine group showed that the compound is 
bioactive. 
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Table 4.10: Observed ulcer area, inhibition (percentage), pH and mucus by Zn(BzSO-
HAP)2 in rats 
Animal 
Group 
Pre-treatment 
(5 ml/kg dose) 
Ulcer area 
(mm)
2
 
(Mean ± S.E.M) 
Inhibition 
(%) 
pH of gastric 
content 
Mucus weight 
of gastric 
content 
1 Tween 20 
(Ulcer Control) 
 
840.00 ± 4.60
a
 
-  
3.78 + 0.154
a
 
 
0.73 + 0.065
a
 
2 Cimetidine 
(50 mg/kg) 
 
145.00 + 4.91
b
 
 
82.74% 
 
6.20+ 0.491
b
 
 
1.18 +0 .069
b
 
3 Zn(BzSO-HAP)
2
 
(50 mg/kg) 
 
85.40 + 4.43
c
 
 
89.83% 
 
5.10 + 0.379
ab
 
 
1.33 + 0.086
b
 
4 Zn(BzSO-HAP)2 
(100 mg/kg) 
 
00.00 + 0.00
d
 
 
100% 
 
5.54 + 0.415
b
 
 
1.40 + 0.140
b
 
 
All values are expressed as mean ± standard error mean. Means with different 
superscripts are significantly different. The mean difference is significant at the 
p<0.05 level. 
 
The ulcer areas in the benzenesulfanohydrazone treated groups were significantly smaller 
than the control group. As can be observed in Table 4.10 the oral administration of the 
metal complex (50 mg/kg and 100mg/kg) at 30 min before ethanol administration markedly 
reduced the mucosal damage by up to 100% in animals treated with a high dose of the 
compound. At the same time the compound did not induce any significant changes in the 
normal gastric mucosa of the rats of any tested group. The results of the present study 
confirm the known ulcerogenic effects of ethanol. The chemical structure shows that the 
benzenesulfanohydrazones complexes have hydroxyl coordinated groups. Based on its 
structure and potentials to generate hydroxyl radicals, benzenesulfanohydrazone complexes 
can be described as oxidants and appear to increase the load of free radicals.  The carbonyl 
group in the compounds appears to achieve the antioxidant balance and to protect the 
gastric mucosa from injurious agents. Therefore, this group may play a role as an 
electrophilic acceptor in the structure. The mechanism of cytoprotective activity has been 
suggested to be mediated through a reaction between the electrophilic acceptor and the 
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sulfhydryl-containing groups of the mucosa. Also, compounds with the hydroxyl group can 
form hydroxyl radicals, which are known to mediate in the pathogenesis of gastric mucosal 
injury. This result has been reported in a study (Al-Shabanah, 2000) about the effect of 
ninhydrin on the biochemical and histopathological changes in the gastric mucosa of rats. 
Further studies are warranted to identify the detailed mechanism of action of these 
bioactive compounds.  
The administration of ethanol to rats produces gastric mucosal lesions and erosions similar 
to those occurring in gastric ulcer. These lesions are produced because ethanol can affect 
the protective defense mechanisms at the mucosal layer (Repetto and Liesuy, 2002). This 
study describes a model to produce extensive gastric necrosis in rats after induction with 
absolute ethanol. Once administered to rats, the ethanol rapidly penetrates the mucosa layer 
and causes extensive damage (Rajeshkumar, 2001; Abdulla, 2010). This process supports 
the finding that only 30 min was needed to produce acute gastric ulceration in rats. 
Administration of absolute ethanol to fasted rats caused severe gastric damage, which was 
visible from the outside of the stomach as thick reddish-black lines in the ulcerated control 
group (Figure 4.10.2). Administration of the zinc(II) metal complex of 
benzenesulfanohydrazones at 30 min before the administration of absolute ethanol lead to 
good prevention with reduction or absence of the lesions. This result shown in (Figure 
4.10.2) view of the outside of the stomach and (Figure 4.10.3) view of the opened stomach. 
 
 
 
223 
 
 
Figure 4.10.2: Macroscopical appearance of gastric mucosa in rats. (a) Rats pre-treated 
with 10% Tween 20. Severe macroscopic necrosis of gastric mucosa. Absolute ethanol 
produced extensive visible hemorrhagic necrosis of gastric mucosa. (b) Rats pre-treated 
with cimetidine 50 mg kg
-1
). Mild macroscopic necrosis of gastric mucosa. The drug 
reduces the formation of gastric lesions induced by absolute ethanol. (c) Rats pre-treated 
with Zn(BzSO-HAP)  (50 mg kg
-1
). Mild macroscopic necrosis of gastric mucosa. The 
compound reduces the formation of gastric lesions induced by absolute ethanol. (3d) Rats 
pre-treated with Zn(BzSO-HAP) (100 mg kg
-1
). The compound prevents the formation of 
gastric lesions induced by absolute ethanol. 
224 
 
 
Figure 4.10.3: Macroscopical appearance of gastric mucosa in rats in open stomach. (a) 
Rats pre-treated with 10% Tween 20. Severe macroscopic necrosis of gastric mucosa. 
Absolute ethanol produced extensive visible hemorrhagic necrosis of gastric mucosa. (b) 
Rats pre-treated with cimetidine 50 mg kg
-1
). Mild macroscopic necrosis of gastric mucosa. 
The drug reduces the formation of gastric lesions induced by absolute ethanol. (c) Rats pre-
treated with Zn(BzSO-HAP)  (50 mg kg
-1
). Mild macroscopic necrosis of gastric mucosa. 
The compound reduces the formation of gastric lesions induced by absolute ethanol. (4d) 
Rats pre-treated with Zn(BzSO-HAP) (100 mg kg
-1
). The compound prevents the formation 
of gastric lesions induced by absolute ethanol. 
4.10.3. Histological evaluation of gastric lesions  
The histological analysis of ethanol treated and control rat stomachs revealed the presence 
of necrotic debris in the lamina propria of the mucosa.  The lesions extended down the 
mucosal layer involving the surface epithelium (Figure 4.10.4). The treated groups had less 
damage along the surface of the epithelium. Mucosal blood flow has been observed to be an 
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important factor in the damage caused by alcohol and is modulated by prostaglandin 
(Holander, 1984). The effectiveness of benzenesulfanohydrazones complex in prevention 
against mucosal damage caused by ethanol may be an indication of its effect on 
prostaglandin. 
 
Figure 4.10.4: Histological section of the absolute ethanol-induced gastric mucosal damage 
in rats. (a) Rats pre-treated with 10% Tween 20 (ulcer control). Severe disruption of the 
surface epithelium, deep penetration of necrotic lesions into mucosa (arrow) and edema of 
the sub mucosa layer (yellow arrow) with leukocyte infiltration of ulcerative tissues. (b) 
Rats pre-treated with cimetidine (50 mg/kg). Moderate disruption of the surface epithelium 
and edema of the sub mucosal layer (yellow arrow) with leucocytes infiltration. (c) Rats 
pre-treated with Zn(BzSO-HAP) (50 mg kg
-
). There is mild disruption of the surface 
epithelium. (5d). Rats pre-treated with Zn(BzSO-HAP) (100 mg kg
-1
. No disruption to the 
surface epithelium (arrow), and no edema and leucocytes infiltration of sub mucosal layer 
(H&E stain, 10x). 
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Figure 4.10.5: shows the effect of compound on ethanol induced gastric mucosal lesions in 
rats (d) Summarized the effect of compound on mucosal weight. (c) Shows the effect of 
benzenesulfanohydrazones complex on the acidity of the gastric juice in range of (pH=5.1± 
0.04
c 
-5.54±0.03
d
) compared to the cimetidine group (pH=6.2 ± 0.06b). (b) Shows the 
inhibition of benzenesulfanohydrazones Zinc(II) complex 50 mg kg
-1 
and
 
100 mg kg
-1
 
against the stomach ulcer induced by absolute alcohol and the results are compared to the 
standard drug, cimetidine (a) this shows the Ulcer area for the compound compared with 
the control group and standard cimetidine.  Cimetidine has been reported to decrease acid 
output but did not decrease the ulcer area. This supported the present study which both 
doses had indicated better cytoprotective effects in reducing ulcer area formation compared 
with cimetidine with less gastric secretion. 
To determine the safety of drugs and products for human use, toxicological evaluations are 
carried out in various experimental animals to predict toxicity and to provide guidelines for 
selecting a safe dose in humans. The hematological, gastrointestinal and cardiovascular 
adverse effects have the highest overall concordance between animals and humans (Olson, 
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2000). The  liver and kidney of the treated rats showed no significant change compared to 
the control group. Haematology and clinical biochemistry values were within the range of 
the control animals tested and were similar to some of the control reference values 
published by other researchers (Ringler and Dabich 1979; Witthawaskul, 2003). In acute 
toxicity studies, a product is considered nontoxic if no deaths are registered after 14 days of 
observation and no clinical signs of toxicity are obsearved at doses 5 g/kg. Because the 
highest dose of zinc(II) complex that did not cause any toxicity was 5 g/kg body weight, 
these findings suggest that the compound is relatively nontoxic (Brock, 1995). 
The effectiveness of the zinc(II) metal complex with 2’-[1-(2-hydroxyphenyl) ethylidene] 
benzenesulfanohydrazide in preventing mucosal damage caused by ethanol may indicate its 
effect on prostaglandin. The treatment with the benzenesulfanohydrazones complex 
reduced the volume of gastric secretion. In the cimetidine group the gastric contents were 
around (1.18±0.04) g, while those of the treated groups were in range of (1.33 ± 0.01 -1.40 
± 0.01) g. This characteristic indicates that the benzenesulfanohydrazones of the zinc(II) 
metal complex acts similar histamine H2 receptor antagonists. Therefore, the cimetidine 
has been used as standard antiulcer drug in present study as can decrease acid output but 
does not decrease the ulcer area. This previous observation supports the result of the 
present study, in which both of doses of zinc(II) complex showed  cytoprotective effects, in 
terms of reducing the ulcerative area, that were similar to the effect of cimetidine, which 
reduced the gastric secretion. The inhibition activity of the zinc(II) complex with 2’-[1-(2-
hydroxyphenyl) ethylidene] benzenesulfanohydrazide against ulcer formation was excellent 
and was higher than that of the cimetidine group which had a percentage of 89.83% 
inhibition. As the dosage was increased further, the ulcer inhibition increased to 100%. The 
reduced gastric acidity measured after pylorus ligation suggests that the cytoprotective 
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mechanism of action of the extract on gastric mucosa may involve direct inhibition of 
gastric secretion. The reduction of acidity observed after incubation of the gastric juice with 
the extract suggests that the cytoprotective mechanism may involve the simple 
neutralization of the acid secreted in the stomach. Figure 4.10.5 shows the effect of the 
benzenesulfanohydrazone complex on the acidity of the gastric juice in pH range from 5.1± 
0.04
 
 to 5.54±0.03 compared to the cimetidine group (pH=6.2 ± 0.06b). These results agree 
with previous studies (Mahmood, 2010; Murakamu, 1990). In this study Zn(II) 
benzenesulfanohydrazone complex was found to reduce gastric lesions induced by ethanol 
in vivo.  
In conclusion this paper describes a model to produce extensive gastric necrosis in rats by 
induction with absolute ethanol. It also describes good prevention of gastric necrosis by 
administration of zinc(II) complex with benzenesulfanohydrazones 30 min before induction 
with absolute ethanol which reduced or eliminated lesion formation. The compound was 
tested for acute toxicity. Haematology and clinical biochemistry values were within the 
range of the control animals tested and were similar to some of the control reference values. 
The highest dose of zinc(II) complex that did not cause any toxicity was 5 g/kg body 
weight, which indicates that the compound is relatively non-toxic. 
5.0 CONCLUSION 
In the first part of this thesis synthesis, characterization, X-ray structures and biological 
application was presented for synthesized metal complexes. The Schiff-based complexes 
were also highly inhibitive only against the Gram positive bacterium. They exhibit 
significant antimicrobial activities against Methicillin-resistant Staphylococcus aureus. 
Very weak antimicrobial activity was observed with Acinetobacter baumannii and 
Pseudomonas aeruginosa. No antimicrobial activity observed with Klebsiella pneumonia. 
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Further study on time-kill assay is needed to confirm if the compound are bactericidal. The 
study of mechanism of action (MOA) of the compound is suggested to further expand the 
knowledge on its target organism and application.  
Secondly, the anticancer activity of the complexes were analyzed with emphasis to MCF-7 
cell line, we have studied the mechanistic  interaction of Cobalt(III) Schiff base compound 
with nucleic acids and analyzed its biochemical effect on human breast cell line. In the 
cytotoxicity assay the compound showed high in vitro cytotoxic properties with signiﬁcant 
growth inhibition activity against MCF-7cell line. The data from our present study 
suggested the efficient capability of the Cobalt(III) compound to inhibit growth activities as 
anti-cancer compound against human breast MCF-7cell line, and deserves further 
investigation on other human cell lines as potential new antitumor drug 
Lastly, synthesized novel Schiff bases were observed to be potentially useful for acetyl-
cholinesterase inhibition and possible treatment for AD. The compounds also showed 
strong free radical inhibitory activities.  
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Appendix 1: IR spectra of (LMA) 
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Appendix 2: IR spectra of [Zn(LMA)Br2] 
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Appendix 3: IR spectra of Zn(LMA)(NCS)2 
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Appendix  4: IR spectra of [Zn(LMA)(N3)2] 
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Appendix  5: IR spectra of [Cd(LMA)Br2] 
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Appendix 6: IR spectra of [Mn(LMH)Cl] 
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Appendix 7: IR spectra of [Mn(LMH)Br] 
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Appendix 8: IR spectra of (LPA) 
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Appendix 9: IR spectra of [Zn2(LPA)2Cl6] 
 
 
Appendix  10: IR spectra of LPiA 
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Appendix 11: IR spectra of [Mn(LNA)Cl2] 
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Appendix 12: IR spectra of [Ni(LNA)(NCS)2H2O] 
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Appendix 13: IR spectra of [Cu(LNA)(NCS)2] 
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Appendix 14: IR spectra of LNH 
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Appendix 15: IR spectra of [Mn(LNH)Br]  
 
Appendix 16: IR spectra of [Mn(LNH)Cl] 
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Appendix 17: IR spectra of [Ni(LNH)Br] 
 
Appendix 18: IR spectra of [Ni(LNH)Cl] 
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Appendix 19: IR spectra of [Ni(LNH)Br] 
 
 
Appendix 20: IR spectra of [Cu(LNH)Cl] 
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Appendix 21: IR spectra of [Zn(LNH)Br] 
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Appendix 22: IR spectra of [Zn(LNH)Cl] 
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Appendix 23: 1H-NMR spectra of Preparation of  [Zn(LMA)Br2] 
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Appendix 24: 1H-NMR spectra of Preparation of  [Zn(LMA)Cl2] 
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Appendix 25: 1H-NMR spectra of Preparation of  [Zn(LMA)I2] 
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Appendix 25: 1H-NMR spectra of Preparation of  [Zn(LMA)(N3)2]  
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Appendix 26: 1H-NMR spectra of Preparation of  [Zn(LMA)(NCS)2] 
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Appendix 27: 1H-NMR spectra of Preparation of [Cd(LMA)Cl2] 
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Appendix 28: 1H-NMR spectra of Preparation of [Cd(LMA)(N3)2H2O] 
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Appendix 29: 1H-NMR spectra of Preparation of  [Cd2(LMA)2(NCS)4] 
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Appendix 30: 1H-NMR spectra of Preparation of  LMH 
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Appendix 31: 1H-NMR spectra of Preparation of  [Zn(LMH)Br] 
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Appendix 32: 1H-NMR spectra of Preparation of  [Zn(LMH)Cl] 
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Appendix 33: 1H-NMR spectra of Preparation of  [Zn3(LPA)2(Cl)6] 
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Appendix 34: 1H-NMR spectra of Preparation of [Zn(LNA)Cl2] 
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Appendix 35: 13C-NMR spectra of Preparation of  [Zn(LMA)I2] 
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Appendix 36: 13C-NMR spectra of Preparation of  [Zn(LMA)(N3)2] 
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Appendix 37: 13C-NMR spectra of Preparation of  [Zn(LMA)(NCS)2] 
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Appendix 38: 13C-NMR spectra of Preparation of  [Zn(LMA)Cl2] 
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Appendix 39: 13C-NMR spectra of Preparation of  [Cd(LMA)(N3)2H2O] 
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Appendix 40: 13C-NMR spectra of Preparation of  [Cd2(LMA)2(NCS)4] 
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Appendix 41: 13C-NMR spectra of Preparation of  [Cd(LMA)Cl2] 
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Appendix 42: 13C-NMR spectra of Preparation of  [Zn(LMH)Br] 
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 Appendix 43: 13C-NMR spectra of Preparation of [Zn3(LPA)2(Cl)6]
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Appendix 44:1H-NMR spectrum for 2-AP     
 
Appendix 45:13C-NMR spectrum for 2-AP 
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Appendix 46:1H-NMR spectrum for 2,6-DAP 
 
Appendix 47:13C-NMR spectrum for 2,6-DAP 
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Appendix 48:1H-NMR spectrum for BrAP 
 
Appendix 49:13C-NMR spectrum for Br-AP 
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Appendix 50:1H-NMR spectrum for Bs-ZH 
 
Appendix 51:13C-NMR spectrum for BS-ZH 
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Appendix 52:1H-NMR spectrum for Cl-Bs-ZH 
 
Appendix 53:13C-NMR spectrum for Cl-Bs-ZH 
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Appendix 54:1H-NMR spectrum for Zn-Bs-ZH 
 
Appendix 55:13C-NMR spectrum for Zn-Bs-ZH 
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UV-VISIBLE SPECTROSCOPY 
 
Appendix 56: UV-Visible spectra of [Co(LMA)Br2] 
 
Appendix 57: UV-Visible spectra of [Ni(LMA)(NCS)(H2O)] 
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Appendix 58: UV-Visible spectra of LPA 
 
Appendix 59: UV-Visible spectra of  [Zn3(LPA)2Cl6] 
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Appendix 60: UV-Visible spectra of [Cdn(LPA)nCl]n 
 
 
Appendix 61: UV-Visible spectra of LPipA 
 
 
297 
 
 
Appendix 62: UV-Visible spectra of [Zn(LPipA)Cl2] 
 
 
Appendix 63: UV-Visible spectra of [Zn(LPipA)(NCS)2] 
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Appendix 64: UV-Visible spectra of [Mn(LNA)Cl2] 
 
 
Appendix 65: UV-Visible spectra of [Ni(LNA)(NCS)2(H2O)] 
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Appendix 66: UV-Visible spectra of [Zn(LNA)Cl2] 
 
 
Appendix 67: UV-Visible spectra of [Zn(LNA)(NCS)2] 
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Appendix 68: UV-Visible spectra of [Cd(LNA)Cl2] 
 
Appendix 69: UV-Visible spectra of [Cdn(LNA)n(NCS)n]n. 
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